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Abstract of Thesis
Aims: This research project assessed the usefulness of a portable PC-
administered driving performance task, the "AusEd" simulator, in assessing
driving performance in patients with obstructive sleep apnoea/hypopnoea
syndrome (OSAHS), a group known to be at increased risk of motor vehicle
accidents.
Methods: The studies comprised a parallel-limb, randomised single blind,
placebo-controlled trial of 4 weeks of CPAP therapy or an oral placebo and also
a case-control study of AusEd performance. An array of secondary, sleep-
specific outcomes were assessed in each of these trials including FOSQ, SF36,
symptoms scale, IQ decrement and self-reported driving ability and 5-year
accident history. EEG spectral density power and blink behaviour during AusEd
trials were also assessed. Also conducted was a questionnaire-based study of
self-reported driving ability and accident history in a larger cohort of patients and
controls.
Participants: 45 OSAHS patients recruited for two testing sessions before and
after 4 weeks' treatment with CPAP or a placebo [6 female, mean AHI 39 (22),
Epworth sleepiness 14 (3), body mass index 33 (6.)]. Additionally, 19 healthy
control subjects [3 female, Epworth sleepiness 5 (2), body mass index
26(4)kg/m2] matched to the CPAP treatment group by gender and age were
assessed in a case control trial. 138 OSAHS CPAP treated (>2years) patients
[16 females, mean age 54 (8) mean AHI 55 (32)], 82 untreated OSAHS patients
[(11 female, mean age 51 (9.) mean AHI 45 (27)] and 85 community-acquired
controls [5 female, mean age 54 (11)] were recruited for the postal based driving
ability questionnaire study.
Results: Symptom scores and two subscales of the SF36 and 3 subscales of
the FOSO were significantly improved in the CPAP treated group. However no
differences in simulated driving performance were found with CPAP treatment.
In the case-control trial median reaction time was significantly longer in the
xvii
untreated patients than controls in the AusEd performance, and this was
abolished with CPAP treatment. EEG spectral density power showed increased
sleepiness between baseline and the 20 seconds before a crash event recorded
by the AusEd simulator. Time-on-task blink frequency during the driving task
was not significantly different between treated and untreated patients and
controls. In the driving based questionnaire study untreated OSAHS patients
reported more accidents and near miss accidents than treated patients, however
only sleep related incidents were commoner than in community acquired
controls. Treated OSAHS patients also reported fewer accidents than the
controls.
Conclusion: The PC based driving simulator did not distinguish driving
performance between treated and untreated patients and only separated
untreated OSAHS patients and controls by reaction time. Analyses of spectral
density of EEG indicates cortical changes up to 20 second prior to crash and
driving-off road events, but blink rate showed no indication of sleepiness. The
questionnaire study suggests that a untreated OSAHS had more sleep related
motor vehicle accidents (MVAs), but CPAP treated OSAHS patients pose no
greater risk than healthy community dwelling volunteers for involvement in
MVAs.
xviii
Chapter 1: Introducing the obstructive sleep apnoea/hypopnoea
syndrome
1.1 Introduction
The obstructive sleep apnoea/hypopnoea syndrome (OSAHS) is a common condition,
which is estimated to affect between 1-2% of women and 2-4% of men between the
ages of 30 to 60 (Young et al 1993).
At sleep onset the dilator muscles of the throat lose tone resulting in OSAHS patients in
episodes of either complete (apnoea) or partial (hypopnoea) pharyngeal obstruction.
During these periods of obstruction patients struggle in an attempt to breathe, and
reversal of the obstruction usually requires a brief cortical arousal from sleep. Arousals
allow the throat muscles to regain the required activity levels to clear the obstruction.
In severe OSAHS patients the reoccurrence of sleep onset re-initiates upper airway
muscle hypotonia and the cycle of obstruction and arousal recurs.
Therefore OSAHS is associated with multiple episodes of apnoea/hypopnoea, sleep
fragmentation (as a consequence of arousal to clear the obstruction) and sometimes
oxygen desaturation (as a consequence of limited or no airflow), resulting in
predominant nocturnal features of heavy snoring and nocturnal choking. There are also
waking consequences of the syndrome, including excessive daytime sleepiness,
cognitive dysfunction, impaired mood and vigilance and an increase in reaction time.
These features substantially reduce quality of life (Guilleminault 1976) and significantly
impair performance on tasks requiring sustained attention.
This probably explains the increased risk of OSAHS patients having a motor vehicle
accident (MVA). It is estimated that untreated OSAHS patients have between a 1.3-12
times greater chance of having a MVA as compared to healthy matched controls.
(George et al 1999, Teran-Santos et al 1999, Hortsmann et al 2000). Such road
accidents are one of the major risks associated with OSAHS, but there is no clarity
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about precisely which patients are at risk. It would be highly desirable to have a
laboratory-based test that could predict those at risk.
The research conducted for this thesis is based on the validation of a PC based driving
simulator for fitness to drive in OSAHS patients. A review of the literature on OSAHS
and driving can be found in chapter two.
A review of the obstructive sleep apnoea/hypopnoea syndrome follows.
1.2 History of the Recognition of OSAHS
Sleep medicine is still in its infancy compared with many other areas of medicine; in fact
rapid eye movement (REM) sleep was only discovered around 50 years ago (Aserinsky
and Kleitman 1953). Never the less there have been great developments in this area
and the discovery of the obstructive sleep apnoea/hypopnoea syndrome is just one.
OSAHS is not a new condition, merely a newly recognised one. There have been
reports throughout history and literature of obese men who have suffered from
excessive somnolence during the day. Perhaps the best known is Joe the fat boy, in
Charles Dickens' 1830 novel The Posthumous Papers of the Pickwick Club'. Dickens
was amongst the first to report the symptoms of somnolence and snoring and reported
Joe's ability to fall asleep in a variety of situations including during meals and whilst
talking, noting that his snoring was heavy and loud. He was also reported to suffer from
right heart failure and due to his ruddy complexion he was suspected of suffering from
polycythaemia. As more cases of patients with sleepiness, heart failure and
polycythemia were identified, the name 'Pickwickian syndrome' was adopted (Burwell
1956)
In the mid 1960s both Gastaut (1966) and Jung (1965), independently of each other,
provided polysomnographic evidence from nocturnal observations that breathing
pauses occurred during sleep in Pickwickian syndrome patients.
Gastaut (1966) defined these breathing pauses as a cessation of airflow lasting at least
10 seconds and termed them apnoeas. He was able to show using the
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polysomnographic signals that there were three types of breathing pauses. He termed
them obstructive apnoeas, central apnoeas and mixed apnoeas.
All resulted in the cessation of airflow but from different mechanisms;
Obstructive apnoeas result from an obstruction of the upper airway with continued
respiratory effort. These account for most events in sleep apnoea patients.
Central apnoeas result from the temporary loss of ventilatory effort, and are common in
heart failure.
Complex apnoeas, commonly referred to as mixed apnoeas, as the name suggests,
comprise a mixture with both a central and an obstructive component. Physiologically a
mixed apnoea begins with a central apnoea, and as with a normal central apnoea there
is a loss of respiratory effort. However on the resumption of this effort, airflow is still
inhibited due to upper airway obstruction and the term mixed apnoea is used. These
were the least recorded events by Gastaut.
As well as providing evidence regarding the physiological nature of apnoeas Gastaut
(1966) and Jung (1965) provided evidence that arousals from sleep occurred at the end
of an apnoea. Gastaut (1966) concluded that not only were these arousals a
mechanism to end the apnoea, but were also the cause of the severe somnolence felt
by apnoea sufferers during the day. He hypothesised that obesity was the main cause
of these apnoeas, with the extra fat around the neck causing restriction in the upper
airway, and that weight reduction was the obvious treatment.
The next ten years saw a rapid development in our understanding of the mechanisms,
cause and effects of the condition. One of the most significant developments came
when Guilleminault et al (1978) provided evidence to suggest that only a small
proportion of "Pickwickian syndrome" patients suffered from right heart failure and
polycythaemia, with most of the patients presenting only with daytime sleepiness and
suffering from apnoeas. This new information signified a shift in the understanding of
the condition and a new name was adopted for this syndrome, this being the 'sleep
apnoea syndrome'.
The term obstructive sleep apnoea syndrome was then used to clarify that apnoeas in
these patients were predominately obstructive in nature. Although obstructive and
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central apnoeas are rarely seen in isolation it is worth noting that patients with
predominately central apnoeas only account for between 4% (DeBacker 1995) and 10%
of apnoea suffers (Rohers 1985) seen in sleep laboratory populations. Further support
for making this distinction came when patients whose main complaint was somnolence
were reported to suffer predominately from obstructive apnoeas (Sadoul 1972,
Guilleminault 1974). Further developments came with the development of a treatment
for OSAHS called continuous positive airway pressure (CPAP) (Sullivan 1981), which
was found to alleviate nocturnal events and daytime symptoms from obstructive
apnoeas. However some central events also respond to CPAP and may be due to
reflex atonia of the inspiratory muscles following upper airway occlusion.
Apnoeas are not the only important nocturnal respiratory events. Gould et al (1988)
reported that the same symptoms produced by apnoeas were also produced when
airflow was reduced as opposed to completely stopped. This new breathing
abnormality was termed hypopnoea. As with an apnoea respiratory effort is
maintained, but unlike an apnoea there is still airflow although at a reduced level.
Today there is still no consensus over the exact definition of hypopnoea (this will be
discussed in a later section). Gould et al (1988) suggest that a hypopnoea occurs when
continued respiratory effort is accompanied with a reduction of 50% in thoraco¬
abdominal movement in comparison with that during stable breathing in the 2 minutes
preceding the event.
The recognition of the consequences of hypopnoeas caused a significant shift in the
understanding of the syndrome; Gould et al (1988) suggested the syndrome should be
re-named the sleep hypopnoea syndrome. They argued that an apnoea was a severe
form of hypopnoea and so the new name would represent both. While this proposed
term did not immediately take hold, nevertheless the importance of this new event was
recognised and one common name now used for the syndrome is the 'obstructive sleep
apnoea/hypopnoea syndrome', or OSAHS.
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1.3 Defining the Obstructive Sleep Apnoea/Hypopnoea Syndrome.
Once it was recognised that apnoeas and the cortical arousals associated with their
termination were the cause of many daytime symptoms it became necessary to
establish criteria for what was clinically relevant.
Gastaut's (1965) definition of an apnoea as 'cessation of airflow for at least ten
seconds' was widely accepted and is still the definition used. However, there was no
consensus on the frequency of these events that constituted a clinically relevant
syndrome.
The late 1970s and early 1980s saw a surge in recommendations for what should be
used to establish an OSAHS diagnosis, with early definitions including:
30 apnoeas in 7 hours of sleep, (Guilleminualt et al 1976)
10 apnoeas per hour of sleep (Lavie 1983)
5 apnoeas per hour of sleep (Guilleminualt et al 1978)
However these criteria were largely arbitrary and none required the presence of
symptoms to establish the diagnosis.
As the treatment for OSAHS was still primarily surgical in the 1970s and early 80s, it
was vital that diagnostic criteria should be established to ensure only those who needed
treatment should receive it.
Lugaresi et al (1983) aware of the need for describing less severe forms of OSAHS
proposed that sleep apnoea was in fact a:
"Continuum of clinical conditions between trivial snoring and the severest form of
obstructive sleep apnoea syndrome, all of which originate in hypnogenic stenosis of the
upper airway"
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He suggested that a system based on objective monitoring of respiratory behaviour
during sleep and the tendency to daytime sleepiness could be used to characterise
severity. Using this approach he divided this continuum into 4 stages. These were:
Pre-clinical: with sporadic apnoeas
Initial: apnoeas occurring during stage 1,2 and REM sleep
Overt: apnoeas throughout all stages of sleep
Complicated: alveolar hypoventilation persisting during wakefulness
They also divided daytime sleepiness into 4 stages but these stages did not match well
to the nocturnal observations. Although this classification system did not take hold it
was amongst the first to recognise the importance of milder forms of OSAHS and
include the need for symptoms as part of a diagnosis.
Two common indices used to measure the frequency of respiratory events are the
apnoea/hypopnoea index (AHI) and the respiratory disturbance index (RDI). These are
defined as the combined number of apnoeas and hypopnoeas divided by the total sleep
time in hours.
The best current working definition of OSAHS is 5 or more apnoeas + hypopnoeas per
hour of sleep associated with at least two major symptoms out of those outlined in
section 1.5 (ASDA 1999). This is supported by Young et al, who reported symptoms of
OSAHS at this level of disturbance, and by Engleman et al (1999) who showed patients
with an AHI of 5 to 15 per hr perceived benefits of treatment.
The American Sleep Disorders Association (ASDA) propose a two component model of
OSAHS, these being severity of daytime sleepiness and the severity of breathing
abnormality on nocturnal monitoring.
Daytime sleepiness is divided into mild, moderate and severe, depending on whether
unwanted sleepiness or involuntary sleep produces minor, moderate or marked
impairment of social or occupational function.
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Sleep related obstructive breathing events (based on the AHI definition) are divided
into-
Mild; 5-15 events per hour
Moderate; 15-30 events per hour
Severe; 30 or more events per hour
The overall rating of clinical severity is based on the most severe component.
Therefore, even if a patient is only classed as having moderate obstructive breathing
events, they will still be classed as having severe OSAHS if they complain that their
unwanted daytime sleepiness/involuntary sleep is severe.
The above definition is not universal, as many sleep centres use an AHI of 15 per hour
as their clinical cut off and there is still not universal agreement on the definition of
hypopnoea. Some centres require a 50% reduction in oro-nasal airflow rather than
thoraco-abdominal movement, even although this is not truly quantitative (Gould 1988).
Other centres require a 4% arterial desaturation accompanying both apnoeas and
hypopnoeas.
One should also note that these definitions are based on polysomnographic evaluation,
but some centres use limited sleep studies without EEG and others diagnose using
oximetry alone and therefore the AHI and RDI indices cannot be used as they do not
measure time asleep and their results are not directly comparable.
1.3.1 OSAHS as part of a disease continuum
As mentioned in the previous section OSAHS is part of a disease continuum. This
spectrum ranges from partial airway collapse with increased upper airway resistance
which manifests itself as snoring and hypopnoeas, to complete airway collapse with
increased ventilatory effort which manifests itself with periods of snorts leading to
apnoea (Young 1995). A common name for this continuum is sleep disordered
breathing, with the breathing disturbance measured by Al, AHI or RDI, with or without a
measure of oxyhaemoglobin desaturation.
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Recently evidence has suggested that some patients, generally the less obese,
experience increased upper airway resistance terminating in transient alpha EEG
arousal, without the upper airway collapse or oxyhaemoglobin desaturation. These
brief cortical arousals may cause sleep fragmentation and have been shown to increase
daytime sleepiness objectively on the multiple sleep latency test (MSLT) (Guilleminault,
1993) and in turn produce excessive daytime sleepiness (Black 2000). As there is no
occlusion of the upper airway this has been classified by some as a distinct syndrome
from OSAHS called the 'upper airways resistance syndrome' (UARS) (Guilleminault
1993). However the existence of this syndrome is disputed (Douglas 2000).
Guilleminault et al (2000) suggest that patients with OSAHS have an increased arousal
threshold compared to UARS patients. Therefore, UARS patients are more sensitive to
changes in internal respiratory load and this in turn leads to earlier detection of
increased inspiratory effort and arousal before occlusion occurs. However, not all
clinicians believe that UARS is a separate syndrome, and believe that it is in fact part of
the disease continuum of SDB, between snoring and OSAHS. Douglas (2000)
suggests that UARS highlights deficiencies in the definition of OSAHS rather than
highlighting a new syndrome. Douglas also notes that the features attributed to UARS
are not specific to that syndrome and that the major confusion in UARS may stem from
confusion over the scoring of hypopnoeas, which may result from inadequate sensors in
sleep studies, rather than detecting a distinct physiological event. The debate over
UARS as a distinct syndrome continues.
1.4 Obstructive Sleep Apnoea/Hypopnoea - Sequence of events
OSAHS is a result of narrowing of the upper airway during sleep. On falling asleep all
striated muscles throughout the body become hypotonic including the muscles of the
upper airway. Thus the negative pressure within the upper airway during inspiration is
poorly resisted by the tone in the upper airway dilator muscles and upper airway
narrows or even occludes during inspiration. As the apnoea continues, increasing levels
of intrathoracic pressure are generated with each inspiratory effort until a critical level is
reached and an arousal occurs signalling the end of the apnoea and allowing the
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obstruction to be cleared (Remmers 1978). The arousal may be mediated by
mechanoreceptors in the thorax or to central perception of hypoxaemia. On wakening
the person resumes normal breathing and then returns to sleep and in severe cases of
OSAHS an obstruction begins almost immediately and the cycle of occlusion/arousal
continues.
Figure 1.1; Cycle of events in OSAHS
Ventilation and blood ^
oases return to normal
t












1.5 OSAHS Symptoms and Features
There are many reported symptoms of OSAHS but not every OSAHS patient
experiences all of the symptoms. It is useful to note at this juncture that many of the
nocturnal features associated with OSAHS (perhaps with the exception of nocturnal
choking and nocturia), are reported not by the patient but by a family member, most
typically the bed partner. It should also be noted that many of these features affect both
the OSAHS sufferer and family members. A high degree of martial disharmony is often
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reported, with one study finding that 46% of patients sleep in a separate room from their
partner (Kales 1985a). For the purpose of this review features of OSAHS will be
separated into those primarily affecting the patient and events affecting the partner.
1.5.1 Patient affected reports
Excessive Daytime Sleepiness (EDS)
Excessive daytime sleepiness reflects the propensity to falling asleep unintentionally
during the day, especially in less motivating situations (Moldofsky 1992), and is the
most common symptom associated with OSAHS. Sleepiness tends to be a significant
problem in passive and monotonous situations such as watching television, listening to
music, reading, operating a computer or driving on straight roads. However sleepiness
can also intrude into situations not normally considered soporific, for example whilst
lecturing or during sexual intercourse (Dement et al 1978). In many cases EDS is the
main reason for referral to the sleep disorders clinic rather than the presence of other
symptoms of OSAHS or narcolepsy (Roehrs et al 1983, Colt et al 1991).
One should not underestimate the problems that can occur with EDS, as these are
more than a mere annoyance to the sufferer. In many cases these can produce deficits
in performance due to non- or slow- response times. As well as this, EDS can cause
progressive decrements in performance with time, by which the performance of the
individual gradually deteriorates during the task (Melamed 2002). This may, in part, be
responsible for the poor work performance often reported in these patients (Lavie
1983). As well as work-related issues it can also have a large impact on family and
social life (Roth et al 1980). Many people suffering with EDS will alter their lifestyle to
reduce the impact of sleepiness (Kryger 2000). By minimising contact with family and
friends they take themselves out of social situations in which they may struggle to stay
awake, i.e. going to the cinema or having friends around for supper.
It has been estimated that between 80-90% (Dement 1978, Douglas 2002 pg. 47) of
OSAHS patients report EDS. However, this may not be an accurate reflection of the
prevalence of sleepiness, as many patients who have been symptomatic for long
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periods of time may have lost their frame of reference for what constitutes a normal
level of sleepiness. Conversely, many people whose livelihoods depend on performing
tasks which could be adversely affected by sleepiness, i.e. driving or operating
dangerous machinery, may understate their level of sleepiness in an attempt to
continue in their employment (Dement 1978). It should also be noted that many patients
who do not report EDS on their initial consultation only realise how sleepy they were
after they have been established on treatment. Nevertheless, the estimates for the
prevalence of sleepiness for OSAHS patients is still markedly greater than estimates of
sleepiness in the general population which have been placed between 0.3% and 13.3%
(d'Alessandro et al 1995).
Unrefreshinq nocturnal sleep
Many OSAHS patients will report that they feel unrefreshed upon waking in the morning
(Whyte et al 1989). This is primarily due to the transient cortical arousal required to
terminate apnoeas and hypopnoeas (Stepanski et al 1984). Although normally these
arousals last only a few seconds the cyclical nature of the disorder means that the
sufferer is woken several times an hour and in very severe patients, more than once a
minute. Due to the briefness of these arousals most patients are unaware of them
during the night and wake up perplexed by the residual sleepiness, despite what they
believe has been an undisturbed period of sleep.
Difficulty concentrating
Many OSAHS patients also report problems in their ability to concentrate. This is
probably a combination of the effects of both EDS and the reduction in the proficiency
of short-term memory due to sleep fragmentation (Melamed 2002)
Decreased libido
Decreased libido or impotence is also reported (Whyte et al 1989) with suggestions that
a third of OSAHS patients experience this symptom (Bassiri 2000 pg. 871) that may in
turn place extra stress on the marital relationship.
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Depression
Depression itself can cause sleepiness and therefore many patients presenting with
depression and sleepiness may be misdiagnosed, especially if a detailed history of
snoring etc is not taken. Nevertheless, depression is a common symptom reported by
OSAHS patients (Cheshire et al 1992, Engleman et al 1994a).
Nocturnal choking
Many OSAHS patients (Kales et al 1985a, Whyte et al 1989) report choking on
wakening. This can be a very frightening experience for people as yet undiagnosed
with OSAHS, especially if they are unaware of any other OSAHS symptoms. Choking
episodes are reported more frequently in people with milder OSAHS who have fewer
events per hour, (Douglas 2002 pg. 49) which may suggest that more severe OSAHS
sufferers have a blunted cortical arousal response.
Nocturia
Nocturia is a frequent problem for OSAHS patients (Koening et al 1988), and has been
linked to elevated excretion of atrial natriuretic peptide (ANP) with resulting high urine
output. It is a nightly inconvenience for these patents, many of which make multiple trips
to the bathroom. As well as the annoyance factor it may also contribute to EDS by
reducing the total sleep time available to these patients.
1.5.2 Partners Reports
Snoring
Snoring is a very common symptom of OSAHS and almost all partners of sufferers
report it. In many cases there is a very long history of snoring, which is often into
decades (Stradling 1995). It is a chronic symptom occurring on a nightly basis and is
often reported during naps taken in the day. It is initially associated with lying in the
supine position, however, severe OSAHS patients snore in all positions.
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The noise generated by OSAHS patients when snoring has been suggested to equal
that of a pneumatic drill (pneumatic drills register 130Db!) (Douglas 2002 pg. 50) and
this can be a major disturbance to bed partners and to other occupants of the
household. In many cases bed partners suffer from poor quality sleep (McArdle et al
2001a) and sleep fragmentation. This in part may be due the frequency and loudness of
the snoring and this is the primary reason for many OSAHS patients and their partners
sleeping in different rooms
Apnoeas
Most partners will have witnessed 'breathing pauses' (Davies 1992) and to them these
events appear life threatening and are often a source of considerable anxiety.
Characteristically loud snoring is interspersed with periods of silence (relating to the
occurrence of apnoeas) and if left undisturbed the patient will eventually arouse from
sleep, often accompanied by loud snorts. However if partners become aware of the lack
of breathing noises only little, if any, movements of the chest, this leads the partner to
take action, by shaking or nudging the patient to help induce breathing. This action is
common and understandable, however patients are usually unaware of these apnoeic
events and are less than happy to be shaken awake in the middle of the night!
Restlessness during sleep
McArdle et al (2001a) reported that partners of OSAHS patients complain of
disturbance from their partner snoring, having apnoeas and restlessness. The partners
also reported they themselves had reduced sleep quality and scored poorly on quality
of life outcomes. Restlessness in OSAHS is probably related to apnoea termination.
On arousing to clear the obstruction, many thrash around disturbing their bed partner,
and on rare occasions causing physical injury to their partner by hitting them,
unintentionally, with flailing limbs.
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Other symptoms
There are a variety of other symptoms associated with OSAHS including drooling
during sleep, enuresis, irritability and changes in mood/personality.
However the diagnosis of OSAHS cannot be based on symptomatology alone, Hillerdal
et al (1991) demonstrated that simple snorers and OSAHS patients could not be
distinguished on their symptoms alone.
1.6 Neuropsychological impairment
As well as the clinical symptoms and features of OSAHS, patients also have daytime
neuropsychological impairments and these impairments can often be the reason
OSAHS patients seek medical advice (Guilleminault 1978).
As mentioned in section 1.5.2 daytime sleepiness can have debilitating effects on
OSAHS patients, but in addition to this some OSAHS patients also have cognitive
deficits and impaired psychosocial well being. Greenberg et al (1987) were amongst the
first to compare cognitive performance in OSAHS patients and healthy controls. They
examined 14 OSAHS patients, 10 sleepy controls with EDS not attributed to OSAHS
and 14 controls, matched for age, education and pre-morbid intelligence. They used a
wide battery of tests including tests of IQ, visuo-motor skills, and memory scales,
finding that the OSAHS patients had greater deficits on attention, verbal memory, visual
memory and motor speed as well as of global neuropsychological impairment, than
both the control groups.
Bedard et al (1991) compared 20 OSAHS patients (10 severe and 10 moderate) to 10
control subjects matched for age and sex, comparing their performances on the MSLT,
a vigilance task and a variety of cognitive tasks. The moderate OSAHS patient group
performed significantly worse on tests of manual dexterity, attention and executive
function than the control group. The severe OSHAS group also had decrements in
these areas (performing worse than the moderate apnoeics) and also showed
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performance decrements on general intelligence, reaction time, planning, sequential
thinking and constructional skill than controls. On analysis of these impairments the
moderate OSAHS groups showed impairments of 1 to 2 standard deviations, while the
severe group showed impairments of up to 3 standard deviations.
This study suggested that the cognitive impairment seen in OSAHS patients is
dependent on disease severity, with lower, perceptuomotor cognitive functions affected
first and worsening as the conditions worsens, and higher cognitive functions (executive
functions) becoming impaired only in severe patients.
Naegele et al (1995) compared OSAHS patients to age, education and verbal IQ-
matched controls on a battery of frontal lobe function tests. They found only one of
three tests measuring attention was worse in the patient group. Overall patients were
worse in the area of task learning, and showed small decrements in frontal lobe function
tests. Analysis of the aspects of disease correlated with these deficits found that AHI
was related to memory deficits, and nocturnal hypoxaemia related to tests of executive
functions.
Cheshire et al (1992) also reported correlations between cognitive performance and
nocturnal variables. Cheshire reported that poor cognitive performance on tests of
attention and constructional skill correlated significantly with increasing severity of AHI,
nocturnal hypoxaemia, and sleep disruption.
Redline et al (1997) recruited 52 community dwelling volunteers that were split into the
case group (RDI 10-30 per hr) and control group (n=20) (RDI<5) following
polysomnography and were matched by age, sex and intelligence. These two groups
were tested on a battery of cognitive tests measuring attention, executive function and
information processing. The groups were not significantly different in either subjective
or objective sleepiness levels, and the case group performed significantly worse than
the controls on only two tests of attention and working memory. There were no
differences in the groups on tests of executive functions. As with the Bedard study,
these results indicate that only small cognitive decrements may be found when RDI is
low.
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Thus these studies overall suggest that OSAHS patients have small decrements in
cognitive function with mild OSAHS, which worsen as the severity of the condition
worsens and that additional cognitive functions (executive functions), may become
impaired only at severe levels of OSAHS.
As well as cognitive performance deficits OSAHS patients also show significant
impairments in mood, anxiety and quality of life. Changes in personality and mood are
estimated to occur in half of patients with severe OSAHS (Guilleminault 1978), with
irritability reported by both patients and their families, (Whyte et al 1985) Depression
has been frequently reported in OSAHS patients. Guilleminault (1977) using the MMPI
(Minnesota multiphasic personality inventory), which assessed adult psychopathology,
found 20-25% of OSAHS patients had high depression scores. Millman (1989), using
the Zung self-rating depression scale, found 45% of patients showed signs of
depression, and Cheshire (1992), using the hospital and anxiety depression scale,
found 40% of their sample reported clinically significant levels of anxiety or depression.
However, Cassel (1993) using the Freiburger personality inventory found no evidence
of depression in OSAHS patients. This inventory only has two questions relating to
sleep whereas the Zung self-rating questionnaire asks sleep-specific questions
regarding task performance and sleep disruption. Therefore scores on non-sleep
disorder personality and depression scales that include sleep specific questions may be
elevated in OSAHS as a result of the nocturnal effects of OSAHS.
OSAHS patients also seem to show decrements in quality of life (QOL) measures.
Questionnaires assessing QOL measure well being, including physical and
psychological factors. Generic quality of life questionnaires like the SF 36 (see section
3.9.2) contain 8 domains of health status including vitality, social functioning and
physical functioning. Smith and Shneerson (1992) have shown that OSAHS patients
'requiring treatment' perceive themselves to have low health status, with patients
scoring significantly lower on all domains except the general health sub scale,
compared to normative samples, whereas simple snorers and mild OSAHS patients
were not significantly different from the normal samples. After six months of CPAP
treatment scores on all of the domains had significantly improved and several were no
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longer different to the normal values, suggesting that OSAHS has a negative impact on
many health status sub-scales as measured by the SF 36.
Questionnaires specific to disorders of sleepiness, measuring how sleepiness affects
daily functioning and quality of life, have also shown that OSAHS patients can be
discriminated from non-sleepy populations on the basis of how sleepiness pervades
and disrupts their everyday lives (Weaver et al 1997a)
These studies indicate that OSAHS patients suffer from a wide range of psychological
and psychosocial decrements that affect all areas of their lives. These daytime
decrements in cognitive function and sleepiness can have severe consequences on a
person's ability to safely control a vehicle, as will be discussed is chapters 2 and 6.
1.7 Epidemiology of OSAHS
Like any medical condition it is important to quantify its prevalence. This proves slightly
difficult in OSAHS, as there is no consensus either on a diagnostic threshold for
clinically significant respiratory disturbance or on symptom cut-offs. As mentioned in
section 1.3, the ASDA suggest that an AHI of 5 or more is clinically relevant, but many
physicians will only suggest conservative treatment until an AHI of 15 or more is
present in association with significant symptoms. The definition of sleepiness is equally
problematic.
Nevertheless a variety of epidemiological studies have been undertaken, most of these
concentrated in Europe and North America, with the UK initially much slower to
recognise the syndrome and its importance (Shapiro et al 1981)
Franchesci et al (1982), using unselected inpatients from a general hospital, estimated
the prevalence rate of patients with both EDS and an Al of 10 or greater prevalence
rate of around 1%. Lavie (1983) studying industrial workers also estimated the level of
sleep apnoea at around 1.4%, when an Al of five or greater was accompanied by EDS.
However neither of these studies included hypopnoeas as a measure of respiratory
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disturbance, and employed an apnoea threshold of 10 per hour for their level of clinical
significance. Therefore these studies may underestimate the true prevalence rate.
Cirignotta et al (1989) found 2.7% of their sample (males ages 30-69) had more than 10
apnoeas per hour of sleep, however when the presence of symptoms was included only
0.5% were symptomatic and therefore 'requiring treatment'.
Stradling and Crosby (1991) from a possible cohort of 1596 men used home oximetry
on 900 men to screen for potential subjects to undergo polysomnography. Of these, 45
subjects (5%) had a >4% oxygen desaturation dip rate of more than five per hour, and
of these 3 had severe, symptomatic sleep apnoea. Another 18 had supine-related
sleep apnoea. This study gave prevalence rates of 0.3% for severe symptomatic sleep
apnoea to 2% for milder sleep apnoea. Again these values may underestimate the true
prevalence as it has been suggested that oximetry may produce false negative results
in up to 1/3 of cases (Douglas 1992).
Young et al (1993) estimated that 9% of women and 24% of men (aged 30-60) had an
AH I of five or greater without coexisting daytime sleepiness. When the presence of
sleepiness was required to estimate OSAHS this reduced to 2% of women and 4% of
men with an AHI of five or more per hour. This estimate was similar to that by Bearpark
et al (1995) who found a prevalence rate of 24% in middle-aged Australian men who
with a respiratory disturbance index of five or more per hour, however this was also
reduced to 3% when the coexistence of daytime sleepiness was required.
Jennum et al (1992), using a randomly selected non-patient population found that from
a sample of 748, RDI > 5 was present in 10.9% of men and 6.3% of females. Again
when an RDI >5 and EDS were reported together reduced to the prevalence to 1.9% in
men and 0.9% of females (1.4% of the sample).
Tishler et al (2003) analysed in-home sleep studies five years apart. All 286 participants
had an AHI differing by less than 5/hr from the initial study. On re-test, 47 (16%) had an
AHI of 10 or more, which the authors suggest is mild to moderate in OSAH severity.
Twenty-nine (10%) had an AHI of 15 (severe) or greater; of this the authors suggest
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that 2.5% may represent test-retest variability. Therefore they estimate the annual
incidence to be 7.5% for severe and up to 16% for mild to moderate sleep disordered
breathing. However the distinction between 10 and 15 apnoeas and hypopnoeas per
hour as moderate to severe is not in line with the general view of under 15 an hour
being mild and 30 or over being severe. Further the presence of sleepiness and
symptoms is required for diagnosis of the obstructive sleep apnoea/hypopnoea
syndrome and no measure of EDS this was obtained in this study, therefore the
prevalence of OSAHS may be lower than that of sleep disordered breathing.
In summary these studies suggest that obstructive sleep apnoea/hypopnoea (OSAH) is
a relatively common condition, and that many people in the general population may
have the respiratory events of the condition despite a lack of symptoms. The obstructive
sleep apnoea/hypopnoea syndrome (which requires the presence of symptoms) is less
prevalent with estimates from these studies ranging from 0.5-4% of the populations
studied.
However the prevalence estimates depend on the diagnostic criteria and methods of
measurement implemented. A major issue in estimating the incidence of sleep apnoea
concerns the need for patients to report features in addition to the observation of
respiratory events. Several of the above studies require only the presence of sleep
disturbed breathing to categorise OSAHS, rather than at least two symptoms including
sleepiness as ASDA suggest (section 1.3).
Further reporting symptoms is dependent on subjective perception. Perhaps the two
most common features, daytime sleepiness and snoring, may often be reported as
absent when in fact they are present, and visa versa. This is not necessarily a case of
the patients lying, as Stradling and Crosby (1991) found that if a bed partner was
present during questioning regarding snoring, prevalence rose from 10% to 23%.
Conversely, Bearpark (1995) found that 15% of people reporting snoring did not snore
at all. Snoring is a subjective measure, and patients are dependent on witness reports
to establish its occurrence, hence their reports of snoring will depend on what they have
been told by others. EDS may also be denied if OSAHS sufferers have lost their frame
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of reference for what constitutes a normal level of sleepiness (Dement 1978). If one is
constantly sleepy over a long period of time, it may be perceived as normal.
1.8 Mortality in OSAHS
Untreated OSAHS may be associated with increased mortality. However all of the
studies of survival with OSAHS are potentially flawed, and there are no randomised
controlled trials proving cause and effect - neither are these likely ever to be performed
for ethical reasons of withholding treatment of proven benefit.
Partinen et al (1988) conducted a five-year follow up on 198 patients and found 14
deaths. These all occurred in their conservatively treated patients (n=127), who had
been advised to lose weight, compared to no deaths in the tracheotomised patients
(n=71). On reviewing the cause of death, 8 were cardiovascular in origin and most
occurred during sleep. He et al (1988) found that patients with an apnoea index >20
had a greater mortality than those with an apnoea index <20. Eight of the 98 patients
treated with uvulopalatopharyngoplasty (UPPP) had died compared to zero in the group
treated with either tracheotomy or CPAP. However mortality rates were most apparent
in under those aged under 50.
Veale et al (2000) compared CPAP users who died (n=124) to age and sex matched
patients who commenced CPAP at the same time (n=123), as well as to the general
mortality rate of the French population. Overall the mortality rate was the same as the
general French population, although by case control comparison, factors associated
with subsequent death from past medical history were; cardiac arrhythmia, respiratory
disorders, ischaemic events and neurological or psychiatric disorders. The authors
report that a significant number of the deaths were cardiovascular in nature, but these
patients may have had a history of cardiovascular conditions. Marti et al (2002)
compared 444 patients diagnosed between 4 and 14 years earlier. The treatments
employed were surgery (88), CPAP (124), weight loss (134) and 98 were not treated.
Within the total cohort, 49 patients died. Treated patients had a lower mortality rate
than non-treated patients, and mortality was higher in patients with a history of chronic
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obstructive pulmonary disease. Compared to the general population, untreated patients
adjusted for age and sex showed excessive mortality, but there was no significant
difference in survival between treated OSAHS and the general population.
In summary these studies suggest that untreated patients have a higher mortality rate
compared to both the general population and those treated by either CPAP or
tracheotomy. The survival rate of those treated with UPPP seems to be slightly lower
than CPAP. However, Keenan et al (1994) found no difference between the survival
rate of OSAHS patients treated with CPAP and UPPP, therefore further comparison is
needed to clarify.
Many of these studies are retrospective with relatively small numbers of cases and in
most cases no adequate control group. Ideally a prospective study comparing survival
rate of these treatments (as well as oral appliances) against untreated patients would
clarify the situation much better then retrospective studies. However withholding
treatment to analyse possible outcomes would be unethical.
As well as deaths caused by secondary medical conditions, OSAHS may also increase
mortality in undiagnosed patients through their increased risk from driving and
occupational accidents (Stradling 1989, Findlay et al 1991, Akerstedt, 2002).
1.9 Possible Predisposing Factors for Obstructive Sleep Apnoea
Numerous factors can increase the risk of developing OSAHS. Although not exhaustive
this section outlines and lists a variety of these risks.
1.9.1 Obesity/ Body Mass Index (BMI) /Neck Circumference
Obesity is an important risk factor for both snoring and OSAHS. Obesity can be
measured by the body mass index scale (BMI) which is calculated as weight in
kilograms divided by the square of height in meters (Khosla 1967). A BMI greater than
30 kg/m2 is considered obese. However central obesity anthropometric measures such
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as waist to hip ratio, or neck size, are better predictors of OSAHS severity (Katz et al
1990). Obesity is thought to affect upper airway dimensions through fat deposition
within the soft tissue regions of the neck (Mortimore 1998) and this in turn may increase
pressure on the upper airway, promoting collapse. Mortimore et al (1998) showed that
even non-obese OSAHS patients have excess fat deposition in the areas anterolateral
to the upper airway, when matched to control subjects by BMI and even neck
circumference, which may represent a predisposition to the condition.
1.9.2 Age
Increasing age is also a risk factor for OSAHS. Although the syndrome occurs in all
ages, most prevalence data exists for the middle aged, and the prevalence rate and the
consequences of OSAHS are less clear in the elderly.
However OSAH is common in the over 65 group. Ancoli-lsrael et al (1991) found that
65% of people in this age group had an RDI > 10 per hour, this was in keeping with an
earlier study in which they found 70% and 40% of a nursing home population had an
AH I of >5 and >15 respectively. Bixler et al (1998) also reported that prevalence rate
in the 65-100 year age group was 2%, as compared to 1% under 44 and 5% between
45-66. These data would suggest that the elderly are also at risk from OSAHS. Clinical
recognition within this age group may not occur due the acceptance of daytime
sleepiness in the elderly and because snoring is more common in this age group.
Further research on the prevalence of OSAHS and its effects on the elderly population
are needed.
1.9.3 Gender
It is estimated that 85% of OSAHS patients are male, however discrepancies in the
male-to-female ratio exist between community-based and clinic-based studies. These
were highlighted in a study by Redline et al (1994) who, using an AHI of 15 or greater
as indication of OSAHS, found a ratio of 8:1 (male to female) in a laboratory sample of
patients (n=36) compared to a ratio of 2:1 in a community-based sample (n=65). They
also reported differences between the females in both groups, with the laboratory group
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being younger and significantly heavier than the males, whereas the community sample
tended to be older than the males and were made up of a majority of postmenopausal
women (75%) with no differences being observed in BMI of the males and females in
the community sample.
Bixler (2001) found that the prevalence of OSAHS was higher in postmenopausal
women (2.7%) as compared to premenopausal women (0.6%). However, the
premenopausal women were both younger and more obese than the postmenopausal
women. Postmenopausal women using hormone replacement therapy (HRT) had a
similar prevalence rate (0.5%) to premenopausal women, suggesting female hormones,
especially progesterone, may reduce the risk factor of OSAHS, and that conversely the
menopause may be a risk factor in females for the development of OSAHS.
Testosterone in males may encourage adipose tissue in the neck, and these hormonal
differences may account for the differences in prevalence in younger male and female
subjects, with the prevalence differences reducing in older subjects, although females
of all ages have less severe OSAHS then males. These differences may also include
an effect due to the differences in symptoms being reported by males and females, with
females reporting depression (Young et al 1997), insomnia and difficulty maintaining
sleep (Ambrogetti et al 1991), more commonly than males.
1.9.4 Familial and Genetic Risk
In 1978 Strohl reported a family in which a father and his two sons had OSAHS, with
another sibling demonstrating upper airway occlusion during sleep, but reporting no
symptoms. This was amongst the first reports that suggested the OSAHS might have a
genetic component.
Further evidence for a genetic link came in 1992 when Redline et al compared 29
families with known OSHAS to 21 control families with no known history of OSAHS.
Two hundred and seventy two subjects (first degree relatives and spouses) underwent
polysomnography and provided information on sleep and respiratory symptoms.
Redline et al (1992) reported that the odds ratio (adjusted for age, BMI, and sex) of
habitual snoring, apnoeas, and EDS were 1.34 (95thCI 1.10, 1.62), 1.45 (1.14,1.86) 1.42
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(0.91, 1.39) for those with a relative with OSAHS. These increased to 2.38 (1.34, 4.23),
3.08 (1.46, 6.83) and 2.89 (0.75, 2.68) for habitual snoring, apnoeas and EDS
respectively, with 3 affected relatives with OSAHS.
In a second study Redline et al (1995) found that 13% of OSAHS relatives compared to
6% of a control group had AHI>5 with one major symptom of OSAHS. They calculated
the odds ratios (adjusted for age, sex, race, BMI) of having OSAHS as 1.58 (CI 1.02,
2.45) with one affected relative to 3.97 (1.07, 14.7) with three affected relatives.
Relatives of OSAHS patients were significantly older than the control group and the
initial group of OSAHS patients were obese, and as these two variables are know to
increase the likelihood of OSAHS, interpretation of these results must be cautious.
Douglas et al (1993) assessed 40 first-degree relatives of 20 OSAHS patients. To
reduce the influence of the known inheritability of obesity, the OSAHS patient group
(n=20) all had a BMI of <30 and were therefore not obese. Of the 40 relatives who
underwent polysomnography 10 (25%) had an AHI > 15/hr. These 10 relatives were
older than the 30 with an AHI<15 but were not more obese. Eight of the 10 affected
relatives were described as loud snorers and 8 of the 40 relatives also had more than
five 4% desaturations/hr. Although no control group were recruited for this pilot study,
Douglas et al (1993) compared their data to data published by Stradling et al (1991).
Stradling found that of 893 randomly selected middle-aged men who underwent
polysomnography 45 (5%) had more than five 4% desaturations/hr compared to 8 of the
40 (20%) in the Douglas et al study.
In a follow up study, Mathur and Douglas (1995) provide data to suggest a genetic
component to OSAHS. Mathur and Douglas conducted polysomnography on 51 first-
degree relatives of OSAHS patients and 51 age, sex, height and BMI matched controls.
Results showed that significantly more OSAHS relatives complained of snoring (27
relatives to 7 controls, p<0.001) and EDS (28 relatives to 16 controls, p<0.01) than
controls. OSAHS patients also had significantly more apnoeas and hypopnoeas than
relatives (13/h relatives (CI 3, 82/h) to 4/hr controls (0, 53/h, p<0.001). Relatives also
had significantly more arousals from sleep (30/h vs. 17/hr) as well as more 2%
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desaturations/hr (6/h vs. 3/hr p=0.04) and more 3% desaturations/hr (4/h vs. 2/h
p=0.04).
Mathur and Douglas also measured cephalometry in OSAHS relatives and controls.
The OSAHS relatives differed from the control group by having retroposition of the
maxillae and mandible. Guilleminault (1995) also found differences in cephalometry of
OSAHS relatives (n=22) and a control group (n=6). Although the population size is
small, nonparametric statistical tests found significant differences in 4 out of 5
craniofacial measurements taken, with the author reporting these differences indicate a
heritable morphological component.
Pillar and Lavie (1995) conducted polysomnography in 105 offspring of 45 OSAHS-
confirmed patients. From this Pillar found 49 (47%) of offspring (36 men) had OSAHS
(AHI >5), and of these 14 had an AHI >20. Twenty three (22%) were classified as
simple snorers (snoring with AHI <5). On analysis of age, 10 women and 22 men under
35 had AHI>5<20 and 5 men had an AHI>20. The authors argue that the prevalence of
OSAHS in the general population is around 1-4% and these data suggest OSAHS has
a genetic component, although this study lacks a matched control group.
1.9.5 Anatomical and congenital disorders
As well as genetic risk, anatomical factors may have a role to play in OSAHS.
Attributes such as retrognathia, micrognathia, and acromegaly (Hudgel 1992) physically
affect the size of the mandible and therefore reduce the size of the upper airway,
restricting ventilation. The soft tissues of the pharynx also affect the size of the upper
airway, therefore hypertrophy of the tonsils, tongue, uvular or adenoids can also reduce
upper airway dimensions (Schwab 1995). Lateral narrowing, defined as 'the presence
of bands of tissue impinging into the observable posterior pharyngeal space' also occur
(Schellenberg et al pg. 742, 2000).
Some medical conditions such as the Prader-Willi syndrome and Downs syndrome, in
which obesity is a common problem, may contribute to anatomical predisposition of the
syndrome. In Down's syndrome, macroglossia is a contributant to reduced airway size.
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1.10 Treatment for OSAHS
The most common treatments for OSAHS can be divided into three treatment types-
conservative, surgical and non-surgical treatments.
1.10.1 Conservative
Conservative treatment for OSAHS includes weight loss, as obesity, BMI (kg/m2) and
neck circumference are associated with OSAHS. Weight loss has shown to be effective
in some cases, with a case-report of one OSAHS patient who reduced his weight from
111kg to 85kg, reducing his Al from 59.6 to 3.1, effectively from severe OSAHS to the
normal range (Browman, 1984). Smith (1985) also reported a reduction in apnoea
frequency with weight loss, with 15 severe OSAHS patients reducing their mean body
weight from 106.2 kg to 96.6kg and in turn reducing the mean apnoea frequency form
55 to 29, and attenuating the level of desaturation associated with the remaining
apnoeas. However the Al frequency did not return to normal - but then neither did the
weights.
Other conservative regimens also include avoiding sleeping in the supine position
(Oksenberg 1998), the avoidance of alcohol as this can decrease neuromuscular tone
in upper airway dilator muscles (Issa and Sullivan 1984) especially evening alcohol
before bed (Engleman 1993). However, these conservative treatments tend to only
have short-term benefits.
1.10.2 Surgical Treatments
As obesity is a risk factor for OSAHS, surgery for weight loss has been advocated.
Several different surgical approaches including gastric bypass surgery and vertical
banded gastroplasty have been utilised with this aim. Peiser et al (1984) studied 15
morbidly obese OSAHS patients before and between 2- 4 months after gastric bypass
surgery. Weight loss associated with this surgery was augmented by a reduction in
apnoea frequency, and this was further reduced at revaluation 4-8 months after the
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surgery. Charuzi et al (1985) also found that gastric bypass surgery improved the
polyhypnographic recording of 13 obese OASHS patients, increasing the time spent in
stages 3 and 4 and REM sleep and improving the quality of breathing during sleep.
However, the long-term outcome of these types of weight reduction surgery is not
encouraging with significant weight gain reported in several studies, (Charuzi 1992,
Wolfel 1994, Ramsey-Stewart 1995). Pillar et al (1994) followed up 14 OSAHS patients
who underwent weight reduction surgery and found that although the groups' AHI of
40/hr (SD 28.8) and BMI of 45/kg/m2 (7.2) had been significantly reduced to 11 (16.4)/hr
and 33 (7.5)/kg/m2 respectively at 4.5 months after surgery. However at 7.5 years after
surgery, AHI had significantly increased to 24 (23)/hr even though the mean BMI had
risen only to 35kg/m2.
While weight reduction is in itself advisable, these studies suggest that at least some
types of surgical intervention to reduce weight, as a precursor to alleviating OSAHS,
may not offer long term benefits.
The original surgical intervention to directly treat OSAHS was tracheotomy, a procedure
that bypasses the obstructed airway and is a very effective treatment for OSAHS
(Guilleminault 1981). However, tracheotomy is a very intrusive procedure and requires
long term postoperative care, both of which are less than acceptable to patients.
Uvulopalatopharyngoplasty (UPPP) is a surgical approach originally used as a
treatment for snoring. It was first described in 1981 by Fujita et al as a treatment for
OSAHS. This procedure involves the surgical removal of the uvula and part of the soft
palate, and was a common procedure in the early 1980's. However, there are doubts
over the efficacy of this treatment as a cure for OSAHS (He 1988, Larsson 1991,
Larsson 1994, Miljeteig 1994) and the improvement in SDB may be less than with
CPAP therapy (section 1.9.3.2), (Sher 1996, Douglas 1997). As this treatment removes
pharyngeal and palatal tissue, it is effective in reducing snoring, but as people with
'simple' snoring often develop OSAHS with advancing age, UPPP may not be ideal as a
cure for snoring either, as evidence suggests that after the UPPP surgery OSHAS
patients tolerate CPAP poorly and use CPAP significantly less than matched controls
(Mortimore et al 1996).
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This surgical treatment may provide subjective improvement in snoring and EDS
(Miljeteig 1994) and may provide benefits to certain individuals (simple snorers, mild
OSHAS patients) but is no longer as widely used as a treatment in OSAHS due to
evidence of poor objective efficacy of this surgery at follow-up. Follow-up studies
suggest that only 50% of patients operated upon have benefit to apnoeas and
hypopnoeas after one year.
However a review of literature (Brigman et al 1997) has highlighted many
methodological issues related to UPPP as a treatment of OSAHS, hence further
investigation would be required to determine the suitability of UPPP.
Other surgical procedures may be performed on OSAHS patients where distinct upper
airway abnormalities occur. These can include the removal of tonsils, adenoids, and
nasal polyps. Reconstruction surgery; straightening a deviated septum, or advancing
the mandible (Bear 1980) or hyoid bone (Riley 1993) for patients with retrognathia may
also be employed. However once any surgical procedure is undertaken, especially
when tissue is being removed, there is often no way to reverse the procedure and as
such any surgical treatment for OSAHS and snoring should be very carefully
considered.
1.10.3 Non Surgical Treatments
1.10.3.1 Pharmacological Therapy
Various drug therapies have been used in the treatment of OSAHS, a sample of which
include:
• Progesterone is a respiratory stimulant, and it was thought that it may increase
respiratory drive and as such increase pharyngeal tone. However Hensley (1980)
and Hudgel et al (1998) did not find any improvement over placebo.
• Protryptyline is a trycyclic anti depressant and as a function of this drug REM sleep
is suppressed. As many apnoea and hypopnoeas are REM sleep related it was
postulated it would remove the long respiratory disturbances found in REM. Some
success was noted by Clark, (1979) and Conway (1982), but the effects of
protryptyline were not reproduced by Whyte et al (1988).
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• Acetazolamide (a carbonic anhydrase inhibitor) has been shown to significantly
reduce the number apnoeas from pre-treatment levels, although these were mainly
central in origin (White et al 1982). In a randomised controlled trial (Whyte et al
1988) acetazolamide reduced the number of apnoeas occurring as compared to a
placebo but did not significantly reduce symptoms of OSAHS, and paraesthesia was
a common side-effect.
• Modafinil (provigil) is a novel wake-promoting agent originally designed to reduce
excessive sleepiness in narcolepsy. It acts selectively through the sleep/wake
centres of the brain believed to regulate normal wakefulness, without generalised
CNS activation (www.provigil.com). It does not have any specific effect on sleep
apnoea mechanisms and could only affect sleepiness, not vascular risk.
Arnulf et al (1997) conducted a randomised double blind crossover study and found that
in 6 patients modafinil reduced objective sleepiness, increased the duration of
subjective daytime vigilance and improves long term memory, without adversely
affecting night time sleep or respiratory events. Pack et al (2001) conducted a
randomised double blind crossover study and also found that modafinil significantly
improved both subjective and objective daytime sleepiness as compared to a baseline
test, and significantly reduced subjective EDS compared to placebo, again with no
alteration of night time events.
Although Kingshott et al (2001) found no improvement in quality of life measures,
Epworth sleepiness score or sleep onset latency in the MSLT in their randomised
double blind crossover study, they did find that modafinil significantly improved
alertness as measured by the MWT when compared to placebo. They also found that
CPAP use was reduced in the modafinil limb (6.3h/n) as compared to the placebo limb
(6.5h/n). Both Pack (2001) and Kingshott (2001) used modafinil in conjunction with
CPAP treatment, and although further RCTs (randomised controlled trials) are needed
to ensure modafinil does not reduce CPAP use, it may be a beneficial, if pricey, adjunct
therapy for OSAHS which has not fully responded to CPAP therapy.
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1.10.3.2 Intra-oral Devices
Dental splints and other intra-oral devices are a useful treatment for OSAHS and
snoring. These devices, worn whilst sleeping, generally either hold the tongue forward
or reposition the mandible to increase the area of the upper airway and therefore
reduce obstructive events. These devices are often referred to as mandibular
advancement devices (MAD) or mandibular repositioning splints (MRS), amongst other
names. They are usually cast and fitted by dental professionals. Reported side effects
include tooth discomfort, excessive drooling while sleeping and temporo-mandibular
joint discomfort (Fritsch, 2001). Although CPAP treatment is currently the treatment of
choice in OSAHS (Engleman 2002) these devices may play a role in treating simple
snorers, those with mild OSAHS and patients who are unable to tolerate CPAP.
Stradling et al (1998) performed 2 overnight sleep studies in 15 patients already
established on a MAD, with one night while using the device and one without using the
device (in randomised order) and found that snoring episodes were significantly fewer
whilst wearing the MAD (20/hr) than without it (193/hr). They also found a reduction in
respiratory effort, suggesting an enlargement of the upper airway.
Cohen et al (1998) initiated 25 OSAHS patients (10 mild to moderate OSAHS AHI<21,
and 15 moderate to severe) on a dental splint. Treatment was regarded as successful if
the AHI was <5 while using the dental device. After 2 weeks, polysomnography was
once again performed and they found that 9 of the 10 mild -moderate patients and 9 of
15 moderate-severe patients had AHI<5. Both these studies were short term and had
no control group, but may support dental splints as effective tools for treating snoring as
well as mild and possibly even moderate and severe (Cohen 1998) OSAHS.
Randomised control trials using active and placebo (not protruding the mandible or
tongue, hence no effect on OSAHS) devices, also suggest they may have a role to play
in the treatment of OSHAS. Johnston et al (2002) found that AHI was significantly
reduced in the active MRS period, although the OSAHS with severe OSHAS did not
find them as effective. Gotsopoulos (2002) also used a placebo oral device as a control
for active MRS and found that both the sleep onset latency of the MSLT and the
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Epworth sleepiness score were significantly better than on the control limb. Again
these studies suggest that MRS devices may not only help normalise AHI but are
effective in treating daytime symptoms too. Mehta et al (2001) also used active and
placebo dental devices and found that in 28 patients, 15 patients had a reduction in AHI
frequency less than or equal to 50%, with the AHI remaining over 5, and nine had a
reduction in AHI to less that 5/hr with the active MRS device.
Randerath (2002) in a randomised crossover trial of a dental splint and CPAP, found
that initial use of both treatments reduced significantly reduced AHI and arousal
frequency from their untreated baseline levels, but after six weeks of treatment only
CPAP maintained these levels, although 30% of the dental splint group maintained their
AHI < 10. Randerath also report that patients found the dental splint easier to use.
Ferguson et al (1996) also conducted a randomised crossover trial comparing CPAP
and a dental splint to investigate the efficacy of treatment and patient preference. Each
treatment was used for 4 months and results showed that AHI was significantly lower in
the CPAP limb as compared to the dental device (3.5 SD 1.6 and 9.7 SD 7.3). In the
dental device limb 12 patients showed AHI <10 and 6 an AHI>10 while 6 did not use the
treatment. In the CPAP limb 13 patients had AHI<10, 4 refused to wear CPAP after the
dental splint limb, and 8 were compliance failures. Overall side effects were more
common with CPAP and patients were more satisfied with the dental device.
These results may indicate that although CPAP seems to be more effective in reducing
AHI long term, dental devices may be an effective tool for reducing AHI to less than
10/hr in a subset of device users, and so may be beneficial for mild OSAHS patients or
those who will not tolerate CPAP.
However Engleman et al (2002) compared CPAP to an MRS device in an RCT and
found that CPAP produced significantly better effects than MRS for AHI frequency,
symptom score, subjective daytime sleepiness, as well as measures on the Functional
Outcomes of Sleepiness Questionnaire (FOSQ) and the SF 36 questionnaire of health
status. Patients also reported CPAP as a more effective treatment, but there was no
difference in treatment preference. This held also for mild OSAHS (AHI<15).
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These results imply that CPAP is more efficient long-term treatment for more patients
with OSAHS. Engleman (2002), provided evidence that even mild OSAHS patients find
CPAP more effective, although long term use in mild OSAHS patients may be poor
(McArdle 1999). As such, dental devices may be best used as a first line treatment in
simple snorers and patients opposed to using CPAP, and as a reserve treatment for
those patients who cannot tolerate CPAP.
Further evidence is required, and more randomised trials are required to determine the
long-term efficacy of dental appliances compared to both CPAP and conservatively
treated patients, any future trials should investigate patients with all severity levels of
OSAHS and include measurements of nocturnal events, and both objective and
subjective daytime symptoms. One should note that there are a variety of different
types of dental devices and positive results from studies involving one type of device
that provide evidence that it is an effective treatment for OSAHS does not necessarily
mean all dental devices will be effective.
1.10.3.3 Continuous Positive Airway Pressure (CPAP)
Maintaining optimal area in the pharyngeal lumen is dependent on balancing the
negative pressure caused by narrowing forces, primarily inspiration, and the positive
pressure caused by dilating forces, principally the pharyngeal muscles. As explained
above, during obstructive events the equilibrium of this pressure balance is disrupted,
probably due to the hypotonia of the pharyngeal muscles making them unable to
counteract the negative pressure. This pressure imbalance causes the tongue and soft
palate to be sucked towards the oropharyngeal wall and this can cause substantial area
reduction (hypopnoea) or complete occlusion (apnoea) in the pharyngeal lumen. The
continuous positive airway pressure (CPAP) machine is a flow generator that blows air
into the upper airway via a well-fitted, leak free nasal or oro-nasal mask. At optimal
pressure, which is different in each OSAHS patient, the positive pressure acts as a
pneumatic splint by counteracting the negative pressure caused by inspiration; this
restores the pressure equilibrium in the upper airway and abolishes airway collapse,
snoring, apnoeas and hypopnoeas and the subsequent arousal they bring (Sullivan
1981).
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First developed by Sullivan et al (1981) in the early 1980s, CPAP has become widely
used in the treatment of OSAHS. Studies conducted in sleep laboratories have
provided evidence that after even only one night's use of this treatment, CPAP is
effective in abolishing nocturnal events including: apnoeas and hypopnoeas, (Sanders
1984, Lamphere et al 1989) improving arterial oxygen saturation (McEvoy and
Thornton, 1984, Bonsignore et al 1987), abolishing snoring (Berry and Block 1984),
reducing EEG arousals (Sforza 1993, Fietze, 1997,) and restoring sleep architecture
(Issa and Sullivan 1986, McArdle et al 2001b). There is a good body of evidence to
support CPAP as a treatment that is able to alleviate the nocturnal features of OSAHS,
and as such there is a general acceptance that CPAP is the treatment of choice for
OSAHS.
However as previously indicated OSAHS patients have a range of symptoms and
features associated with the condition. The ASDA (American Sleep Disorders
Association) have recommended that diagnosis of the condition should be based on
nocturnal events and daytime sleepiness (ASDA 1999). This is a significant point, a
person is classed as having obstructive sleep apnoea/hypopnoea when nocturnal sleep
is disturbed by respiratory events, but patients are only classed as having the
obstructive sleep apnoea/hypopnoea syndrome if symptomatic. Therefore any
treatment used for OSAHS should both eliminate nocturnal events and the daytime
features of the condition, by reducing EDS and improving daytime performance and
quality of life measurements.
Many studies have been conducted to investigate the potential of CPAP in alleviating
the daytime features of the condition. Both Kribbs et al (1993a) and Sforza (1995)
evaluated OSAHS patients after one year of CPAP use. Kribbs (1993a) found as well
as a significant reduction in RDI (56.6 /hr to <5) to a level which was considered non-
pathological that 15 OSAHS patients performed significantly better on both the MSLT
and PVT after one year, and the subjective sleepiness score was also lower as
compared to pre-treatment levels. At one year patients also underwent one night
without using their CPAP therapy and there were significant increases in both AH I and
MSLT and subjective daytime sleepiness. The reaction times recorded from the PVT
also increased although not significantly. Sforza (1995) compared 30 OSAHS patients
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(AHI 74.4 (SEM3.0) before and after 1 year of CPAP (mean CPAP use 6.2hrs/night),
who as with the Kribbs (1993a) study, underwent one night using CPAP and one night
without and completed the MSLT on each consecutive day. Again CPAP improved
patients sleep architecture, sleep continuity and alleviated apnoeas. Pre-treatment
MSLT mean sleep onset latency was 3.1 minutes, at one year. Using CPAP this had
significantly risen to 9.8 minutes, and in turn decreased significantly to 5.3 minutes after
only one night without using CPAP. CPAP at one year had also improved subjective
sleepiness. Sforza also compared patients whose MSLT score was still pathological
(<10minutes) to those who were not (>10minutes) and found that those scoring
>10minutes had a higher AHI at baseline, had a greater level of improvement of
hypoxaemia and used CPAP more. This study confirms the results of Kribbs and
reinforces that CPAP not only alleviates nocturnal features but daytime features also.
As reported previously CPAP has been shown to have immediate effects on sleep
quality after only one night of use, the Kribbs and Sforza studies however reinforce that
CPAP is a therapy and not a cure, as reflected in the immediate reversal of many
features, after only one night without use.
Investigation in to the time needed for CPAP to produce optimal effect was conducted
by Lamphere et al (1989) looking at the effect of CPAP on sleep architecture,
respiratory disturbance and MSLT at one day, 12 days and 42 days after commencing
the therapy. Thirty-nine OSAHS patients with a mean age of 50.1 years (SD 11.6)
underwent nocturnal PSG and 13 OSAHS patients were randomly assigned to each
follow-up group. The three groups were not significantly different at baseline for any of
the parameters measured.
Sleep architecture was restored (reduction in stage one and increase in all other
stages) after only one night on CPAP and no further improvements were noted at 12 or
42 days. The mean respiratory effort index for the three groups at baseline was 73,
falling to 22 after one night of CPAP, to 17 after 12 nights of CPAP and 7 after 42 nights
of CPAP, which effectively changing the group status from severe OSAHS to no
pathology whilst using CPAP. Baseline MSLT results were not significantly different in
the three groups ranging from 3 to 4 minutes. After one night of CPAP the sleep
latency were significantly improved to six minutes, and further improvement was found
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at 14 days to 9.6 minutes. No further improvement was found 42 days. This early
study provides evidence that CPAP is able to alleviate many symptoms of OSAHS after
just one night; further benefits of the therapy are seen after a few weeks.
Kingshott et al (2000) incorporated all areas measured in the above studies by
evaluating, sixty two patients' (mean age 51 SD11) baseline results of nocturnal
variables, cognitive performance, quality of life and objective daytime sleepiness after 6
months of CPAP therapy. They found significant improvement in nocturnal variables
including AHI (62 SD 33 to 9 SD7 p<0.0001), arousals (63 SD 30 to 21 SD12
p<0.0001), percentage of REM sleep (15 SD 8 to 26 SD 15 p<0.0001). Significant
improvements (all at the level p<0.01) were found in the MWT (27 SD 13 to 32 SD 10),
ESS (13 SD 5 to 6 SD 4), symptom score (24 SD 7 to 9 SD 7), digit symbol test (53 SD
11 to 56 SD 13), PASAT 2 sec (22 SD 11 to 37 SD 13), simple RT (0.32 SD 0.09 to
0.29 SD 0.04) as well as significant improvements in all 8 subscores of the SF-36.
Kingshott et al provided intensive support for CPAP treatment by contacting patients on
days 2 and 21 as well as seeing patients in an outpatient clinic at months 1, 3 and six,
and the mean CPAP use for the six months was 4.8 (SD 2.4) per night.
These studies suggests that CPAP can alleviate both nocturnal and daytime features of
OSAHS after only one night of treatment, that the optimal benefit of CPAP may only be
found with continued use and that these benefits are still appreciable at six months to a
year, however only one night without CPAP therapy can see deterioration on symptoms
associated with OSAHS.
However none of these studies incorporated an adequate control group and the results
of these studies may in part be influenced by placebo effects. As such these results
should be interpreted with caution. Nevertheless they do indicate that improvements of
symptoms are reported with CPAP even after relatively short periods of use.
Controlled trials are seen as a more robust design of investigation and several research
groups have employed these in investigating CPAP and its effect on daytime function.
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Engleman et al have produced several RCTs investigating the role of CPAP in cognitive
and QOL outcomes. An early study (1993) comparing 21 CPAP treated OSAHS (mean
AHI 57/hr) to 16 conservatively treated OSAHS patients (mean AHI 45/hr) in a parallel
trial design. Engleman et al reported that moderate improvements in objective daytime
sleepiness were recorded in the CPAP treated patients compared to the conservatively
treated patients, all re-tested after three months. However both groups showed
significant improvement in cognitive and QOL measures that were not significantly
different from each other. This highlights the need for controlled trials. On looking at
good compliers on CPAP (mean use of >4.5 hrs/night) as compared to the
conservatively treated group, the CPAP group again showed decreased levels of
objective sleepiness and an improvement in mood. However in other domains
improvements were reported in a four-week cross over trial of CPAP and oral placebo
Engleman et al (1994a). This reported that symptom complaint, objective and
subjective daytime sleepiness and levels of snoring were significantly better at the end
of the CPAP treatment limb than on placebo. Further, cognitive function, vigilance and
general health and depression scores were also significantly better improved in the
CPAP limb. Although several of these tests showed learning effects, the study used a
randomised treatment order to control for these effects on treatment analysis. Some of
these improvements seen with CPAP have also been reported in mild OSAHS (5-15
AHI/hr) (Engleman et al 1999). In a crossover trial of CPAP and oral placebo 34
patients, despite a relatively low mean usage of 2.8/h night (SD 2.1) CPAP significantly
improved symptom score, subjective ESS, two of seven cognitive function tasks,
depression scale and five of eight domains on the SF36 in 14 with and AHI <10/hr of
the sample. However patient preference was higher for the oral placebo.
These studies using oral placebo or conservative control methods highlight
improvement in mild to severe OSAHS patients in sleepiness (objective and subjective)
and in a variety of cognitive tasks and QOL outcome measures.
Stradling et al (2000) compared the effect of CPAP and sub-therapeutic CPAP on
daytime symptoms. Sub-therapeutic CPAP (also known as sham CPAP) is achieved by
setting a CPAP machine to its lowest setting (<2 cmH20) and by increasing the number
of holes on the CPAP mask. Hence the pressure received by the patients is not of a
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level that can prevent apnoea and hypopnoea. Using a CPAP machine that does not
have any therapeutic effect quantifies placebo effect (as patients are unaware that it is
not an active treatment). Stradling et al, using a parallel study design compared both
subjective (ESS) and objective (modified MWT) sleepiness and two outcome measures
of the SF36 vitality and energy and the mental component summary score, pre-
treatment and after 29 days of CPAP or sham CPAP. The authors report that the sham
CPAP had no effect on nocturnal sleep apnoea activity. Both groups significantly
improved in subjective sleepiness, and on both the SF36 factors, but the therapeutic
CPAP produced a significantly greater improvement over the sham CPAP. Only the
therapeutic CPAP group improved significantly on the objective measure of sleepiness.
Jenkinson et al (1999) used a similar study design to compare CPAP and sham CPAP
effects on subjective (ESS) and objective sleepiness (MWT) as well as the SF36
questionnaire. The results obtained were similar to that of Stradling (1999), with the
sham CPAP group showing small but significant changes in subjective sleepiness, and
the therapeutic CPAP group reporting significantly improved ESS scored compared to
their baseline and to the sham CPAP group post-treatment. The authors also report
only the therapeutic CPAP group showing significant improvement in objective
sleepiness. The SF36 results showed significant improvements in all 8 domains and
the two summary scores in the therapeutic CPAP group. The sham CPAP group
showed significant improvements in the mental health and vitality domains as well as in
the mental and physical component summary scores.
Montserrat et al (2001) also used sham CPAP and CPAP to compare subjective
measures of sleepiness (ESS), OSAHS symptoms and outcomes on the SF36 and
FOSQ. Both groups showed significant improvement in subjective sleepiness, OSAHS
related symptoms and sub-scores of both the SF36 and FOSQ questionnaires as
compared to their baseline levels, however the therapeutic CPAP group showed
significantly greater improvement in ESS score, OSAHS related symptoms and general
productivity and vigilance scale on the FOSQ questionnaire. After a wash out period of
10 days the sham CPAP group were established on therapeutic CPAP and a greater
improvement in ESS and OSAHS related symptoms was found than when using sham
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CPAP, and these results were similar to those obtained from the original therapeutic
CPAP group.
These studies suggest that CPAP is in fact a suitable treatment for alleviating objective
and subjective daytime sleepiness as well as perceived health benefits. However they
indicate that placebo effects may play a part in the perceived subjective improvement of
symptoms associated with CPAP, and as such results from trials not adequately
controlled, may inflate the subjective improvements in reported symptoms.
Other research groups conducting questionnaire-based studies have shown that CPAP
produces subjective improvements on ESS (Engleman 1994a, Engleman 1999,
Ballester 1999, Keily 1999) OSAHS related symptoms, (Ballester 1999, Engleman
1999), quality of life, (Jenkinson 1997, Weaver 1997a, Ballester 1999, Monasterio
2001) and daytime function (Ballester 1999, Engleman 1999). However some studies
looking at objective daytime sleepiness and/or cognitive ability have found that although
these may improve with CPAP many patients' scores do not return to normal levels.
Bedard et al (1993) suggest that although CPAP significantly improves daytime
vigilance some patients remain more somnolent by comparison to control groups, and
some cognitive tests, especially those relating to executive functions and manual
dexterity still show deficits. Bedard et al hypothesised that persistent cognitive deficits
and daytime somnolence may be a result of long-term hypoxaemic effect on the
brainstem, and as such would not necessarily be reversed the introduction of CPAP.
Valencia-Flores et al (1996) investigated cognitive function and daytime vigilance in
OSAHS patients with varying degrees of hypoxaemia (as measured by oxygen
desaturation levels during sleep without treatment). OSAHS patients were tested on a
battery of cognitive tasks and a single sleep latency test before and after the
commencement of CPAP. The authors grouped patients that showed increased
alertness into baseline non-hypoxaemic and baseline hypoxaemic samples. They
report that OSAHS patients who showed no signs of hypoxaemia at baseline showed
greater improvement on some cognitive functions as compared to those OSAHS
patients with hypoxaemia. Suggesting that OSAHS patients free from hypoxaemia
performed poorer at baseline on the cognitive tests due to their hypersomnolence,
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whereas the hypoxaemic groups deficits were thought to be a combination of both
somnolence and hypoxaemia.
Both the Bedard and Valencia-Flores studies have limitations in that both used small
patient samples and neither used control groups. The Valencia-Flores study was
conducted after only two nights of CPAP therapy and the Bedard study after only six to
ten months, hence one cannot rule out the reversal of these deficits after a longer
period of treatment. However both do report that improvements are seen whilst using
CPAP even if scores do not return to levels expected when no pathology exists.
It is important to note that in many of the studies mentioned not all of the daytime
symptoms associated with OSAHS were improved to normal levels by CPAP. This may
in part reflect the different study designs, level of sleep-disordered breathing in the
patients, the test used to measure sleepiness, cognitive function and daytime function,
or other confounding variables like hypoxaemia. Nevertheless these studies conducted
into the efficacy of CPAP do consistently show that CPAP is effective in reducing levels
of both objective and subjective daytime sleepiness and that subjective measures of
quality of life are also improved.
One aspect that affects the effectiveness of CPAP is patient compliance. Compliance
is a generalised term for patients' adherence to their medical practitioner's advice and
prescription. Compliance can be measured in frequency terms as the proportion of
patients who undertake the regime i.e. 40% of a sample, or on an individual basis as a
proportion of the recommendation observed, i.e. patients take drugs only 70% of the
time.
Compliance with CPAP can thus be defined as the percentage of OSAHS patients
using their machine at the optimal level or as the average nightly use of a given period
of time. This is possible as most CPAP machine have time clocks that can record the
run time of the CPAP. Many of the newer models of CPAP also have the ability to
record the time that the CPAP mask was worn, the time at optimal pressure.
Prospective studies using both objective and subjective measure (with a range of CPAP
use from 1 month to 2 years), report levels of compliance ranging from a mean use of
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2.5hrs/night to 6.5 hrs/night (Krieger 1988, Krieger 1992, Kribbs 1993b, Rauscher 1993,
Engleman 1994b, Pieters 1996, Meislier 1998, Hui 2001, Lewis 2004).
The proportion of patients still using CPAP at 3-14 months issued with CPAP range
from 60 to 80% of populations sampled (Waldhorn 1990, Kreiger 1992, Kribbs 1993b,
Meslier 1998, Pepin 1999). The use of the CPAP machine in the first to third month is a
good indicator of long term use (Kribbs 1993b, McArdle 1999) and good long term
compliance has been associated with pre-treatment OSAHS symptomology (Meurice
1994), high pre-treatment AHI (Kreiger 1992), intensive support (Chervin 1997, Hoy
1999), living with a partner (Lewis 2004), and no or few side effects associated with
CPAP in the first month (Lewis 2004). CPAP related 'side effects' can included mask
discomfort, nasal congestion or dryness, as well as discomfort caused by wearing the
mask straps to tight, mask leak and noise from the machine. Most of these problems
are easily rectified and as such initial support from trained sleep specialist staff is
recommended. It should be noted that subjective use of CPAP might be over reported
(Kribbs 1993b, Rauscher et al 1993) and as such compliance rates may be more
accurate when based on objective data.
Measures of compliance with CPAP are more easily audited than those with other
treatments, for example pharmaceutical therapies. However, while suboptimal, CPAP
use may not be substantially different from patients' use of other treatments. It is
important to recognise that 40 to 50% of patients do not use medications as prescribed
(Ley et al 1998). 70% of patients with obstructive lung disease did not adhere to their
drug regime (Rand et al 1992) and anti-epileptic medication was used correctly in only
39% (3248 days) of days observed in other studies (Cramer et al 1989).
In recent years CPAP technology has advanced and new auto titration machines are
now available. These machines do not give a fixed pressure but are able to provide
variable positive pressure to the upper airway in response to apnoeas, hypopnoeas and
snoring. Fixed pressure machines are set at the highest pressure required to eliminate
the majority of events but low enough not to cause mask leak and irritation. The auto
titrating machines detect each episode of airflow limitation and this is counteracted with
the optimal level of pressure, which can vary from episode to episode. This means
during periods of no airflow limitation that the pressure can be reduced to a minimum
and can ramp up when required.
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Comparisons of patients treated with fixed pressure and variable pressure CPAP
machine have found that there are no significant differences in the AHI, snoring, sleep
fragmentation, subjective sleepiness, or compliance between the two treatments (Ficker
1998, Ayas 2004, Hussain 2004, Noseda 2004). Some studies also suggest that mean
or median pressure is lower and nightly hours usage of the variable machine is higher
than fixed CPAP (Hudgel 2000, Teshler 2000, Massie et al 2003). As the cost of
variable CPAP is currently substantially higher than fixed pressure CPAP, its usage
may be most cost effective for using for CPAP titration, research and in patients who
have severe difficulty in tolerating fixed pressure.
The efficacy of CPAP has been questioned in an early systematic review (Wright 1997).
However since this publication several adequately controlled trials have demonstrated
that CPAP can alleviate both the nocturnal and daytime features of OSAHS. Recent
systematic reviews (Cochrane review 2001, SIGN guidelines 2003) have shown a
growing evidence base that CPAP improves nocturnal and daytime features of OSAHS.
Evidence exists that the effects of CPAP can be immediate, and failure to use the
treatment can see the symptoms of OSAHS return quickly. It has been shown to
reduce mortality compared to non-treated patients (Partinen 1988, He 1988, Marti
2002) and overall compliance with this treatment is good and as such there is
justification for CPAP as the treatment of choice for OSAHS.
CPAP and its effects on driving ability are discussed in chapter two and six.
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1.11 Discussion
OSAHS is a multi-factorial condition with both nocturnal and daytime features. It is a
common condition with wide reaching implications physiologically psychologically and
socially and it's impact and on these is not completely understood. Treatment for the
condition is primarily CPAP although some surgical procedures and intra-oral devices
may be more acceptable for patients with simple snoring or mild OSAHS. CPAP is an
effective treatment, however with 10-16% of patients refusing it after their CPAP
titration (Waldhorn 1990, Krieger 1992), and its ambiguous use in mild OSAHS patients
further research must be conducted to find a better treatment that is acceptable to all
OSAHS, and ideally finding a cure would be desirable in the long term.
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Chapter 2: OSAHS and driving ability
2.1 Introduction to OSAHS and driving
Patients with OSAHS have high rates of motor vehicle accidents (MVAs) (Findley et al,
1988, George et al 1999) and impaired driving performance (George et al, 1987). This
section aims to both review data on real life and simulated driving performance, and
discuss the need for objective fitness-to-drive tests. This review covers literature and
published data to 1999, when the current study was designed.
2.2 Aspects of OSAHS impairing driving
OSAHS patients suffer from a wide range of daytime problems, such as sleepiness and
impaired concentration, which may affect their ability to perform tasks necessary to
daily life. These problems include; attention and visuo-motor performance (Greenberg
1987), memory (Berry et al 1986), intellectual performance (Telavaki et al 1986),
impaired executive functions (Naegele et al 1995), impairments in tracking and reaction
times (George et al 1996b), time-on-task deficits (Dinges and Kribbs 1991) and difficulty
in concentrating (Greenberg 1987).
It is not yet clear whether these deficits are the product of the sleep fragmentation,
hypoxaemia, or both of these. It is most likely a combination of the two. Studies have
shown that disturbing sleep with noise induced arousals can produce sleepiness and
deficits in daytime performance, even after only one night (Martin et al 1996). However,
daytime function correlates better (although still relatively weakly) with the degree of
nocturnal hypoxaemia, rather than the frequency of arousals (Bennett 1999, Kingshott
et all998).
Regardless of the actual mechanisms causing these performance deficits, it may be the
interaction of impaired daytime abilities and severe sleepiness that increases the risk of
motor vehicle accidents in OSAHS sufferers. The safe operation of a motor vehicle
requires alertness, accurate perception, and the ability to judge and react rapidly and
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effectively to external factors. OSAHS patients suffer from both excessive daytime
sleepiness and perform poorly in neuropsychological tests, especially those requiring a
high degree of vigilance and concentration (Bonnet 1985). Therefore, they might be
expected to be at an increased risk of involvement in motor vehicle accidents and have
more near-miss accidents.
2.3 Driving impairment due to sleepiness
OSAHS patients have poor driving abilities, with an increased number of motor vehicle
accidents and, reports of feeling sleepy and falling asleep at the wheel. Several studies
have shown that sleepiness is a major factor in Motor Vehicle Accidents (MVAs) that
occur in the general population.
McCarrt (1996) conducted random telephone interviews, enquiring about sleepiness
and MVAs, with 1000 New York residents. Twenty three percent reported that they had
at some point fallen asleep whilst driving, while 2.8% reported a MVA that was a direct
consequence of having fallen asleep. This was similar to the results of Maycock (1997)
who reported that, of 4621 males that responded to a questionnaire survey in England,
29% admitted to falling asleep at the wheel in the last year. He also reported that 17%
of this population admitted to having a MVA, and tiredness was a contributory factor in
20%, 14% and 7% of accidents occurring on motorways, rural roads and roads in built
up areas, respectively.
In studies, the proportion of accidents attributed to sleepiness has ranged from 1-27%.
For example, Maycock (1997) estimated that tiredness accounted for between 9-10% of
all accidents reported whereas Parsons (1986) reviewed 223 unexplained MVAs and
concluded that 27% of these were sleep-related. Parsons also noted that falling asleep
at the wheel caused 83% of those deaths attributable to trauma.
Further evidence comes from Home et al (1995). They conducted two studies
assessing whether accidents had been caused by the driver falling asleep. From the
first study, which included one motorway and several major and minor roads, they
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found that 606 sleep-related accidents accounted for 16% of all accidents reported in a
5-year period. In their second study (1995), police attending the scene of accidents
completed a short structured sleep questionnaire, regardless of whether the officer
believed sleep was a contributory factor in the accident. On analysis they found that 73
accidents were sleep-related, which accounted for 23% of all the accidents to which the
police were called.
It has been suggested that accidents caused by sleepiness account for between 1-3%
of MVAs in the USA (Pack 1995, Lyzniki 1998). Unfortunately, these sleep-related
accidents seem to be more serious and more often result in high casualty rates. Pack
(1995) estimated that 3-4% of all fatal accidents are sleep-related. This is similar to the
estimate of Summala and Mikkola (1994) who reported that 7% of all fatal accidents in
Finland were due to the driver having fallen asleep, and 3% were due to driver fatigue.
Mitler et al (1988) estimated this rate to be even higher in the USA, at 13%.
Further, Benbadis et al (1999) examined subjective sleepiness levels in a driving
population in the USA. Using the Epworth sleepiness score (ESS) they found that of
526 drivers, with a mean age of 37 (SD 15), 26% had an ESS score over 10, and 2.5%
had an ESS greater than 15. This suggests that a quarter of this driver population
reported subjective sleepiness that could be considered pathological in terms of being
well above the 95th centile of Epworth Score (Johns 1991,1993). These studies
examined sleepiness as a predictor of accidents, but did not separate sleepiness from
likely OSAHS when assessing overall accident rates.
2.4 Characteristics of crashes caused by sleepiness
Accidents caused by falling asleep at the wheel are associated with a high mortality
(Pack 1995). This high fatality rate in sleep-related accidents is not surprising given
that drivers who have fallen asleep will be unable to brake before an impact or before
leaving the road, and so will crash at a greater speed (Home 1992). Investigators at
accident sites can often attribute these fatal crashes to sleepiness by the lack of skid
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marks at the crash site (Pack 1995), although antilock braking systems complicate this
interpretation.
It has also been suggested that as a consequence of falling asleep, a driver is more
likely to cross the edge of the lane onto the verge rather than veer into the path of
oncoming cars. This theory is supported by Sagberg (1999) who found that over 40%
of sleep-related accidents resulted in deviation off the road while 15% resulted in
crossing the centre line. Both Pack (1995) and Garder (1995) also support this
suggestion. Pack found that in accidents related to sleepiness most were drive-off-the-
road type (78%), and Garder (1995) found that 62% of a random sample of motorists
and student drivers reported that on occasions when they fell asleep while driving, they
had at least one pair of wheels off their lane on waking, with the majority of these being
the offside wheels.
Where sleep is involved, these driving-off-road events are probably more common than
other types of crash due to the typical transverse section characteristics of most roads,
which incorporate a camber. This design is used for water drainage and, therefore, the
elevation is higher at the centre line of the road and lower at both edges. Hence, a car
travelling at speed will follow the natural incline of the road and veer towards the edge if
no steering correction is applied (Sagberg 1999)
Although these studies were not specifically investigating driving accidents in OSAHS
sufferers, they are important. They clearly implicate sleepiness as a major cause of
MVAs in the general population, and as sleepiness is often a major symptom in OSAHS
patients, it suggests that sleepiness plays a large part in MVAs in OSAHS patients.
2.5 Evidence of driving impairment in OSAHS.
In an early study using self-report, Guilleminault et al (1978) found that most of their
sample of 50 OSAHS patients reported falling asleep whilst driving, while 54% admitted
to having an accident due to falling asleep at the wheel. This study was amongst the
first to create awareness among doctors and researchers that these road accidents
could be a potential source of morbidity and mortality in OSAHS patients. However, as
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this study did not use a control group it is impossible to say with confidence that the
levels of sleepiness and accidents were elevated.
George et al (1987) used objective accident data obtained from the regional department
of motor vehicles to compare the MVA rates of 27 OSAHS patients and 270 age and
sex matched controls, randomly chosen from the database. They found that 54% of the
controls compared to 93% of the patients had at least one accident and the mean
number of accidents was 2.63 for OSAHS patients, twice that of the control (1.28).
Unfortunately, in their letter to the Lancet, the authors do not report the period of time
covered by the motor vehicle records. Additionally, seven of the patients had not had
their diagnosis of OSAHS polygraphically confirmed, but were included in the analysis
on the basis of symptoms alone. In fact, the authors' note that if these patients did have
another sleep disorder then the results would lose significance.
Findley et al 1988 found that OSAHS patients (AHI >5) had a rate of MVAs seven times
greater than patients attending the sleep centre who did not have OSAHS (AHI <5).
Specifically, 0.41 accidents per driver per five years in the OSAHS group compared to
0.06 in the control group. Findley et al also found that the rate of accidents in which the
driver was at fault was significantly higher in the OSAHS group (0.24 /driver/ 5 years)
than the control group (0.03 /driver /5 years). Further examination of the distribution of
accidents showed more OSAHS patients (31%) had at least one MVA in the five-year
period compared to the controls (6%). This suggests that it was not merely a small sub-
sample of the OSAHS patients who were having a large number of accidents.
Findley et al were also able to compare the accident rates of these two groups to those
of the 3.7 million drivers in the state of Virginia. Again they found the OSAHS group
had a significantly higher MVA rate than the normal population in a five-year period
(0.41 compared to 0.16 per driver). However, the non-OSAHS patient control group had
significantly fewer accidents than the licensed drivers of Virginia.
A further control group (n=30) was obtained and matched to the OSAHS patients for
age and sex. The OSAHS group reported significantly higher frequencies of falling
asleep at the wheel than all three of the other groups. 67% of the OSAHS patients
admitted falling asleep at least once when driving, whereas only 38% of patients without
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sleep apnoea and 30% of the age and sex matched control group reported this. More
striking was the difference in the number of OSAHS patients admitting to falling asleep
at least once a week when driving (24%) as compared to the patients without sleep
apnoea (3%) and the control group (0%).
In an extension to this study Findley et al (1989a), still using objective accident data,
recruited 44 patients with OSAHS, who were classified as having mild (n=16), moderate
(n=17) and severe (n=13) OSAHS on the basis of the severity of their nocturnal
hypoxaemia. They compared the MVA rate of these three groups to that of all licensed
drivers in the state of Virginia and found that all three groups of OSAHS patients
showed at least a two-fold rise in motor vehicles accidents compared to normal
controls. However, only the severe OSAHS group had a statistically significantly higher
rate of MVAs than the Virginia drivers (0.46 vs. 0.16 accident/driver/5 years). The
authors suggest that patients with severe OSAHS are at particular risk. Although this
study did use objective measures of MVA the small number of OSAHS patients and the
lack of a dose response across the severity groups weaken the support for this
conclusion.
Aldrich (1989) and Cassel et al (1990) add further support to the proposition that
patients with more severe OSAHS may be at increased risk of MVAs. Aldrich (1989)
compared reports of sleep-related accidents in patients with an AHI of less than 60 an
hour to those with more than 60 an hour. The more severe patients were twice as likely
to have had a sleep-related MVA (30% for men and 20% for women in the severe
group) as the moderate group (15% for men and 12% for women).
Cassel et al (1990), using a questionnaire administered prior to diagnoses of OSAHS,
found that patients with severe OSAHS, defined as an apnoea index (Al) greater than
20 (n=31) and moderate OSAHS (Al 5-10, n= 31) reported fatigue while driving
significantly more often than patients without OSAHS (Al 0-5, n=10). Although there
were no significant differences in the average mileage of the three groups, those
patients with an Al greater than 5 also reported falling asleep at the wheel at least once
a week more than non-OSAHS patients. In addition, the non-OSAHS group reported
only three accidents and none of these were attributed to EDS whereas patients with an
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Al greater than 5 reported 14 accidents; 11 of which were attributed to EDS. When
asked whether they had reduced the amount they drove in the preceding few years,
and the associated reason, none of the OSAHS patients gave EDS as a reason for
driving less. In fact, the mean distance driven by the three groups, 23,200 km/year was
higher than the German average at that time (15,000 km/year), and the severe OSAHS
group reported driving a mean of 26,400 km/year.
Although there are large differences in the thresholds for sleep-disordered breathing
events used to define OSAHS in these studies, they complement each other as they
report increased driving problems as the severity of the condition increases.
In a larger study conducted by George and Smiley (1999) driving records of OSAHS
patients were compared to those of age and sex matched controls, randomly selected
from the Ministry of Transportation of Ontario (MTO). Four hundred and sixty OSAHS
patients, all confirmed by polysomnography, were divided into three groups; AHI 10-25,
AHI 26-40 and AHI>40, and were compared to 581 controls extracted from the MTO
database. On analysis of the accident rate, 155 of the OSAHS patients and 150 of the
controls had one or more accidents in the preceding five years, giving an accident/year
for the preceding five years as 0.09 compared to 0.07 for the control group. However,
this small yet significant difference was accounted for entirely by the accident rate in the
AHI>40 group (0.11 MVA/year) as the accident rate in the AHI 10-25 group (0.06
MVA/year) and AHI group 26-40 (0.08 MVA/year) did not differ significantly from that in
the control group.
The number of driving related citations for both OSAHS patients and controls was also
analysed. Citations were given for a variety of reasons including speeding, unsafe
driving, failure to stop, improper turns and driving whilst intoxicated. Two hundred and
seventy two OSAHS patients had one or more citations as compared to 240 of the
controls (x2 =32.7, p<0.001), and OSAHS patients had twice as many citations (1.74 SD
3.13 vs. 0.86 SD 1.43 p<0.001) as the control group.
Although this study estimates a slightly smaller accident rate than their previous study,
George and Smiley did use polysomnography to define the severity of these patients.
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The results are thus comparable with those of Findley et al (1989a) and Aldrich (1989)
who indicated higher accident rates in OSAHS. It also suggests that the higher MVA
rate seen in OSAHS patients may mainly arise in the more severe patients.
Additionally, the greater number of citations in the patient group also lends support to
the hypothesis that OSAHS patients have poorer driving performance than controls-
even when the measure is not solely accident rate.
Teran-Santos et al (1999) conducted a case-control study to investigate the relationship
between sleep apnoea and MVA risk. They found that drivers in accidents sufficiently
severe that they received emergency treatment at hospitals in Burgos or Santander,
Spain were more likely to have sleep apnoea than a control group recruited via primary
health-care centres, matched for sex and age. The adjusted odds ratio of having an
MVA was 11.1 (CI 4.0-30.5) 7.2 (CI 2.4 - 21.8) and 8.1 (CI 2.4-26.5) when AH I was
greater than 5, 10 and 15, respectively. They also noted that patients who reported
feeling drowsy just before their accident had a mean AHI of 24 (SD 25) as compared to
drivers who reported being alert just prior to the accident, who had a mean AHI of 13.8
(12). Further interpretation of these results must be cautious as the confidence
intervals (CI) for the odds ratios were wide making it difficult to pinpoint the real impact
OSAHS may have played in these MVAs.
Barbe et al (1998) also investigated MVAs in an OSAHS population. MVA rates for a
period of three years were obtained from subjective reports and insurance companies
for 60 OSAHS patients (47 SD lyears, mean Al 58 SD 3) and 60 age and sex matched
controls (free from OSAHS as determined by previous medical history). The control
group had significantly lower BMI (27 SEM 0.8 versus 33 SEM 0.8 P<0.001), ESS (3
SEM 0.3 versus 12 SEM 1 p<0.001) and had consumed significantly less alcohol at
weekends (13 SEM 3 versus 31 SEM 6 g/d, p<0.05) than the OSAHS patient group.
There were no differences between the groups in the amount of drugs ingested that
could influence driving. The percentage of patients with OSAHS reporting one accident
in the three year period was higher than the control group, and the OSAHS group also
reported a higher mean number of accidents in the same three year period (0.53 SEM
0.1 versus 0.22 SEM 0.06, p<0.05). The OSAHS group reported driving more
kilometres per year (27,305 SEM 2,905 versus 15,695 SEM 1,580 km/yr p<0.01) and,
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after adjusting for this, the odds ratio for having an MVA was OR 2.3; 95th CI 0.97 to
5.33 p=0.06.
Data obtained from these studies show that despite some methodological issues, both
self-reported and objective MVA risk seems to be greater in OSAHS patients, and may
be greatest in those with the highest apnoea/hypopnoea frequency. However, it has
been suggested that some patients with sleep apnoea may under-report symptoms
related to OSAHS, especially sleepiness, either because they lack a normal frame of
reference, or because making such an admission might lead to negative outcomes
(Dement et al 1978).
In order to assess whether this may commonly happen, Engleman et al (1997)
questioned patients (AHI >5) about their subjective level of sleepiness (ESS) and
driving impairment by asking if they had 'had' or nearly had an accident because of
falling asleep. These questions were asked twice, once on initial presentation to the
sleep clinic, before diagnosis, and again after starting CPAP therapy, to retrospectively
assess their pre-treatment impairment. The median ESS scores for pre-treatment rose
significantly from 12 (range 0-24), when assessed at the time of diagnosis, to 14 (5-24)
when reported retrospectively. Driving impairment was initially reported by 23% (n=19)
of the sample, rising to 37% (n=31) after treatment use.
This study confirms that patients underreport these symptoms at the time of initial
presentation, suggesting that the prevalence rate of sleepiness and sleep-related MVAs
estimated in the self-report studies mentioned previously may be artificially low. The
changes in admitted impairment level seen in the study may be due to active treatment
which would allow patients to feel the difference in their daily levels of sleepiness before
and after treatment. Alternatively, it could reflect deliberate under-reporting of
symptoms in an attempt not to risk losing a driving licence. However as patients in the
UK are normally allowed to continue to drive once established on CPAP treatment, any
fear of licence withdrawal would no longer exist, possibly making patients feel more
comfortable about answering these questions accurately.
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Young et al (1997) used participants in an ongoing population study of sleep disordered
breathing to estimate MVA rate. A cohort of 913 (542 men) aged between 30-60
underwent polysomnography to determine their sleep-disordered breathing status
(SDB), and MVA rate was obtained from a state-wide database holding information of
traffic violations and road accidents. Controlling for age and miles driven per year,
Young et al estimate that men with an AHI between 5-15 are four times more likely to
have a MVA in a five year period (OR 4.2,95th CI 1.6-11.3) than those without SDB.
Men with an AHI>15 were three times more likely (OR 3.4 CI 1.4-8.0) to have MVAs
than those without SDB. However, no statistically significant differences were found in
females with SDB. Compared to the male sample without SDB, men with an AHI>15
were 12 times more likely to be involved in multiple MVAs in the five year period (OR
11.9 1.1->25). When both sexes were analysed together (controlled for age, miles
driven per year and gender) they found that an AHI>5 was associated with a 4.6 times
greater risk of multiple MVA.
This study is free from clinic selection bias, employs objective methods for both
quantifying SDB status and MVA rate and indicates that men with even mild OSAHS
are at a higher risk of being involved in at least one MVA. However, as with the Teran-
Santos (1997) study, the confidence intervals are wide, mainly due to the small number
of participants having accidents (167), with only 24 of these having multiple MVAs. If
the true value lies at the lower end of the CI then the real impact of SDB on MVAs may
be small. Conversely, if the true value lies at the higher end, it would suggest that
OSAHS has a greater impact on MVAs than previously speculated.
2.6 Effect of OSAHS treatment on driving
George et al (1995) interviewed 124 untreated OSAHS patients, 35% of whom reported
experiencing sleepiness whilst driving and all of whom reported that the sleepiness was
present during long drives (>60 minutes). Only 17 reported feeling sleepy during city
driving, adding support to those who suggest that monotonous roads, such as
motorways, induce sleepiness. Only one of the 124 patients (0.9%) admitted to having
either an accident or a near-miss accident. In a second part of the study, George et al
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contacted 100 OSAHS patients using CPAP treatment. Of the 65 questionnaires
returned, 72% reported trouble staying awake while 28% admitted to having an
accident due to sleepiness. 97% of these patients reported that their daytime
sleepiness was 'some' or 'a lot better' than before CPAP therapy, and 33% reported
they could and did drive longer without problems. However, as the two groups were not
matched, it should be noted that this could account for the dramatic differences
between the levels of reported sleepiness and accidents.
Further support for an increased accident rate in OSAHS patients comes from Krieger
et al (1997) who compared retrospectively self-reported accidents including MVAs
before commencement of CPAP therapy, and recent accidents at 6 and 12 months after
the start of CPAP therapy. The questionnaire enquired about vehicle, domestic, work
and other unspecified accidents asking for the number of actual and near-miss
accidents that had happened in each time period, and how many of these were related
to sleepiness, fatigue or reduced vigilance. Although they do not report the statistical
differences between each subtype of accident, the authors note that the average
number of actual accidents per patient decreased after treatment (p<0.01) as did near-
miss accidents (p<0.01). The number of real MVAs fell from 46 (49% of all accidents
reported) to 14 (34%) and the number of near miss accidents fell from 505 (75%) to 39
(66%). All near-miss accidents, both before and after CPAP, were related to a lack of
vigilance, while 53% and 33% of the actual accidents were attributed to lack of vigilance
before and after CPAP, respectively (These are expressed as a percentage of all
accidents reported). Although this study employs self-reports, which may be error
prone (Engleman 1997), the statistically significant reduction of all types of accidents
before and after CPAP allows speculation that CPAP may reduce MVAs. This in turn,
may suggest an elevated MVA rate in these patients as a consequence of OSAHS.
Minemura et al (1993) also found a reduction in reported MVA rates after CPAP, in a
very small study: prior to treatment. Initially 42% of the 14 patient group had reported
having at least one accident in the previous 3 years whereas during a year of CPAP
treatment, none of the patients reported any MVAs. The small sample size and lack of
control group again limit conclusions that can be drawn from this study. Engleman et al
(1996) also reported a statistically significant reduction in near-miss accidents when
53
comparing the period five years before treatment and the time since starting CPAP.
They also reported that 77% of their 204 sample reported improvement in their ability to
drive long distances safely after CPAP. However, they did not find significant
differences in actual accident rate.
These studies suggest that OSAHS patients have higher MVA rates than control
populations. Interpretation of many of these studies is difficult due to methodological
problems, particularly small sample size and/or lack of a control group. Additionally,
many studies have not adjusted MVA rate for the average mileage driven per year,
which is a risk factor for driving accidents. However, while these studies have shown
that many OSAHS patients have MVAs, it should be noted that many drivers with sleep
apnoea have not had accidents. Therefore, there is an issue as to whether it is
reasonable to prevent all people with OSAHS from driving. As there is still no
consensus regarding which consequences of the condition cause these MVAs it may be
problematic to prevent driving based on one aspect of the condition alone i.e. AHI
severity.
Currently in the UK, any person diagnosed with OSAHS who is sleepy when driving,
and holds only a non-commercial driving licence, must inform the Department of
Vehicles and Licensing Authority and should be advised by their clinician that they must
not drive if they feel sleepy. HGV (Heavy good vehicle) and PCV (passenger carrying
vehicle) licence holders must stop driving commercially until treatment has been
established. However, as previously mentioned, many patients under-report their
sleepiness levels. If this is due to an inability to recognise internal cues of sleepiness
then advising patients not to drive while sleepy may not be preventative. In addition,
patients with OSAHS may not be aware of the effect the condition has on their driving
ability. Indeed, most studies suggest that only a small number of OSAHS patients have
MVAs compared to controls. A method of screening potentially sleepy people for
fitness-to drive is thus clearly desirable.
54
2.7 Current methods to assess fitness to drive.
In the UK, drivers may continue to drive once established on CPAP treatment, although
in some individual cases the Driver and Vehicle Licensing Agency (DVLA) requires
objective evidence of a person's fitness to drive, especially if they hold a commercial
driving licence. Currently, the Maintenance of Wakefulness Test (MWT) is used in
some centres to establish patients' ability to remain awake during four forty-minute tests
conducted over the day at two-hour intervals starting at 10am. This test assesses
polysomnographically the ability of an individual to remain awake in a soporific situation.
If patients cannot remain awake for 20-40 minute periods when motivated in the test
situation, one may argue that their ability to remain fully vigilant whilst driving may be
impaired. But the MWT test itself does not and cannot assess one's ability to safely
control a vehicle. Staying awake for forty minutes on four separate occasions does not
necessarily mean one could safely handle a motor vehicle for a prolonged period of
time. Indeed, many OSAHS patients can remain awake for these four tests before
being established on treatment, begging the question as to whether they might be
unimpaired. In addition to the fact that the MWT does not directly assess driving
fitness, the test is both time-consuming and expensive to run - during each of the four
forty minute tests, the polysomnographic trace must be monitored constantly by an
experienced sleep technician so that the test can be stopped if the individual falls
asleep.
Therefore, as a method for assessing fitness to drive, this test not only lacks face
validity, but also lacks the validation of what level of sleepiness corresponds with the
inability to safely operate a vehicle. These issues, as well as the fact that most health
boards would not be in a financial position to use the MWT to test the increasing
numbers of patients being diagnosed with OSAHS, inhibits this sleep resistance test as
being a widely used, valid or reliable test for fitness to-drive.
55
2.8 Do patients with OSAHS need to be assessed for fitness to drive?
As previously mentioned in section 2.4, research supports the suggestion that patients
with OSAHS are at an increased risk of MVA, reporting more incidents of feeling sleepy
and falling asleep while behind the wheel. Estimation of the increased likelihood of
OSAHS patients, compared to non-sufferers, having an MVA ranges from twice
(George et al 1987) to seven times (Findley et al 1988). As the condition becomes
more widely recognised in both the medical profession and by the general public, the
numbers of people presenting to sleep centres, and being diagnosed with OSAHS
increases each year. This in turn increases the potential number of accidents that may
be attributed to OSAHS. However, it is still very likely that many people with OSAHS
are not being diagnosed, and it may be likely that some of the MVAs that occur on our
roads each year are a result of this condition, but are attributed to other factors.
Sleep-related accidents are often fatal, and a method for screening patients with
OSAHS seems desirable to reduce loss of life, associated injuries and the cost of the
accidents.
The number of patients attending sleep centres increases annually (BTS/SIGN
guideline 2003), as treated patients are followed up and new patients diagnosed and
added to the follow-up list. However, for most NHS based centres funding does not
match the increase in attending numbers and, as a result, waiting times for both
diagnosis and treatment are also increasing. This has several implications:
Firstly, there are thousands of people awaiting diagnosis who are still able to continue
driving, most of whom may not be aware of the dangers associated with the condition.
Secondly, there are patients who have been diagnosed with OSAHS but are still
awaiting treatment. In many cases patients are advised not to drive if they report
feeling sleepy, but are otherwise allowed to continue to drive. This is not an ideal
situation.
Although there is evidence to suggest that, once established on CPAP for OSAHS
driving ability (as measured by number of MVA's, near misses and sleepy spells behind
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the wheel) returns to a normal level, there is still no evidence that this level of ability is
maintained over years of treatment. Also, one must not forget the consequences for
patients who are unable to use or tolerate CPAP treatment, and hence are often
untreated.
Taking all these factors into account it would be highly desirable that a tool which is
objective, reliable, re-usable (on potentially several occasions), and can accurately
measure the main aspects of driving (tracking and visual searching) is developed and
employed to try to identify those patients with OSAHS who are at risk when driving.
2.9 What aspects of driving need to be analysed for fitness to drive?
As mentioned in section 2.2 people with OSAHS perform poorly on most aspects of
cognitive testing, showing reduced abilities in vigilance, thinking, perception, memory
and perceiving new information. This, coupled with evidence that they also perform
poorly in psychomotor tests that require high levels of sustained attention and
concentration (Kales et al 1985b, Findley et al, 1986), and the diurnal hypersomnolence
that patients often experience, adds support to the hypothesis that OSAHS patients
could be impaired in their ability to safely control a motor vehicle.
However it is still not evident which aspects of the condition, (sleep disruption or
hypoxaemia) cause these driving impairments, and it is not known whether each
OSAHS patient's driving is impaired. It is not ideal to assess each of these cognitive
areas in isolation to determine a person's fitness to drive, as all of these abilities are
required to safely operate a motor vehicle. Therefore, it would be advantageous to
assess actual driving performance. This can be done by splitting driving into its
component tasks;
Tracking: this involves the person's ability to accurately perceive the road in front of
them and manoeuvre the vehicle appropriately. To do this they must be aware of the
contour of the road and any upcoming changes in road layout i.e. from straight to corner
to chicane, and be able to apply the correct amount of steering correction.
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Visual search: this involves a person's ability to search each area around the vehicle
i.e. red lights, people stepping out from the kerb, cars behind speeding. This
component involves reaction time, as many of these incidents are unpredictable and
require immediate and effective action.
Speed control: this involves a person's ability to maintain the speed of the vehicle as
regulated by both speed limit and road conditions.
However, one aspect often attributed to actual MVAs and near miss accidents is
sleepiness, both of feeling sleepy and actually falling asleep at the wheel. This cannot
be assessed directly in terms of a component of driving but is measured through
presence or absence of sleep spells as reported by the driver or actually measured
sleep episodes while driving. The ability of drivers to acknowledge sleepiness was
supported by a study comparing driving ability on a car simulator with driving
performance after a nap, caffeine drink, or placebo caffeine drink. Home and Reyner,
(1996) found that normal subjects who were drivers were always aware of the presence
of sleepiness whilst driving and concluded that it would not be possible to fall asleep at
the wheel without noticing this.
However, this study was conducted on non-OSAHS subjects, and, due to the fact that
many OSAHS patients under report their levels of sleepiness, (perhaps because of the
loss of a normal frame of reference following years of sleepiness), this may not be
applicable to OSAHS patients. A more practical way might be to compare subjective
sleepiness before and after a drive with the use of a state questionnaire like the
Karolinska sleepiness scale (Akersdedt and Gillberg, 1989). Alternatively, one could
take a subjective measurement of sleepiness during a driving performance as Home
and Reyner did (1996). However, as this requires the subject to internalise how they
feel and then scale their sleepiness level by verbal statements, it may in turn act as a
stimulus and as such may cause sleepiness to be under-reported. Although it has
limited practicality, the Road Transport Research Laboratory has monitored EEG during
a driving task. Again, this represents a data rich research resource, but is an
expensive, labour-intensive and time consuming option, as well as inhibitory for the
driver. There is also a subjective element when deciding which aspects of the EEG are
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significant. Therefore, the methodology of fitness to drive tests will essentially be
determined by which aspects can be measured.
2.10 Objective methods of fitness to drive
2.10.1 Real life driving tests
One method of screening OSAHS patients would be to test them in real life driving
situations. However this method has several limitations, not least of which is the cost;
large patient numbers, numerous re-tests for each patient, employee costs
maintenance of suitable cars and insurance are almost sufficient to exclude this as a
viable tool to assess fitness to drive in OSAHS patients, at least at the current time.
There is also the issue of who should be directly assessing these patients. It may
require several disciplines including sleep physicians, technicians, psychologists and
DVLA trained testers. There would have to be several places in the country that would
be able to provide these services, as a central agency would necessarily involve more
travelling for patients in outlying areas. Although ethical guidelines of acceptable
practice would have to be drawn up, real life driving would not give a rigorously
controlled assessment, and any such test could face potential legal and financial
challenges.
The natural testing of a person's reaction to their surroundings (for example by
incorporating a test of reaction time and/or possible dangerous situation) would also be
difficult without placing the tester and patient in danger. It would not be reasonable on
safety grounds to ask testers to allow a potentially dangerous situation to progress
before they intervened (by applying steering correction, or braking).
However, the main factor inhibiting real car driving as a tool for assessing fitness to
drive is the difficulty inherent in objectively and validly assessing tracking and visual
search, the two components of driving. Establishing whether the subject is accurately
performing a visual search of the surroundings is not easy to quantify, despite EEG and
tracking/steering data from highly equipped vehicles, driving on empty roads.
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Therefore, it is unlikely that real time driving would be the first choice to assess fitness
to drive.
2.10.2 Driving simulators as a method to assess fitness to drive.
Driving simulators might provide a safer and more reliable way to objectively measure
the two main aspects of driving performance - tracking and visual search - as well as
being able to assess sleepiness as a factor in MVAs. The two main advantages that
driving simulators have over other testing methods is that they are safe and can be
specifically designed to incorporate the aspects one wishes to analyse.
Many studies measuring driving ability on patients with OSAHS also include data from
patients diagnosed with narcolepsy, another sleep disorder which produces diurnal
hypersomnolence. As this thesis is designed around the validation of driving simulator
in OSAHS patients and does not include narcolepsy patients, results concerning this
other sleep disorder will not be mentioned unless the data also incorporates results
from OSAHS patients.
One of the initial "driving simulators" used to assess driving performance in patients
with OSAHS is the Steer Clear test (Findley et 1989b). This is a PC based vigilance
task - not a true simulator at all - which depicts a bird's eye view of a two-lane road, a
car and intermittent obstacles (cattle or American Steers- hence the name). As part of
the simulation, the car progresses down the lane (going from the bottom of the lane
towards the top). Steers appear on both lanes of the highway at irregular intervals of
between 2 seconds and 2 minutes. The obstacle free period of up to 2 minutes
increases the monotony of the test. Subjects must move the car to the other lane when
a steer appears in their lane. Subjects alternate the position of the lane by pressing the
space bar on a standard computer keyboard. If the subject is unsuccessful in changing
lanes in time they hit the steer and they are automatically placed back at the beginning
of the left hand lane. They also return to the beginning of the left hand lane if they
successfully travel to the top of either lane without hitting any steers. Patients are
generally given a one-minute practice run before commencing a 30-minute drive in a
darkened room.
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Several studies have utilised the Steer Clear test and found significant differences in
the performance of OSAHS patients and matched controls, as well as evidence to
support changes in performance after CPAP treatment.
Findley et al (1989b) compared 12 OSAHS patients (nine men) with a mean age of 50
years (SD 14) and a mean apnoea Index of 55 (SD 32)/hr to 12 age and sex matched
controls (mean age 45 years SD 15) with no history of OSAHS. As suspected the
OSAHS patients hit significantly more obstacles than the control group (44 SD 52 and 9
SD 7 respectfully). Findley et al also compared six patients with pre-treatment
desaturations of 61 SD 33/hour of sleep, on SteerClear after treatment. The paper
does not state the length of time patients received CPAP treatment. They found that
post-treatment desaturations were reduced to 3 SD 2 per hour of sleep on CPAP and
again found significant differences in the number of steers hit, falling from 29 SD 19 to
13 SD 8. The normative data established from a later study by Findley (see below)
(1995), brings these six patients from the category of poor to normal score range.
This change in performance by treatment was reproduced in a later abstract by Findley
et al (1992). Twelve patients, with a mean oxyhaemoglobin desaturation index of 64
SD 8 per hr of sleep before treatment, hit 3.7 SD 0.6% of obstacles on the steer clear
test. After 3 to 5 months of CPAP treatment patients' oxyhaemoglobin desaturation
levels dropped to 2 SD 1 per hour of sleep, and they hit significantly fewer obstacles on
steer clear (1.4 SD 0.3%) than before treatment.
In a further study Findley et al (1995) compared 62 (53 men) OSAHS patients, as
defined as an AHI >5 (with a mean AHI of 51 SEM 4), with a group of 12 age and sex
matched non-OSAHS patients who had been referred to their sleep centre for
symptoms of OSAHS, but who had an AHI <5. A group of ten volunteers, who showed
no symptoms of hypersomnolence, were also matched to the OSAHS group. There
were no differences in age between the three groups, with the mean age of the OSAHS
patients being 51 (SEM 1). Normative data was assimilated from age and sex matched
controls (free from any sleep disorder) in this study. A normal score was reported as <
1.8% obstacles hit, a poor score as >1.8% but < 4.5 % obstacles hit, and a very poor
score as > 4.5% obstacles hit.
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The OSAHS patient group hit significantly more steers (4.4% SEM 0.6%) than both the
non-OSAHS patients (1.4 SEM 0.3%) and the volunteer group (1.2 SEM 0.3%). When
the OSAHS patient group were split into mild (n=41) moderate (n=13) and severe (n=8)
cases (based on oxyhaemoglobin desaturation rates), the severe group hit significantly
more steers than the other groups.
Interestingly, Findley also found significant mild to moderate correlations between
performance on Steer Clear and the percentage of steers hit and desaturation index
(r=0.55, p<0.01); oxyhaemoglobin desaturations per hour (r=0.50, p< 0.01) and AHI per
hour of sleep (r=0.29, p<0.01), however, it is notable that these relationships only
explain a maximum of 30% of the variance in performance. These relationships add
some support to the belief that SteerClear might be measuring vigilance.
The study also included data from ten untreated patients with narcolepsy (3 males),
who were age and sex matched with 10 patients who were not diagnosed with
narcolepsy, but who had been referred to the authors' sleep centre with symptoms of
daytime sleepiness. Both groups had AHI<5. There was also a third volunteer group
matched to the narcolepsy patients for age and sex, who had no previous symptoms of
excessive daytime sleepiness. These three groups performed Steer Clear and the
narcolepsy group hit significantly more obstacles than the non-narcolepsy patients and
the volunteers (7.7 SEM 3.2%, 1.2 SEM 0.3% and 0.9 SEM 0.3% respectively).
Patient groups (OSAHS (n= 62) and narcolepsy (n=10)) were categorised into normal
(n=22), poor (n=26) and very poor (n= 22) performance groups (see above for cut of
values). The authors were able to obtain driving records for 21 of the normal
performance group who had 1 accident in 5 years (0.05 acc/driver/ 5yr). These were
compared with driving records for 25 of the poor performance group who had 5
accidents in 5 years (0.02 acc/driver/5yr) and 21 of the records for the very poor
performance group who had 8 accidents in 5 years (0.38 acc/driver/5yr). Thus, the very
poor performance group not only hit significantly more obstacles during the steer clear
task, but they had a significantly higher MVA rate than the normal performing group.
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Although these results are hard to interpret, as both sleep disorder groups are analysed
together, they serve to show that SteerClear does seem to differentiate between sleep
disordered patient groups known to have high incidences of excessive daytime
sleepiness, and control groups. It further differentiates between people with good
driving abilities in real life (few accidents) and those with poorer abilities (a higher
number of accidents).
Barbe et al (1998) looked at MVA rate subjective sleepiness and vigilance as measured
by SteerClear and a PVT (see section 2.5 for participant details). Not only did they find
that the OSAHS group had significantly more MVAs in a three year period than the
control group, but that the group performed significantly poorer on both SteerClear (2
SEM 0.5 versus 0.4 SEM 0.1 % hit, P<0.01) and the PVT (measuring reaction fatigue) -
0.04 SEM 0.007 versus -0.03 SEM 0.004 p<0.07. Although they did not find any
correlation between SteerClear and the number of MVAs reported, this is one of the first
studies to report performance decrements in both simulated and actual MVAs in a case
controlled study.
Other studies have also shown that SteerClear is sensitive to change in performance
after treatment (Findley et al 1991, Engleman et al 1994a, Findley et al 1999) showed
that performance on the SteerClear simulator can deteriorate with time on task in
narcoleptic patients, with a trend towards this in OSAFIS patients.
SteerClear does seem to show performance differences between untreated OSAHS
patients and healthy non-OSAHS matched controls, and this performance deficit does
seem to be reduced once treatment for OSAHS is established.
However, this test is not a driving simulator, but would more accurately be described as
a vigilance test. It does not test reaction time and it requires only one action to be
performed- very different to the actual experience of driving. Driving requires multiple
tasks to be performed in tandem and, as such, any driving simulator trying to emulate
real life driving, with the aim of providing a method by which to assess fitness to drive,
must incorporate a divided attention task. SteerClear also lacks face validity for a
driving simulator. It does not incorporate any features of real driving and it lacks a
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steering wheel and foot pedals. More basically, the test is performed with a bird's eye
view on a continually straight road that does not allow for any tracking or any real visual
search. As such it would be hard to justify to patients why their driving licence was
being suspended on the basis of this task. Nevertheless, SteerClear is an important tool
for measuring vigilance, and is widely used. However, although vigilance does play a
major role in ability to safely control a vehicle, it is not the only psychocognitive factor
involved and to test fitness to drive one must test the other areas of psychocognitive
and psychomotor skills required.
A second driving simulator designed by George et al (1993) is the Divided Attention
Driving Test (DADT). This simulator consists of a PC screen that is connected to a
steering wheel with mounted buttons, which is in turn interfaced with the computer. A
screen display taken form the George et al (1997) paper is shown in figure 2.1 below.
Figure 2.1; Screen display of the DADT simulator




9 Position Target Digit -> 2
The DADT requires subjects to divide their attention between two tasks.
The visual task requires subjects to monitor the single digits displayed in the four
corners of the screen. The digits from 0-9 are programmed to change in a randomly
appearing pattern around the four corners. At the beginning of the simulation the
subjects are given a target number, which the authors standardised as the number '2'.
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This target number is displayed for anything between 5 and 15 seconds. When it
appears in one of the four corners subjects must react by pressing a button mounted on
the steering wheel. Four buttons, corresponding to the four digits on the screen, are
mounted on the steering wheel roughly at the 10 o'clock and 2 o'clock positions so that
the thumbs can easily reach them.
The tracking task used in the DADT requires the subject to keep the cross hair position
indicator within the area of the tracking box. The cross hair, which represents a car,
travels at a constant forward speed. However, to increase the difficulty of this task, the
DADT employs a subcritical tracking task. In a subcritical tracking task subjects control
an unstable element that, in the case of the DADT, is represented by pseudo-randomly
appearing gusts of side winds. This results in the lateral shifting of the cross hair, and
requires a steering correction by the subject to maintain their position in the tracking
target box. If no steering wheel movement has been detected for 30 seconds, the
subject is assumed to have fallen asleep and a buzzer sounds. Neither accelerator nor
brake is required for the DADT task.
The DADT task is initially tested on subjects in six five-minute blocks with a period of 2
to five minute intervals in between each run. This allows a practice period for the
subjects, but also allows for the establishment of a learning curve.
To determine if the DADT is sensitive to driving impairment, George et al (1996b)
compared driving performance in ten (8 males) healthy sleep disorder free subjects
(mean age 45 SD 6yrs) under control (normal drive) and intoxicated (drunk) drive.
Alcohol was used as a comparative impairment agent to sleepiness, as there is a blood
alcohol level over which driving ability is impaired and driving illegal. Subjects were
tested twice each day, morning and afternoon, and conditions were counterbalanced to
reduce any order effect. On the control days subjects drank 300ml of grapefruit juice
over a thirty minute period and then performed the DADT one hour after completion of
the drink.
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On days when the subjects received alcohol they were given 0.75g/kg of alcohol mixed
through with grapefruit juice, which again was drunk over a thirty min period and testing
commenced on the DADT one hour after it was finished. For the afternoon trial,
subjects' alcohol dose was adjusted according to the first blood alcohol level and the
authors aimed for a blood of 80 to 100mg/dl. The mean blood alcohol level for the
subjects was 95 SD 25 mg/dl. Hence, not all subjects were legally impaired; the current
legal limit in the UK being 80 mg/dl.
There were significant differences between the normal and alcohol conditions in both
the tracking error (p, 0.001) and the visual task (p, 0.05), with both tasks impaired
following alcohol. Out of bound events increased from 0.5 SD 0.7 times under normal
conditions to 15 SD 22 times following alcohol. Although the authors do not report the
values, they do note that there was an increase in missed and incorrect responses for
the visual task from the control to alcohol condition.
Having shown that the DADT could detect impaired driving performance George et al
(1996a) compared the performance of 21 OSAHS patients (AHI 73 SD 29) with 21 age,
sex and driving experience matched controls (AHI 3 SD 6). The OSAHS groups showed
significantly greater tracking error. The mean tracking error for the OSAHS groups was
228 SD 145cm compared to the controls which was 71 SD 31cm(p=1x10"9), with over
half of OSAHS patients doing worse on the tracking task than the worst control subject.
The OSAHS patients' even performed more poorly on the tracking task than the original
alcohol impaired controls (228 cm vs. 161 SD 11 cm). The control group maintained a
steady performance in the tracking task over the 20 minute task, while the OSAHS
patients (as a group) were consistently worse than the controls at all times within any
given 20 minute run, regardless of time of day the test was done.
With the visual task element, average response times for digit recognition were
significantly quicker in the control group (2.9 SD 0.8) than the OSAHS group (3.3 SD
0.8), and the control group (38 SD 2.5) responded to the target digit correctly
significantly more times than OSAHS patients (36 SD 4.2). There was much more of an
overlap in these two groups with the visual task than the tracking task. The authors do
not report how the OSHAS patients compared to the original alcohol impaired controls.
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Out of bound events are recorded when the position indicator crosses a lane boundary.
The OSAHS group recorded significantly more (12.6 SD 20) out of bounds events than
the controls (0.1 SD 0.3). Further, due to a lack of steering correction for 30 seconds,
three subjects in the OSAHS group were assumed to have fallen asleep. This occurred
twice in one patient, thrice in another and six times with the worst patient, which may
have resulted in the subject sleeping through 15% of the driving simulation.
Interestingly, the authors note that while over half of the OSAHS patients performed
significantly worse than the control subjects, a number of them did as well as or even
better, than the control subjects. This is encouraging in that the simulator appears to be
measuring an actual element required in real life driving. Many of the previous studies
in section 2.4 confirm that it may only be a sub-sample of OSAHS patients who are at
increased risk of MVA's.
In an extension of this study, George et al (1997) re-tested 17 of the OSAHS patients
on overnight polysomnography, MSLT and the DADT. Eighteen of the control subjects
were also re-tested on the MSLT and the DADT. As these patients were OSAHS free
and were still free from any associated symptoms, it was assumed that overnight
polysomnography would not have been statistically different on a second night of
testing. Patients underwent their polysomnography night and subsequent day of testing
between 1-12 months after establishment on CPAP (Mean 9.2 SD 4.2). The control
group underwent the MSLT and DADT between 2-12 months (mean 8.4 SD 3.4) after
initial testing.
Before CPAP treatment, OSAHS patients had significantly more micro-arousal's,
awakenings, and had a greater AHI than the original control polysomnography studies.
After commencement of CPAP there were no significant differences in the overnight
sleep measures between the CPAP-OSAHS group and the control group.
This trend was followed with the MSLT changes. Before CPAP treatment OSAHS
patients had a mean MSL of 7.2 (SE 0.8) minutes compared to the control group, which
had a mean of 12.3 (SE 0.9) minutes, whereas post CPAP patients mean MSL
increased to 13.2(SE 0.8) minutes and was not significantly different from the controls.
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There was no significant change in the MSLT results for the re-test of the MSLT in the
control group (Mean 12.9 SE 0.8) minutes.
Both groups were given practice trials on the DADT (six 5-minute tests) on each testing
day. There were no differences in the performance of control subjects on either the
tracking or visual search task, for both within-test learning and practice trials (from initial
trial to re-test). There was also no difference in the OSAHS group for both within-test
learning and practice trials, although the magnitude of tracking error was significantly
higher (p<0.001)-pre CPAP treatment. The OSAHS patients learned at the same rate
as the controls on both test tasks. This provides evidence that there is little learning
effect in DADT test and, as such, shows a good level of test-retest reliability.
The authors compared changes in performance of the two groups. They calculated this
by subtracting the mean outcome values of test one from two (i.e. retest score of
controls minus initial score of controls) for both groups, and then analysed the
difference in changes between groups. The control group showed no significant
changes in either of the DADT test tasks, or in the number of out of bound events.
The OSAHS patients showed significant improvements in performance relating to
tracking error (mean difference 106 (95th CI 75-135cm)). In fact only one post CPAP
OSAHS patient did not improve to the control range for tracking error. Also observed
were significant improvements in the number of correct responses (1.2 CI 0.4-1.9),
number of missed responses (1.7 CI 0.9-2.3) and number of out of bounds (10 CI 7.9-
13.6). However, reaction time did not improve (0.1 CI 0.3-0.2s).
It should be noted that the authors did not enquire about real MVA's and near misses in
the two groups, and so it is not possible to determine if the improvement in simulated
performance was mirrored in real driving, or in fact if the OSAHS group prior to
treatment had an increased level of the MVA's/near misses as compared to the control
group.
The DADT has shown that it is sensitive to changes in driving performance, as is shown
by the changes in the controls from normal to intoxicated and in OSAHS patient's pre
and post CPAP treatment. It seems sensitive to the differences in driving performance
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between control subjects without sleep disorders and untreated OSAHS patients. It
also seems to show an improved driving ability in OSAHS patients on CPAP treatment
who, by measurement of nocturnal sleep measures, are similar to that of non-OSAHS
sufferers. As it is PC based and the equipment required to use the machine (steering
wheel) can be easily purchased and adapted, it is does appear to be functional,
affordable and reliable for re-test situations.
However, much like the Steer Clear Simulator, it lacks face validity with its bird's eye
view and screen layout. Although the tracking task does seem to be sensitive to
impairment in driving ability, it does not simulate real driving in that the subject does not
need to correct steering as a function of the oncoming road layout, but instead as a
function of lateral movement caused by the "side wind". Of course positioning oneself
laterally in a safe area of the driving lane is essential for safety, but so is the ability to
maintain this safe position while controlling the speed at which one travels forward, and
it is not possible to measure this ability with the DADT. Also, the DADT does not
incorporate any chicane or changing element in oncoming road layout. This also
reduces its face validity as a measure of real life driving, as most roads, other than
possibly motorways, will not be so regular in layout.
Additionally, the visual search element of the DADT, requires the subject to react when
a number appears in the corner of the screen, and is therefore more a test of vigilance
and reaction time, as commonly monitored by other psychomotor tests like the
psychomotor vigilance test - it does not reflect real life driving. The type of visual
search required when actually operating a motor vehicle is much more complex,
requiring the person to be constantly checking other items such as their speed, looking
for pedestrians, traffic lights and the manoeuvres of cars in front. Therefore, the DADT
visual task may be too simplistic to actually measure one's ability to perform the visual
task required when driving.
In summary, the visual presentation on the DADT does not resemble a real life road
layout, it lacks foot pedals to control speed and it does not represent a realistic visual
search task. The suspension of patients' driving licences on this basis might be
questioned.
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The DADT appears to be a good tool to measure changes in certain aspects of one's
fitness to drive, and it showed promise for research to assess CPAP related
performance improvements. However, it does not seem to be an ideal tool to use,
especially as the main goal of a driving simulator is to assess fitness to drive- and
conversely to suspend driving if performance is poor.
In Sweden, Haraldsson et al (1990) created a computerised driving program to be used
in conjunction with the advanced Swedish Road and Traffic Research Institute's
simulator. This driving simulator is state of the art technology and is based in the front
of the cabin of a SAAB 900 car. The shell of this car is mounted on a moving base that
allows the whole car to move laterally and the nose of the car to raise and lower. It is
fully interactive with every action performed by the driver, which simultaneously feeds
into a computer. This in turn updates the visual representation and causes momentum
in the steering wheel. The simulator is surrounded by three colour TV projectors, which
give a wide-angle view, showing a real life view of a two-lane road. It is also equipped
with a sound system which emulates engine and wind noises.
Haraldsson et al developed a monotonous driving task in which subjects drive the
vehicle at 55mph in a one lane, narrow (3.5m) curving road at simulated twilight.
Subjects also had to respond to flickering quadratic shapes that appeared in the front
view TV in one of six equally distributed positions along the top of the screen. The
stimuli either appeared as red/green requiring the subject to brake immediately (this is
used to calculate reaction time) or yellow/black (not used to calculate reaction time)
when the subjects had to press a signal button as fast as possible. The yellow/black
stimuli appeared four times more often during the 90minute drive than the red/green.
The quadratic stimuli (regardless of colour) appeared in intervals of 1- to 81 seconds at
an average of 40 seconds. This design was the basic driving task. A second protocol
was developed in which an additional signal button was triggered when steering wheel
movement was smaller than 1° for two seconds.
Fifteen male OSAHS patients and ten male control subjects of similar age (OSAHS
patients mean age 54 vs. controls mean age 55years, with regular driving experience of
average miles per years 28,000 vs. 21000km) were recruited for the study. The authors
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do not report any respiratory disturbance index. However, the patient group
complained of symptoms of heavy snoring sleep disturbance, excessive daytime
sleepiness and hypersomnia while driving, recurring almost always or often. The
control group were free of these symptoms although some did report some snoring.
Ten patients and 6 controls were tested on the basic drive, while 5 patients and 4
controls drove on the second driving protocol. All subjects were given a 15 minute
practice session on the simulator before being served lunch, and then were given
another 10 minute practice immediately before the actual drive.
Overall, the OSAHS patients' performance was poorer than the controls' regardless of
which program they drove on. Although both patients and controls were asked to drive
for 90 minutes, three of the patients gave up within an hour due to sleepiness and,
therefore, the average test period was shorter for the patients (77 minutes) than for the
controls (87 minutes). The driving programs allowed analysis of lateral position
deviation (LPD) which is the deviation of the car from the straight road line (tracking)
and break reaction time (BRT), which is the time it takes to press the break when the
appropriate stimuli appear visual search. It also recorded the number of times they
drove off road. The LPD was sampled twice per second and the standard deviation
was calculated every 5 minutes. The number of "off road" episodes was also recorded.
The OSAHS patient group performed significantly more poorly on all three-outcome
measures, regardless of which driving program was used. Eight of the OSAHS drivers
had off road episodes with the total number of off road events being 101, where as only
one control subject went off road twice. Overall the OSAHS group had significantly
increased reaction times (1.89 SD 0.57 seconds) and deviated more from the straight
line (LPD 0.39 SD 0.10) than the controls (1.31 SD 0.2, 0.29 SD 0.05, for reaction time
and LPD respectively). This was also the case when the groups are split into the two
different driving programs. The average 90th centile of the BRT of patients was 1.2
seconds longer than the control patients. This would mean that in real life, when driving
at 55mph, they would take an extra 30 meters to stop.
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Haraldsson et al (1991) re-tested two of the patients and five controls and reported no
change in performance on the outcome measures. This suggests the simulator has
test-retest reliability. They then re-tested the 15 patients three months after under
going the UPPP surgery for treatment. Significant group improvements were found for
LPD, BRT and the number of drive-off-road events (all p<0.05). The average
improvement of the 90th percentile BRT corresponded to a reduction of stopping
distance of around 20m driving at 55mph (although three patients were classed as
treatment failures due to their subjective feelings of non-improvement of symptoms,
patients showed no improvement in any of the driving outcomes on their postoperative
drive). Nevertheless, as a group there were no significant differences between the
postoperative driving outcomes for the patient and control groups for BRT and LPD (for
both mean and 90th percentile). In a further continuation of the study (Haraldsson et al
1995a), 13 of the patients and the five controls were then re-tested an average of 45
months (range 35-49months) after the UPPP. All thirteen patients subjectively reported
reductions in the number of sleepy spells occurring while driving and that they felt more
vigilant whilst driving. In addition, their level of EDS had significantly reduced
(measured on a visual analogue scale). The improvement of performance on the LPD,
BRT and the number of drive off the road events were still maintained at 45 months
postoperatively, with the control and patient group showing no significant differences
between performances.
These studies had small sample size, the presence of OSAHS was based on daytime
PSG with the Al not reported by the authors at the 45-month mark, and UPPP is no
longer considered a first choice of treatment for OSAHS. Nevertheless, these studies
highlight that the simulator is sensitive to the differences in driving performance
between untreated OSAHS patients and OSAHS free controls, as well as being
sensitive to treatment interventions. Although they do not report any objective
improvement in real life driving (i.e. reductions in actual number of accidents etc), they
do support the hypothesis that simulators may be sensitive to driving impairment in
untreated OSAHS patients and as such, could provide an effective tool in measuring
fitness to drive.
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This true simulator has obvious advantages over both SteerClear and the DADT. With
the far superior design of the car mechanism and the visual display it would be hard to
improve on the look and feel of the simulator. Furthermore, it is sensitive to the
differences between the two groups in terms of lateral performance and brake reaction
time. However, even this simulator is not a practical tool for assessing fitness to drive.
This Swedish simulator has good face validity, but it still employs a visual search task -
a flickering quadratic shape that does not relate to normal driving. This simulator may
have improved characteristics over the DADT, as the response to these stimuli is to
depress the brake pedal rather than a signal button. A more realistic target in the path
of the car could also improve its realism.
The most negative aspect of this simulator as a widely used, realistic and objective tool
for the assessment of fitness to drive is the fact it is so high tech and expensive. The
simulator is the property of the Swedish Road and Traffic Research Institute, which
uses the simulator for multiple tasks including training of drivers, research into road and
traffic solutions, and assessing young drivers. Just like real world driving tests, it would
be prohibitively expensive to run and maintain, and staff would have to be specially
trained to test on it. Also, as a tool to assess driving ability, there would need to be
many such simulators based around the country, indeed possibly several per site, to
ensure that the waiting list for tests is short enough that is does not mirror the waiting
lists for diagnosis or treatment. Thus this advanced simulator would also have
limitations in a clinical laboratory setting for the assessment of fitness to drive in
OSAHS patients.
Results from each of these simulators have helped inform the research community
about what aspects of driving need to be assessed and, indeed, the DADT and the
Swedish driving simulator have both tapped into some of the requirements. Therefore,
the ideal driving simulator might incorporate some of these features, as well as adding
or refining certain tasks.
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2.11 Development of the AusEd driving simulator
The AusEd driving simulator was designed as a laboratory based tool to assess fitness
to drive in patients with the obstructive sleep apnoea/hypopnoea syndrome. The
simulator was designed in collaboration between the Royal Prince Albert Hospital
Australia (Aus) and the Department of Sleep Medicine (Ed) Edinburgh, Scotland.
The simulator is PC based and incorporates a steering wheel and, an accelerator, and
brake pedals. It requires a 19-inch computer screen, on which a two-lane road, with
road marking posts and side verges, is visible. A speedometer is also situated on the
top left-hand side of the screen. The simulator was designed to be non-stimulating to
increase the likelihood of attention lapses or brief sleeps. It simulates a night time drive;
hence, the sky and horizon are pitch black.
The AusEd simulator has advantages over the views of the Steer Clear and DADT tests
as it incorporates a first person perspective view of the road layout. There is no car
representation on the screen.
Picture 2.1: Patient view of AusEd screen
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Picture 2.2: AusEd computer set-up
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For the AusEd tracking task, subjects must keep their position in the middle of the left-
hand lane. The road layout changes between monotonous periods of straight road (five
minute blocks) and the more demanding chicane (two minute blocks) layout. This
mimics real life driving, as the subject must be aware of the upcoming changes in road
layout to be able to adjust steering correction and remain in the lane. Unlike the DADT
and the Swedish Road and Traffic Research Institute simulator the AusEd simulator
does alert the driver if no steering correction is applied. As one outcome of the
simulator was to measure the number of driving-off-road events and crashes, a buzzer
or alerting device sounding after a period of inactivity may alert a driver on the cusp of
inattention. This stimulus may be enough to allow them to regain control of the vehicle
and prevent and off-road event from happening. In real life driving (except cars with in-
car attention devices), there is no beeping or buzzing if no steering correction is
applied. In the AusEd driving task, if no steering correction is applied the simulator is
designed to drift towards the left-hand edge of the screen. When this hits the perimeter
of the screen the simulation temporarily stops, the word crash appears on the screen,
and a loud buzzing sound is heard. Only after a crash event does the AusEd simulator
alert the driver.
The visual task element of the AusEd task requires drivers to bring the vehicle to an
immediate stop when a truck appears in the distance in front of them. This corresponds
to vehicles coming into sight whilst driving and is more like the type of visual task that
one must carry out in real life driving. Reaction time is taken from the time of the truck
appearing to the time the brake pedal is 90% depressed. If no braking occurs the car
will travel on until it crashes into the back of the truck. If this happens, the word crash
appears and a loud buzzer sounds. If the car is stopped for more than 10 seconds the
crash screen also appears.
The task also requires the driver to keep their speed within the range of 60-80Km; the
speedometer is located on the top left corner of the screen and is out of the line of sight
for the road. If they speed over this range they must apply the brake to reduce speed to
the required level.
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Hence, the AusEd simulator incorporates three main aspects of driving; tracking, visual
search and speed control.
A sub program created in-house (see acknowledgements) calculated the outcome
measures. These outcome measures of AusEd include;
• Mean area of deviation from the lane centre (cm)
• Mean area of deviation from required speed (km/h),
• Numbers of crashes, which are categorised as driving-off-road crash, stop crash or
truck crash.
• Number of driving-off-road incidents (where the person drives along the grass verge
before returning to the lane)
• Number of trucks presented (held constant at ten for each person and 30 minute
drive), the reaction time for each individual presentation and mean RT value,
(AusEd samples the road position and speed 12 times per second).
The analysis program can provide the mean values for these outcome measures for;
• The full 30 minutes drive,
• Four quarters of 7.5-minutes (consisting of 5 minutes of straight road and 2.5
minutes of chicane road)
• Mean values for four 5-minute blocks of straight road and five 2-minute blocks of
chicane.
The AusEd driving simulator has a good level of face validity as it incorporates the first
person perspective from the driver's seat of a car. It utilises a steering wheel and foot
pedals, both of which are essential to mimic a real driving situation and also includes
tracking and visual tasks that mirror those required in real life driving. Additionally, the
speed control mimics lower and upper safe levels of a speed limit.
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2.12 Discussion
Due to economic and mass-screening demands, a cost-effective, portable simulator
appeared to serve a clinical need, and the AusEd-driving simulator was designed to
incorporate aspects of those mentioned previously as well as including aspects that
were missing in these simulators which inhibited them form being used an effective tool.
Chapters four to seven in this thesis incorporate data from the validation of the AusEd-
driving simulator as a laboratory based task for fitness to drive.
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Chapter 3: Methods of measurement
The laboratory research conducted for this thesis was undertaken to validate the AusEd
PC based driving simulator program as a potential test of fitness to drive. All research
included within this thesis was completed in the Edinburgh Sleep Centre between
February 2000 and December 2002.
3.1 Nocturnal Polysomnography
Polysomnography (PSG) the most sensitive and specific test of sleep disordered
breathing currently available, was the main diagnostic procedure in patients and its
merits and validity for use in OSAHS patients are well-established (Gould et al 1988,
Douglas et al 1992).
All studies were performed in the same sound-proofed and electrically screened
bedroom in the hospital-based Edinburgh Sleep Centre.
Sleep states were monitored using electroencephalography (EEG), electro-oculography
(EOG), and electromyography (EMG) recorded from bipolar montages from silver
chloride surface electrodes. To measure and score sleep quality and quantity, a
modified Rechtschaffen and Kales (1968) method was employed. EEG was recorded
from two vertex scalp sites (CZ/PZ) of the international 10/20-electrode placement
system (Jasper 1958). Eye movements were monitored from frontal electrodes (placed
at sites Fp1 and Fp2) and referred to an electrode at the contralateral outer canthus of
each eye, allowing eye movements to be recorded in all directions. 'Mixed' channels
were recorded using EEG/EOG signals (Cz/Fp1 and Cz/Fp2) resolve frontal EEG. Sub¬
mental EMG was recorded from two electrodes placed under the chin on the belly of the
genioglossial muscles. A grounding electrode was also place at site Fpz.
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Figure 3.1; Electrode placement
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Respiratory monitoring in the PSG comprised -
• Thoracic and abdominal movements using inductive plethysmography,
• Airflow from oro-nasal thermistry,
• Arterial oxygen saturation from pulse oximetery (Ohmeda Biox 3700).
All signals were subject to 50Flz notch filtering and high and low band pass filtering to
reduce artefact an were recorded on a 16 channel computerised polysomnography
system (Compumedics S, Australia).
Other PSG channels included leg EMG recorded from electrodes placed on the right
and left anterior tibialis, body position recorded using a mercury tilt switch, heart rate
from electroencephalogram (ECG) chest electrodes placed on the left and right of the
thorax, and snoring from a discrete microphone on the headboard.
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3.2 Scoring Of Nocturnal Variables
3.2.1 Sleep Scoring
Sleep was staged from EEG, EOG and EMG using modified criteria of Rechtschaffen
and Kales (R&K 1968). Staging of sleep was performed on an epoch-to-epoch basis,
with 30-second epochs. Each 30-second page is assessed as a whole and scored as
sleep when 15 seconds or more of sleep (regardless of stage) occupies the page,
rather than by looking at changes on a second to second basis. Thus R&K scoring
rules are very much time based rather than event based, regardless of whether an
event indicative of a stage of sleep is seen, it must be within the context of 15 seconds
of sleep before the stage can be scored.
R&K (1968) defined seven stages.
Stage wake: Wakefulness is defined when EEG frequencies are in the alpha (8-13HZ)
or sigma (>13HZ) range. This stage is characterised by high EMG tone and eye blinks
on the EEG.
Stage 1: Sees intrusions of theta EEG frequency (4-7Hz). It is characterised by vertex
sharp waves, a reduction of amplitude on the EMG and rolling eye movements on the
EOG.
Stage 2: Again EEG is predominately of theta frequency (4-7Hz), with stage two
characterised by the presence anywhere on the page of either a sleep spindle (fast
burst of activity, 0.5-2sec in the frequency of 12-15Hz) or K complex (a negative
deflection in the EEG followed by a positive one).
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Rechtschaffen and Kales (1968) suggest that stage one should be scored after a page
of wake before stage two can be re-scored. However OSAHS sufferers can often
arouse briefly and regularly due to the termination of apnoeas and then return directly
into stage two. Due to this, an in-house scoring technique subsequently recommended
by Carskadon and Rechtshaffen (2000) and Thorpy (1992) has been implemented. If
an epoch has either characteristics of stage two (sleep spindle, K complex) it is scored
as this rather than stage one as R&K guidelines suggest.
Stage 3: EEG frequency of slow wave delta frequency 1-3Hz. This is a transitional
stage scored when delta activity occupies between 20-50% (6-15 seconds) and
amplitude reaches at least 75pV.
Stage 4: This is scored when 50% or more of the epoch is occupied by slow wave delta
EEG activity.
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Slow wave sleep: Stages three and four are often collectively known as Slow Wave
Sleep (SWS) or Delta sleep. Due to the frequency of arousals that are associated with
OSAHS, patients often can not pass from the lighter stages of one and two down to
stage three and four before another arousal.
Stages one through four are collectively known as Non-REM sleep; In adults (60 years
and under) NREM accounts for 75-80% of night-time sleep, with slow wave sleep
mainly occurring in the first third of the night.
Stage REM: EEG frequency similar to that of stage one with waves resembling saw
teeth on the EEG channels. The EMG tone is at its lowest during REM except for bursts
of phasic twitches. Rapid eye movements are seen on the EOG, giving this stage of
sleep its name. These characteristic eye movements are not always seen on each
epoch, and R&K criteria allow three minutes (six epochs) without an eye movement.
This stage of sleep occupies between 20-35% of night time sleep and REM periods last
longer in the last third of the night.
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In adults free from sleep disorders non-REM and REM sleep periods tend to follow a
90-minute cycle (William, Karacan and Hursch 1974)
Movement time: This is scored when either amplifier blocking or movement artefact
obscures more than 15 seconds of the EEG and EOG channels. This does not include
muscle activity seen with an arousal when the patient is waking up.
3.2.2 Respiratory Scoring
There are two types of respiratory event routinely scored in the sleep
apnoea/hypopnoea syndrome.
Apnoea: This is defined as a complete cessation of airflow for at least ten seconds but
associated with continued thoraco-abdominal effort (Guilleminault et al 1978). These
events can produce oxygen desaturation and are usually terminated with an arousal
from sleep. However not all events terminate with a visible arousal on the EEG (Dingli
et al 2002).
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Hypopnoea: Was defined as a reduction in airflow of 50% for at least ten seconds
(Gould et al 1988; AASM 1999), and did not require either oxygen desaturation or










Epoch based R&K scoring cannot resolve arousals shorter than 15 seconds. Flowever
as mentioned earlier due to the termination of apnoeas and hypopnoeas sufferers of
OSAHS tend to have brief arousals from sleep lasting for less than 15 seconds. These
'micro-arousals' are an important aspect of the condition, as they can inhibit slow wave
sleep. PSGs were scored for in house Cheshire arousals (Cheshire et al 1992)
subsequently validated by Martin et al (1997). Cheshire arousals were defined as a
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return to alpha or theta rhythm for at least one and a half seconds with an increase on
the EMG, however short.
The total number of arousals is divided by the total sleep time (TST), which gives the
number of arousals per hour of sleep.
3.3 Reproducibility of Polysomnography Scoring
Although all sleep scoring was conducted using the above guidelines, there is an
element of subjectivity involved. To ensure that scoring of the studies within this thesis
are reliable 13 of the 45 nocturnal polysomnography studies were re-scored by me,
blind to subject name or previous score.
The results of these intra-rater scoring assessment are shown in table 3.1.







































* All significant at P= 0.01 level
Small differences are not unusual when re-scoring. These differences can result from
the both apnoeas/hypopnoeas and epochs of sleep being marginal, for example when
an apnoea is just ten seconds long, when an arousal lasts around 15 seconds or when
the person is drifting in and out of sleep. It is these "is it -isn't it?" events, which call
upon the scorer to make a judgement call which inevitably will vary from time to time
and person to person. This unfortunately, is a limitation of manual scoring of
polysomnographic recordings and many believe an automated program would be more
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advantageous. However a high level of correlation is found within the present study, in
all variables the means and standard deviations of both scores were very close
indicating high reproducibility.
3.4 Measure of Objective Daytime Sleepiness
Excessive daytime sleepiness (EDS) is a major consequence of the OSAHS and is
thought to play a major role as a determinant of driving ability, and therefore was
studied using a range of subjective and objective instruments.
There are many subjective methods of measuring a person's sleepiness level. Many
examine 'state' sleepiness by asking for a verbal description or numeric score of how a
person is feeling (Stanford Sleepiness Scale, Hoddes et al 1973, Karolinska sleepiness
scale Akersdedt and Gillberg, 1989). Others like the Epworth Sleepiness Scale (ESS)
(Johns et al 1991) assess longer term general levels of sleepiness by asking about
sleepiness levels in a variety of different situations. There are also questionnaires like
the Functional Outcomes of Sleepiness Questionnaire (FOSQ) (Weaver et al 1992)
which are designed to assess quality of life as it is affected by sleepiness. All these
methods are easy to administer and are not excessively time consuming, however, they
are all subject to personal perception. Some people who suffer from OSAHS may not
be aware of their own level of sleepiness, perhaps because their perception of what is
normal is influenced by their life style, adapted to compensate for the debilitating effects
of their sleepiness. Many OSAHS sufferers adapt their social and working lives to avoid
situations in which they might struggle to remain awake. Thus when asked if they feel
sleepy in meetings or in the cinema for example, they will deny this, not because they
are not affected by sleepiness in these situations, but because they avoid these.
Also many clinicians often ask partners of OSAHS patients to indicate how sleepy they
perceive their partners to be, and this can different from how the OSAHS patients
perceives themselves (Kingshott et al 1995)
Carskadon et al (1986) was amongst the first to try to quantify objectively how 'sleepy'
an individual is by developing the Multiple Sleep Latency Test (MSLT). This is a
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standardised polysomnographic procedure utilising EEG, EOG and EMG (electrode
positions are that described in section 3.1), and is used to assess and diagnose
disorders of excessive sleepiness such as OSAHS and narcolepsy. It is administered
in five tests across the day in which subjects are asked to actively fall asleep. Sleep
onset latency (SOL) is measured as the time from the start of the test until either the
first three 30-second epochs of stage one or the first 30-second epoch of any other
stage of sleep. The SOL is measured for each of the tests and is then averaged to give
an outcome measure of sleepiness. Hence the MSLT measures the drive for sleep or
the sleep propensity of an individual.
A modification of the MSLT, the Maintenance of Wakefulness test (MWT) (Poceta et al
1992), also utilising EEG, has been developed to measure ones ability to remain awake
in soporific situations. The MWT is also administered in four tests across the day, but
patients are instructed to try and remain awake. Again SOL is measured in each test,
averaged and used as an outcome measure of objective daytime sleepiness, but with
an emphasis on sleep resistance.
For this research the MWT was employed for a variety of reasons. Firstly it is believed
that the MSLT and MWT are measuring two separate physiological drives, with the
MSLT measuring the tendency for sleep and the MWT the ability to remain awake
(Mitler et al 1982, Sangal et al 1992a). As such, the MSLT may be more useful for
diagnoses of excessive sleepiness whilst the MWT may be a better tool to measure the
ability to remain awake. Therefore MWT may be more valid when occupational or
driving safety is a concern. At study inception there were indications that the MWT was
able to discriminate sufferers of excessive sleepiness from the normal population
(Doghrammi et al 1997) and evidence to support that it is sensitive to treatment
interventions (Sangal et 1992b). Because its setting and instruction may be nearer to
everyday roles than the MSLT, the MWT may offer better ecological validity.
For this research study the MWT test was conducted in the patient group on their
baseline visit. It was administered in four evenly spaced trials at 1000, 1200, 1400 and
1600 hours, to allow for circadian effects on sleepiness. Participants sat comfortably
upright on the bed with head and neck supported, they were instructed to try and
remain awake and not to use any behavioural methods such as singing, exercising or
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reading that may help keep them awake. The tests are terminated if the patient has
successfully maintained wakefulness for forty minutes, if three consecutive epochs of
stage 1 sleep or one epoch of any other stage of sleep (Poceta et al 1992) is recorded.
However we have in-house modification for the termination criteria to allow termination
after one epoch of any stage of sleep. This was because sufferers of OSAHS often
have respiratory events during episodes of sleep in these tests which may terminate
with an EEG arousal making it difficult for patients to maintain stage one for three
epochs. However for this thesis, in many cases two consecutive epochs of sleep as
defined by Rechtschaffen and Kales (1968) (section 3.2.1) were recorded before the
test was terminated to further reduce the chance of the test being stopped in error.
The average SOL (sleep onset latency) from the MWT is used as an objective outcome
measure of sleepiness in the patient sample.
3.4.1 Reproducibility of MWT Scoring
To ensure my scoring of the 45 MWT sets was reliable, 12 sets (48 tests) were chosen
at random by our research technician, which I re-scored, blind to patients' identity and
previous score, at least one year after the original score.
Reproducibility of the mean (SD) of the SOL for each test time, as well as the overall
mean produced strong correlation co-efficients, assessed by Pearson correlation and
suggesting high reproducibility. The correlation between these scores is shown in table
3.2.
Table 3.2; Correlation of SOL between the first and second score on MWTs (n=12)
Daytime nap First score Second score R Difference first
Mean (SD) Mean (SD) value* score mean -
In minutes in minutes second score
mean in minutes
1000MWT 17.8±14.1 17.8±14.1 .98 -0.04
1200MWT 13.3±9.6 13.3±9.7 >.99 -0.08
1400MWT 14.1 ±13.1 14.2±13.0 >.99 -0.13
1600MWT 21,7±14.4 22.7±14.3 >.99 -0.03
Overall 16.9±12.9 16.8+12.9 .98 -0.07
*AII values significant at level p<0.01
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Figure 3.7; Linear relationship between First and Second scores of MWT
3.5 Recruitment and Procedures for the AusEd Driving Simulator Study
Procedures
Potential patients were identified using the Edinburgh sleep centre patient appointment
dairy. Patients booked for a polysomnography investigation night were identified as
potential recruits on the basis of their referral letter for assessment of OSAHS. Patients
were recruited under the following criteria:
Inclusion criteria: Epworth Sleepiness score (ESS) > eight; an AHI of five or greater; two
major symptoms of OSAHS (Whyte et al 1989); aged between 18-70; ability to
understand the consent procedure; holds full drivers licence; no serious neurological,
cardiovascular or respiratory disease; no other co-existing sleep disorder.
Exclusion criteria: Lives more than 50 miles form sleep centre; driving as their
occupation; not been seen by sleep consultant; to receive treatment other than CPAP
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treatment; MSLT, MWT, or clinic appointment already booked for day after PSG; CPAP
titration night already booked by consultant.
Patients were initially contacted by letter not less than one month prior to their
polysomnography (PSG) investigation night and invited to participate. They were also
called by telephone to provide further information if requested and confirm their interest
in participating in the study.
Patients who agreed to participate in the study attended their PSG investigation and
remained in the sleep centre the following day. On the morning after their PSG night, I
spoke with the patients and completed the consent procedure. At this point patients
completed the ESS on the basis of which they were assigned to a higher (ESS >14) or
lower (ESS <14) randomisation schedule. Stratified, within group block randomisation
was used to determine both AusEd simulator test time (morning or afternoon) and their
treatment group (CPAP or placebo). This served to reduce the effects of circadian
rhythms on driving performance, and ensured that neither ESS group were completely
randomised to one of the treatments.
On successful completion of baseline testing, patients were given provisional dates to
return, initially for their CPAP titration night and subsequently for repeat daytime testing.
Patients were informed that continued inclusion in the study was dependent on results
of their diagnostic overnight studies, and that they may not progress further within the
study.
This was to allow scoring of the PSGs and ensure that if they did not then meet the
study criteria (e.g. AHI >5) that they could be excluded from the study and returned to
the clinical system to be seen at clinic by their consultant. If they were eligible to
continue they were then contacted by their consultant to advise them they had been
diagnosed with OSAHS. I also contacted them to confirm their study appointment
dates.
Letters were sent to the general practitioners of all patients who continued to the
treatment limb of the study, detailing their participation in the study and informed the
patient would be randomised to either CPAP or a capsule treatment. A sealed
envelope was included with this letter containing information on the capsules. With it, a
request not to divulge the nature of the capsule treatment and to contact us if the
envelope needed to be open.
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The sealed enveloped contained the following:
The capsule treatment is a placebo (inactive). Please do not hesitate to contact
Professor NJ Douglas or Dr. TW Mackay if you have further queries.
Letters used in the recruiting of the patients are included appendix 1
3.5.1 Second Assessment day
After not less than 28 nights using the CPAP or placebo treatment, patients returned for
a half day of testing when they were re-tested on the AusEd-driving simulator and
repeated the baseline questionnaires.
The re-test of the AusEd driving simulator commenced no later than 12noon, on the day
of testing. No afternoon drives were conducted. Once patients had completed the
study, I was un-blinded to the treatment that they received. If the patient had been
randomised to CPAP, I re-issued patients with a home CPAP machine, set at the
pressure from their overnight CPAP titration. This also allowed me to trouble-shoot with
staff help any issues with the mask etc. If patients had been randomised to the placebo
capsule, I then re-educated them about the CPAP machine and issued them with a
home CPAP machine, again set at the pressure from their CPAP titration night
Table 3.3 shows the demographics of the 45 patients who completed the study.
Table 3.3; Demographics of study population
Mean and SD Range
Age (years) 50.9 (8.7) 35-68
TST (mins) 367.7 (63.5) 159-454
AH I (/hr slept) 38.9 (22.0) 8.3-97.1
BMI (kg/m2) 32.6 (6.2) 23-53.46





3.5.2 CPAP Titration Night
All patients underwent a CPAP titration study regardless of their treatment
randomisation. Patients were educated about sleep apnoea/hypopnoea syndrome and
CPAP on their baseline visit, fitted with a CPAP mask and offered the opportunity to ask
questions. They then had a 30-minute CPAP trial in a darkened room. This not only
provided an opportunity to ensure the mask fitted correctly but also provided the
opportunity to experience the feeling of the positive pressure before their overnight
titration study.
Titrations were conducted using either AutoSet or AutoSet T CPAP machines (ResMed,
Australia) under the supervision of experienced specialised sleep nurses. Any
problems, for example, mask fitting or leak, inability to get to sleep etc were dealt with
as they occurred and remedied. Titration usually commenced between 10.30 and
11.00pm and ended around 6.30-7am the next morning.
3.5.3 CPAP Treatment
Patients randomised to receive CPAP treatment for the month were interviewed by a
research technician in the morning. They explained care and usage instructions for the
machine and made sure any questions the patients had were answered before sending
them home with the AutoSet T unit. Patients were given a number to call if they had
any problems during the month. I was blind to the treatment and did not have any
contact with them for the month, apart from if their return date had to be changed.
Initially patients were given the AutoSet T machine capable of varying pressure
between four and twenty cmH20. However since these patients were naive users,
some had difficulty in dealing with the ramping pressure from the machine, both in
terms of breathing with the higher pressure and the noise from the machine itself. As
this problem was listed by patients as one reason why they were limiting home CPAP
use in the one month trial, it was decided that a maximal pressure of four cmH20 above
the titrated pressure recommended by their over night titration. This was programmed
on the AutoSet T machine. Hence patients received variable pressure across a
restricted pressure range.
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At the end of the treatment trial, the AutoSet T memory was downloaded and this
provided data on night-to-night use, leak and a pressure profile for the period used.
Both the AutoSet and AutoSet T machines calculate the 95th percentile pressure levels
required during the titration study and median mask leak values. These values are
used to determine if there has been high leak from the mask over the night. If not, the
95th centile pressure value is usually used to determine the fixed pressure for long-term
home CPAP treatment.
3.5.4 Placebo Treatment
The current study used a parallel group design to assess effects of CPAP on
performance on the AusEd-driving simulator on OSAHS patients before and after
treatment. A second arm with oral placebo treatment was incorporated, which allowed
quantification and to control for learning and placebo effects with permission from both
the local and university ethics committees.
Patients were not randomised to treatment until the morning after their CPAP titration
when they were informed that the oral placebo capsule might be useful in the treatment
of OSAHS. At the study inception 'Sham' CPAP had not been fully developed and
tested and concerns regarding its effect on both sleep disruption and oxygenation
existed. Therefore an oral placebo, which has no capacity to harm, was chosen. An
oral placebo has been used in a variety of OSAHS studies conducted of physiological
changes with treatment (Faccenda et al 2001), neurocognitive changes with treatment
(Engleman et al 1994a), and subjective awareness of treatment (Mcardle et al 1999).
As with patients randomised to CPAP, a research technician saw the placebo-assigned
patients the morning after their CPAP titration night and issued them with the "capsule
treatment". This was given in a sealed white medicine bottle containing 35 white
caplets, labelled 'trial medication'. They were instructed to take one capsule with water
before going to bed. Patients were also given a number to call if they had any
problems during the month. Again I had no contact with patients unless appointment
dates had to be changed. It was stressed to patients on each visit that if they were
randomised to receive the capsule treatment, they could be placed on CPAP treatment
either on completion of, or withdrawal from the study.
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3.5.5 Control Subjects
Adverts seeking drivers 30 years and older were placed on notice boards in and around
the hospital area. An advert was also placed on the Edinburgh University staff web
page and e-mail was sent to all NHS staff in the Edinburgh Royal Infirmary.
An advertisement was placed in the local free paper, as well as in the hospital monthly
newsletter. One hundred and forty-four local businesses including food stores, libraries,
sports clubs and health centres were contacted by letter, requesting they place a copy
of the volunteers wanted poster on their staff and public notice boards.
Copies of the adverts and the letters sent to companies are in appendix 2.
Entry criteria for volunteer subjects were as follows:
Inclusion criteria: ESS <11; holds full drivers licence; no serious neurological,
cardiovascular or respiratory disease; aged between 18-70; ability to understand
consent procedures;
Exclusion criteria: Symptoms of sleep apnoea, frequent snoring, witnessed breathing
pauses, regular napping in day or evening; symptoms of other sleep disorders.
Volunteers were matched with patient's randomised to CPAP, for their age (±5years),
sex and time (morning or evening) of their initial AusEd driving test. Volunteers were






Include in study if initial inclusion Criteria
Attend for PSG Night
Stay next day for testing (baseline)
Randomised to high or low ESS group
Volunteer Study Schedule
Advertise for volunteers
Send screening questionnaire and
Information pack




Randomised to either CPAP or Placebo
Treatment period (1 month)
Repeat testing day
3.6 AusEd Pilot Study
Before patients were recruited for full the randomised control trial of simulated driving
performance, a small pilot study was undertaken. Eight members of the Edinburgh
sleep centre staff volunteered to 'drive' on the AusEd simulator and to undergo the
cognitive tests used for the study. A further two volunteers underwent testing,
completing the full day of assessments that patients would undergo at the baseline
assessment. Statistical analysis of these limited data was not conducted. The pilot
study served to ensure that all methods used for the study were possible in the
allocated time and allowed practice of setting up, administering and saving data on all
of the procedures of the study. These practise sessions highlighted any problems with
the original layout of the study, and were corrected and tested before patients entered
the study. Three problems were highlighted by the first eight volunteer subjects. Firstly
four volunteers noted that they were unable to feel the accelerator and brake pedals
due to the thickness of the soles of their shoes and two volunteers 'drove' in their bare
feet, to compensate. Secondly a similar issue was raised that the sole of their shoes
could become stuck under the side of the brake pedal whilst their foot was resting on
the accelerator and this could inhibit them from moving between the accelerator and
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brake pedal quickly (which was part of the task). The third problem concerned the
placement of the actual AusEd driving simulator PC. Its initial placement inhibited a
clear view of the subjects and the screen of the PC from a video camera overhead.
This inhibited the recording of concurrent EEG whilst the patients were driving on the
simulator, and would not allow me to see if any problems occurred during the test.
Wearing slippers whilst driving reduced the problems the volunteers experienced with
the pedals. The thinner soles of the slippers allowed better feeling and reduced the
amount of material around the edge of the feet, which reduced the chance of it
becoming stuck in-between the pedals.
The AusEd simulator was also repositioned to allow full view of the patients and the
screen of the PC.
These changes were then implemented, and tested by the two volunteers who
completed full days of assessment.
Once all ten volunteers had completed the pilot study, recruitment began for the actual
AusEd driving simulator study.
3.7 Psychometric measures In the AusEd driving simulator validation
study.
All participants in the AusEd driving simulator validation study completed questionnaires
concerning sleepiness, quality of life, OSAHS symptoms and driving history, at
baseline. Patients completed these again after one month of treatment. Questionnaires
included in the validation study were given to the participants in one batch, with verbal
instructions on how to complete the questionnaires, and were then left alone to
complete them.
The cognitive tests and the SteerClear vigilance task were only administered at
baseline in both groups. Figure 3.8 shows the outline of the questionnaires and tasks
the two groups completed. Copies of all the questionnaires are in appendix 3.
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Both patients and control subjects had the following data collected.
Height was measured using a standardised height bar; this was recorded as meters
and centimetres. Weight was measured using the standard Sleep Centre scales (Seca,
Germany), which are calibrated annually, and recorded as kilograms and grams, these
were used to calculate BMI (BMI = weight/height2'.
Neck circumference was measured at the level of the circo-thyroid membrane, and was
recorded in centimetres.
These variables were recorded at each visit.
Education level was recorded at baseline as one of three levels, basic high school
education (e.g. O grades), higher education (e.g. A levels or higher grades) or further
education (HND or degree). Previous medical history was recorded prior to inclusion in
the study, to assess exclusion criteria.
3.7.2 Measures of Daytime Function
Short Form 36 UK Version (SF36 UK)
(Ware 1993, Jenkinson et al 1996)
BACKGROUND: This generic, self-administered, health questionnaire measuring
perception of ones own health has 36-items assessing 8 multi domains and a single
item on health change in the past year. Responses are either yes/no, true/false or
frequency responses. Raw scores from each domain are summed and then
transformed, giving each domain a scale of 0 (worst possible health perception) to 100
(best possible health perception). Table 3.4 show the main 8 domains of the
questionnaire
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Table 3.4; SF-36 Domains - areas of measurement
SF-36 Domain
(No. of items)
Low score High score
Physical
Function (10)
Limited a lot in performing
physical task e.g. bathing due
to health
Able to perform all types of




Frequent interference of social
activities due to physical or
emotional health problems
No interference of social activities




Problems with work or daily
activities due to physical health
Work and daily activities
unhindered by physical health
Role limitations-
emotional (3)
Problems with work or daily
activities due to emotional
problems
Work and daily activities
unhindered by emotional problems
Vitality (4)
Feels tired and with no energy
all of the time
Feels full of energy all the time
Bodily pain (2)
Activities limited due to bodily
pain




Feels depressed and nervous
all the time
Feels calm and happy all the time
General Health
perceptions (5)
Believes health is poor and is
likely to get worse
Believes Health is excellent
The single item measuring perceived health change in the last year is measured on 5-
point scale from 1 (health much better) to 5 (health much worse). The eight scales form
two principle components, the physical components summary (PCS) and mental
components Summary (MCS). Table 3.5 shows how the summary scores are derived.
Table 3.5; Components comprising the Physical and Mental summary scales
Summary Measures Derived from scales
Physical component
summary
Physical functioning, role physical, bodily pain, general health
Mental component
summary
Social functioning, role emotional, vitality, mental health
VALIDATION: This questionnaire was validated and normative data produced by the
Oxford Healthy life survey (Jenkinson 1996). This postal survey incorporated the SF-36
with questions on life style and demographics. Completed results were obtained for
9332 respondents from a possible 13,042 randomly unstratified subjects. As normative
data was to be calculated, the sample had to be shown to be representative of the
population norm. The socio-demographics of the sample were found to represent the
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general population when compared to both the 1991 population estimates and social
class distribution from the 1981 census.
Using Cronbach's alpha statistics, Jenkinson et al (1996) demonstrated that the internal
reliability, which is defined, as the extent to which there is a correlation between each of
the variables within a scale, was good for each of the 8 dimensions. There is some
disagreement over the acceptable level of alpha for the level of internal consistency,
however most well developed scales in practise should gain alpha values of 0.8 or
greater (Carmines and Zeller, 1979). The SF-36 scales all produced alpha scales of
0.8 or greater except that of social functioning, which was 0.76, however as there are
only two items in this dimension the result is acceptable.
Factor analysis was also conducted for the two summary scales of PCS and MCS. The
internal reliability of these two summary scales were broken down to provide estimates
for males and females, those reporting long standing illness and those not, all of which
gave alpha values of .09 an greater for both the PCS and MCS.
The SF36 has been used to provide health profiles for a large variety of illnesses and is
documented in OSAFIS studies. Smith and Shneerson (1995) found that the SF-36 was
indeed sensitive to OSAHS, with subjects requiring treatment for OSAHS scoring lower
on all scales of the SF 36 (P < 0.05) than the normative scores for the general
population. They reported that after six months of CPAP treatment there was an
improvement in all scores. Jenkinson et al (2001) also provided support that the SF-36
was sensitive to change in OSAFIS. Comparing CPAP to sham CPAP they reported no
significant differences between the groups at baseline, however, at one-month follow up
there were significant and substantial improvements on the active CPAP as compared
to SHAM. The sub-therapeutic group improved to similar values as the original active
group after 5 months of active CPAP, providing evidence for both the sensitivity of the
SF-36 and the treatment capacity of CPAP.
The SF-36 has normative data, established internal reliability and previous study results
indicate it is sensitive to change in the OSAHS population.
TIME NEEDED FOR COMPLETION: 10 MINUTES
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Functional outcomes of sleep questionnaire (FOSQ)
(Weaver et al 1997a)
BACKGROUND: This sleep specific questionnaire assesses the impact of excessive
daytime sleepiness (EDS) on multiple daytime activities. This self-administered
questionnaire consists of 30 questions measuring five multi-item domains, these five
domains being: activity level (9 questions), vigilance (7), intimacy and sexual
relationships (4), general productivity (8) and social outcome (2).
Functional status is defined within this questionnaire as
"Everyday behaviours encompassing the areas of physical, mental, and social
functioning in daily life" (Weaver et al pg.192).
Thus, each item asks about how sleepiness (instructions distinguish between
sleepiness and physical fatigue) affects a variety of daily activities. Respondents
choose the answer most appropriate to them at the time from 'no difficulty' to 'extreme
difficulty'. For some questions, for example attending a church service or participating
in physical exercise there is the option of 'I don't do this activity for other reasons'.
A mean-weighting system for the scoring of the responses is used allowing for analysis
only of the activities the respondent participates in. The mean weighted system gives a
score out of 4 for each of the domains, and these scores are used to calculate a total
score out of 20. However for the current study we omitted from the questionnaire the
questions concerning sexual activity and intimacy, to prevent causing offence or
diminishing rapport with our patients and volunteer subjects. Hence for analysis in this
study the sub-scales are still out of 4 but our total score is 16. A low score indicates
that sleepiness is affecting quality of life and functional status.
VALIDATION: This questionnaire has been validated for use with OSAHS patients and
control populations (Weaver et al 1997a).
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Three groups were used in the validation study for the FOSQ. Group 1 consisted of 133
people seeking medical attention for a sleep disorder and 20 controls of a similar age,
groups two (n=23) and three (n=51) comprised of patients from two sleep disorder
clinics diagnosed with OSAHS. Factor analysis confirmed the five subscales now
routinely used in the FOSQ and internal reliability of these domains were acceptable
with Cronbach's alpha co-efficient greater than 0.8 in each domain and an alpha value
of 0.95 for the global score. This study was also able to provide evidence to support
that the FOSQ is sensitive to the functional outcomes relevant to daily life, by
discriminating between patients attending for a sleep problem and controls of a similar
age (p=0.0001). A sub-group (n=32) of the patients attending for diagnosis of a sleep
disorder were analysed to assess test - retest reliability over a one-week period. This
yielded acceptable coefficients ranging from 0.81 to 0.90 for the sub-scales and 0.90 for
the global score.
Faccenda et al (2002) used FOSQ as an outcome measure in a randomised placebo
controlled trail of CPAP on blood pressure in patients with OSAHS, in which four of the
five domains, as well as the global score were significantly improved on CPAP in
comparison to oral placebo. General productivity being the only sub-scale not to show
a significant difference. Montserrat et al (2001) used the FOSQ as functional outcome
measure in CPAP and sham CPAP groups. They found significant improvement for
four of the five sub scales and the global score in the active CPAP group compared to
their baseline score. Three of the five as well as the global score in the sham improved,
again in comparison to their baseline score. Between-group comparison showed
significant differences for the domains of vigilance and general productivity only, and
not in the global FOSQ score. However the authors themselves suggest this may be a
result of the small sample size (n=45).
The FOSQ is a useful tool in OSAHS research as each domain represents a life area
which may be adversely affected by sleepiness. The aforementioned studies add
support to OSAHS sensitivity to treatment change.
TIME NEEDED FOR COMPLETION: 10 minutes
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The Epworth Sleepiness Scale (ESS)
(Johns etal 1991, 1992, 1993, 1994)
BACKGROUND: This is a subjective, self-administered questionnaire. It was
developed to measure subjective sleepiness as it occurs in eight every day situations.
These situations vary in their soporific nature and respondents rate their chance of
falling asleep in these situations on a scale of zero (no chance of falling asleep) to three
(high chance of falling asleep). Therefore the maximum score on the test is 24, and the
higher the score the sleepier they perceive themselves.
VALIDATION: The ESS is a simple, widely used and, to some extent, a validated scale
for measuring perceived sleepiness. As a trait measure of sleepiness the scale aims to
quantify sleepiness over a period of time rather that from an instantaneous measure.
Ideally the scale would show, all things remaining equal, that scores on the ESS hold
over time as well as show that it is sensitive to changes in sleepiness by either
treatment intervention or changes within the condition.
Johns et al (1992) were able to provide evidence of reproducibility by re-testing 87
healthy non-sleep disordered medical students at five months apart. Scores from the
two administrations did not change significantly and were highly correlated (r=0.82). In
treatment sensitivity, they found that scores from sufferers of OSAHS reduced to near
normal levels (<8) after 3-9 months of CPAP treatment. Factor analysis of the scale
found high internal consistency (Cronbach's alpha of 0.88) and showed the ESS had
only one factor for both a group of healthy non sleep disorders medical students and a
group of patients with various sleep disorders.
The ESS scale has been employed in a variety of studies in which its usefulness as an
indicator of sleepiness after treatment (Hardinge 1995, Faccenda 2002) has been
established, as well as its use in studies documenting significantly higher scores in
OSAHS than scorers and non-sleep disordered breathers (Hayakawa 2002).
TIME NEEDED FOR COMPLETION: 5 minutes
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In house symptom scale
BACKGROUND: The Edinburgh Sleep Centre symptom scale consists of 16 symptoms
that are classically associated with the sleep apnoea/hypopnoea syndrome, these
symptoms being;
• Snoring in sleep;
• Breathing pauses in sleep;
• Choking attacks in sleep;
• Unrefreshed by night time sleep;
• Falling asleep in the daytime;
• Falling asleep in the evening;
• Tiredness;
• Feeling sleepy whilst driving;
• Falling asleep when driving;
• Feeling depressed and 'low';
• Low sex drive;
• Excessive irritability with friends, colleagues or family;
• Concentration problems;
• Forgetfulness;
• Falling asleep at work;
• Poor performance at work.
Respondents indicate how they are affected by these symptoms on a four point scale
from 'not present' to 'a constant problem', with the option of 'don't know/NA' for those
who have no partner to witness night-time events, or if they are unemployed or retired.
Each symptom has a minimum score of one and a maximum of four; these individual
scores are added together to give a total score out of 64.
TIME NEEDED FOR COMPLETION: 5-8 minutes.
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In house driving questionnaire (Patients baseline) part 1
BACKGROUND: This in-house driving questionnaire investigates driving history for the
previous 5 years. It consists of 6 questions and takes around 15 minutes to complete.
In it we ask how long the respondent has held a drivers license, how many miles they
drive a year, if driving is required by their occupation and how many days a week they
drive. It also asks the respondent to indicate how they perceive their ability to drive
long distances (>75 miles) as compared to other drivers, on a 5-point scale from 'very
poor' to 'very good'. They are also asked how many accidents they have had in the past
five years. These are split into:
• Near Miss Accident - Almost had a collision but avoided at last moment
• Minor Accident - Collided with property or person, but no people injured
• Major Accident - Collided with property or person, and people were hurt
They are then requested to indicate how many of these accidents were caused by
sleepiness. A second page allows space for a brief description of the accident
circumstances.
TIME NEEDED FOR COMPLETION: 10-15 minutes.
In-house driving questionnaire (Patient follow up and Volunteers) part 2
BACKGROUND: This questionnaire repeats the same questions in the same order as
in part 1, however, it now asks about driving ability and accidents rates in regards to the
last month as well as asking about accident rates in the last five years. This allows
comparison of perceived driving ability before and after treatment of our patient groups
as well as between our patients and volunteers.
TIME NEEDED FOR COMPLETION: 10-15 minutes.
106
In-house computer usage questionnaire
BACKGROUND: This is an in-house, self-administered 8-question survey. It is used to
assess previous computer experience of our participants. This very basic questionnaire
asks about use of computers for work, leisure and games. Answers are in the form of
yes/no, frequency response or a choice from an option. Questions include:
• Do you use a computer in your place of work?
• In an average week how many days do you use a computer for work?
• Do you have access to a computer at home?
• In an average week how many days do you use a computer for leisure
purposes?
• Do you use your computer to play games?
TIME NEEDED FOR COMPLETION: 6 minutes.
Karolinska sleepiness scale
(Akersdedt and Gillberg, 1989)
BACKGROUND. This scale is used to assess the level of subjective sleepiness at the
time of completion. It is a 9-point, verbally anchored scale, in which respondents
indicate how they are feeling. The scale is as follows:
Extremely alert (score 1), Alert (3), Neither alert nor sleepy (5), Sleepy but no difficulty
remaining awake (7), Extremely sleepy - fighting sleep (9). The steps in between have
a scale value but no verbal label. It is extremely easy to use and takes minutes to
complete. This is a useful tool assessing sleepiness ratings at a particular moment
rather than general sleepiness level. As a standardised scale it allows comparison
between respondents under the same conditions.
VALIDATION: This scale has been shown to be sensitive to increases in sleepiness
and shows high correlations with performance tasks (Gillberg et al 1994).
TIME NEEDED FOR COMPLETION: 1 minute
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In house side effect questionnaire
BACKGROUND: These questionnaires were designed to assess if patients were
affected by side effects from their treatment. For the active treatment group (CPAP),
there was a list of 13 common problems associated with using CPAP treatment these
being:
Nasal stuffiness/nose bleeds; Dry throat; Wake up with mask off; Red or sore eyes;
Difficulty in falling asleep or frequent wakenings; Stomach bloating or 'wind'; Chest
Wheeze; Difficulty in exhaling with mask; Sore or rubbing mask; Leaking of air from
mask; Unpleasant appearance of CPAP equipment; Excessive noise from CPAP unit
(for you or your partner); Inconvenience not worth the benefits.
Each of these side effects were rated on their severity from 5 options these being:
Problem not present; Problem present but not affecting CPAP use; Problem present-
limiting CPAP use; Problem present stopping use; Problem present even before CPAP
use.
Although the 'capsule treatment' was inactive, 'placebo side effects ' are commonly
found, and so those randomised to placebo were also given a side effect questionnaire.
A balance was sought between listing possible side effects of an active
pharmacological treatment and between overloading the questionnaire so 5 possible
side effects were listed these being:
• Dry throat




These were graded on severity on the same scale as the CPAP side effects mentioned
above, with the word capsule used instead of CPAP. Both questionnaires also gave
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the option for the respondent to note any other side effects they felt they had as a result
of the treatment and they were asked to rate their severity also.
This questionnaire sought the problems associated with the treatment (which can be
used to help assess if the subjective usage report) is accurate and so they can be
addressed, which will increase the chance of the patients using the treatment long term.
TIME NEEDED FOR COMPLETION: 10 minutes
In-house treatment satisfaction and subjective usage questionnaire
BACKGROUND: This questionnaire is given to patients after they have completed their
one-month of treatment, either using an Auto Set T CPAP machine or taking an oral
placebo capsule. The questionnaire asked patients to rate treatment they had been
using for the previous month on three 10-point scales. They were asked to indicate
how effective their treatment was for improving symptoms (useless and completely
ineffective to completely effective), how acceptable they found the treatment (extremely
inconvenient and unacceptable to extremely convenient and acceptable) and how
satisfied overall they were with the treatment they had been using for the previous
month (extremely unsatisfied to extremely satisfied). They were also asked to provide
details on how many nights per week they used their treatment, how many hours per
night they used it and finally, how long they used their treatment on the night before
returning to the sleep centre.
This questionnaire allows comparison of treatment satisfaction between the active and
inert treatments and gives a measure of subjective treatment usage.
TIME NEEDED FOR COMPLETION: 5 minutes.
In-house sleep/wake questionnaire
BACKGROUND: The function of this questionnaire in the present study is to screen
possible volunteers for inclusion, not for statistical analysis within the study. It was
adapted from a clinical questionnaire in use at the Edinburgh Sleep Centre as a method
of gaining background information from our patients before attending for their initial
consultation. This information included smoking/caffeine and alcohol intake, previous
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health issues (including present medications), sleep pattern, nocturnal events, OSAHS
symptoms, perception of subjective sleepiness and driving ability, as well as symptoms
of other common sleep disorders. The questionnaire was sent to possible volunteers
and on its completion and return I reviewed it before calling possible participants to
discuss it with them. If an absence of subjective symptoms of sleepiness, sleep apnoea
or other sleep disorders was confirmed they were invited to attend the sleep centre for
inclusion in the study.
TIME NEEDED FOR COMPLETION: 15-20 minutes.
SteerClear
(Findley et al 1989b)
As discussed in section 2.10.2 this is a thirty-minute PC based vigilance task.
TEST ADMINISTRATION: Subjects sit looking directly at the PC screen. There is
presented a birds-eye view of a two-lane road, on which cows randomly appear on
either lane. The subjects' aim is to avoid hitting the cows (steers) by pressing the
space bar on the PC keyboard placed on the computer table directly in front of them.
Subjects are given a one-minute practice test before beginning the thirty-minute test.
The test was performed in darkness to enhance any soporific effect.
3.7.3 Cognitive Performance Tests
The National Adult Reading Test (NART)
(Nelson 1982)
This test was designed as a tool for estimating the pre-morbid intelligence of adults who
may be suffering from intellectual deterioration.
It is based on the rationale that word reading ability and general intelligence are highly
correlated in normal adults and that reading ability is retained even under conditions like
dementia. It provides an estimate of intellectual functioning before the onset of illnesses
like OSAFIS. It consists of 50 words that have generally accepted pronunciation, but
that are 'irregular' with respect to the normal rules of grammar. Hence pronunciation
using these rules would be incorrect. The correct pronunciation is expected only if the
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subject knows and recognises them when written. It was originally designed as a tool
for predicting pre-morbid IQ in sufferers of dementia. Research has shown that word
reading ability is highly correlated with general intelligence in normal healthy adults and
that this ability is both held over time (Nelson et at 1975) and in subjects with dementia
(Nelson et al 1978). In recent years the NART has become a widely used tool for to
predicting pre-morbid IQ levels of intelligence in neuropsychological research in areas
out with dementia sufferers (Bright et al 2002), including OSAHS (Kingshott et al
1999a), diabetes mellitus (Taylor et al 2003) and age related cognitive decline (Starr et
al 1997). Recent research has shown that the NART is still a valuable tool for
predicting pre-morbid IQ as Crawford et al (2001) were able to correlate current NART
performance scores to IQ scores obtained 66 years prior.
The NART is a quick and easy test to administer and is not stressful for the majority of
the respondents.
TEST ADMINISTRATION: Participants were given the list of words and are asked to
pronounce each of them. They are made clearly aware that there may words with
which they are unfamiliar and are asked to give their 'best guess' in these cases. The
administrator records the number of words correctly pronounced. This raw score is
then translated into predicted IQ scores using published tables (Nelson 1982).
There is no time limit for this test, and it usually takes around five minutes to complete.
After robust training in the accepted pronunciations of each of the words it is an easy
test to administer and an enjoyable test to complete.
Ravens Standard Progressive Matrices (RSPM), Sets A-E
(Ravens 1998)
The Ravens Standard Progressive matrices are based on observations and theories
postulated by Charles Spearman. Spearman proposed a 2-factor theory of intelligence.
According to Spearman's theory of general intelligence the performance of any
intellectual act requires some combination of a general intelligence factor 'g', which is
available to the same individual to the same degree for all intellectual acts, and of
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specific factors or's', which are specific to that act and which vary in strength from one
act to another.
The RSPM is a non-verbal assessment of the eductive component of general
intelligence 'g. Eductive ability refers to the ability to from new concepts, to be able to
identify patterns and meaning in confusion, and the ability to identify relationships.
The RSPM test hopes to measure the ability to form perceptual relationships by
analogy independently of formal schooling or language. The Ravens Standard
Progressive Matrices (RSPM) consists of five sets of
"Diagrammatic puzzles exhibiting serial changes in two dimensions simultaneously"
(Ravens 1998, pg. 1)
The term progressive is used because the items are arranged so that the person taking
the test is gradually absorbed into the particular frame of thought needed for their
solution.
The test has 60 items split into five sets, A-E with each set comprising 12 puzzles.
Below each puzzle there are 6 (rising to 8 in set C onwards) possible pieces that can
complete the figure, only one piece in each item is correct, the person talking the test
must chose the appropriate piece to complete the puzzle. Each of the 5 sets is based
upon a different principle 'theme' and items get progressively harder in each set.
As standard, there is no time limit for the test. IQ values are established from the raw
scores and converted to a percentile rank by using the appropriate published norms.
For this study, completion of the RSPM was limited to 20 minutes to limit both time and
patient stress. The 20 minutes method of administering the RSPM has not as yet been
validated for use with the published normative data, but has been used elsewhere
(Deary et al 2003) in conjunction with other validated IQ tests as a method of estimating
general intellectual decrement.
As the RSPM hopes to measure eductive component of general intellectual functioning
or 'g', many studies have used factor analysis to estimate the construct validity of the
test as regards its loading on 'g'. Cross cultural studies conducted on both adults and
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children have shown high loading on 'g' ranging from 0.81 in American children to 0.83
on British children and as high loadings in adult samples ranging from 0.86 to 0.94
(Raven et al 1998)
TEST ADMINISTRATION: Subjects were given verbal instructions on the aim of the
test. They are then asked if they understand the instructions and are given an
opportunity to ask any questions. They are then shown the first item in Set A and
asked to choose the appropriate answer to complete the puzzle, if they answer correctly
they are then reminded they have 20 minutes to complete the test and asked to
continue. If they are unable to give the correct answer the instructions are repeated and
they are then asked to choose again, if they give the wrong answer again further
training is required before they can progress. All participants in the current study gave
the correct answer initially.
3.7.4 General intellectual decrement scores
IQ decrement scores were produced by subtracting the standardised z scores of the
raw SPM score from the standardised z scores of the NART raw score. These
difference values were named as 'change' scores with a negative value indicating IQ
decrement and poorer performance than pre-morbid z-score.
3.8 The AusEd driving simulator
The AusEd driving simulator program was designed in collaboration between Dr.
Heather Engleman (Edinburgh Sleep Centre, Scotland), Professor Ron Grunstein
(Royal Prince Albert Hospital, Sydney), Dr. David Joffe (Royal Shore Hospital, Sydney)
and Mr Ben Constable (University of New South Wales, Sydney). The Program was
written using PIRACE © engine technology.
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Technical requirements
The minimum specification required to run the AusEd program;
Pentium II processor @350Mhz
Matrox™ G200 or G400 graphics card
64 bit sound card - generic
19 Inch VDU
128Mb RAM
Windows™ or Windows 2000 operating system
Sound speakers
Internal Zip™ Drive 250/100
Printer capability
Thrustmaster™ T2 steering wheel accelerator and brake pedals
As previously noted in section 2.11 the AusEd driving simulator was designed as a
potential test for fitness to drive and the research contained in this thesis was a
validation study of its usefulness with obstructive sleep apnoea/hypopnoea sufferers.
The task was built to provide monotony and visuomotor challenges in turn, in an
affordable and portable format, to discriminate driving performance yet be practical and
relatively easy to use regardless of previous computing experience.
The following outcome measures from the AusEd simulator are used in chapters 4, 5
and 6*.
Outcome measures-
• Mean area of deviation from the lane centre (cm)
• Mean area of deviation from required speed (km/h)
• Mean road position
• Mean speed
• Number of driving-off-road events - left and right lanes*
• Number of crashes*
• Brake reaction time
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3.8.1 Road layout for the AusEd simulator
The simulator was designed to replicate a lane width of 360cm and a hard shoulder
width of 340cm. The analysis program of the simulator provides data based on these
real life dimensions. Figure 3.9 demonstrates the layout and size of each lane and hard
shoulder. The instructions for 'drivers' is to keep to the centre of the left lane, a mean
lateral position of 0cm would indicate that the participant drove along exactly on the
centre of the left lane.
Figure 3.9; Overhead diagram of the AusEd road layout and dimensions.
3.8.2 Road Settings for the AusEd Simulator
The AusEd simulator program presents a choice of road characteristics. On entering
the set up menu the administrator is prompted by an interactive menu (see figure 3.10)
to input both patients details and details on the length of the drive, the number of trucks




Chicane period (mm:ss) n
Straight period (mm:ss)
Total time (mmnrss)
Number of trucks 0











C Left-hand (e.g. USA) <•" Right-hand (e.g. Japan)
Table 3.6 shows the settings that were used in the current study.
Table.3.6; Variables used in the AusEd set-up menu
AusEd set up variables Practice run Test drive
Total time 5 mins 30 mins
Chicane period 1 mins 2 mins
Straight period 2 mins 5 mins
Number of trucks 5 10
Seed number 2611 153
I drives were conducted as a right-hand drives.
The total time refers to the length of the drive, the chicane and straight periods refer to
the road layout. Each drive starts with a block of twisting chicane road layout. The lay
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out then changes to straight road for the time period requested in the set-up menu.
This means that the drive is made up of an alternating road layout of periods chicane
road and straight road until the drive is over.
For the ten-minute practice run the road layout consisted of four, one-minute period of
chicane road interspersed with three, two-minute periods of straight road. The 30-
minute test drive consisted of five, two-minute periods of chicane road interspersed with
four, five-minute periods of straight road.
Although the administrator determines the length of the time blocks for the chicane and
straight periods, it is the seed number that determines the specific road layout. By
pressing the generate button a random seed number would be produced and each
drive would be different in terms of the properties of the chicane periods and whether
these curvatures of the road were to the left or right. As this is a validation study, seed
numbers were kept constant to ensure that each drive was identical in overall road
layout.
The AusEd simulator was administered on a PC system via a 19-inch monitor on which
a 2-lane road is displayed. White boundary posts divide the edges of both the out side
lanes and small grass verges. As the simulator was designed as a night-time drive the
areas beyond the grass, the horizon and the sky are all dark. The speedometer is
situated on the top left hand side of the screen. Subjects sit with their eye level central
to the computer screen and this gives the impression of being "behind the wheel".
Although it was designed to be realistic as well as feasible, there is no hood of the car.
This ensures that the 'drivers' cannot use the side of the car as indicators of road
position.
Patients and controls were given both verbal and written instructions prior to performing
the simulator task. After reading these, they were re-iterated to each subject verbally.
All subjects were instructed to drive on the left hand side of the road, trying to keep to
the centre of the left lane; not to leave the road and to bring the 'car' to a complete halt
as soon as they saw a truck appear on the road in front of them. They were also asked
to keep their speed between 60-80km as displayed on the speedometer. If they kept
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their speed in this area between the 60 and 80 marks the speedometer turned green, if
above or below this speed the area appeared red.
AusEd measures three cognitive skills important for driving, tracking ability, visual
search and reaction time.
Subjects are given a ten-minute practice drive before commencing on a 30-minute 'real'
drive. This practice run was to ensure that subjects understood the instructions and to
give them the opportunity to ask questions if required. The results from the practice
runs were not used for any statistical analysis.
3.9 Secondary Methods of Analysis
In addition to the main outcomes from the AusEd driving study secondary methods of
measurement were employed.
3.9.1 Analysis of on Task EEG
Whilst performing on the AusEd simulator and the 'SteerClear' vigilance task both
patients and volunteers had EEG, EOG and EMG recorded. Electrode placement was
that described in section 3.2 again utilising a computerised polysomnography system
(Series S Compumedics, Australia).
The bedroom in which all daytime recording for this research was performed was
equipped with an infra red short circuit camera system, the PC on which both the
AusEd and SteerClear programs were installed and were positioned so both the PC
and "driver" were visible at all times. This made it possible to acquire concurrent EEG
and EOG with AusEd and SteerClear output, as the EEG recording was started when
the patients or volunteer commenced their drive.
Each person was given the standardised practice run as appropriate to each test, at this
point the EEG and EOG signals were checked to ensure their clarity. If the wires
118
required maintenance or changing this was done before the 30-minute test
commenced.
Concurrent EEG recordings from the AusEd driving simulator were produced and were
used to analyse parts of the EEG that correspond to the following events;
• Crashes
• Driving-off-road events not leading to crashes
Figure 3.11 shows the types of events that were analysed and the period of analysis
(POA) that was conducted.
Figure 3.11; EEG Periods of analysis (POA)
Crashes
CRASH
Period of analysis (POA) POA W
I 10 seconds (s) I 8s I 2s I 1sl
Off Road Events Returning to Road
LEFT ROAD
POA POA yfr
10 seconds 8s I 2s I1sl
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Crashes
Three types of crashes are recorded. These being:
• Off road crashes - the car swerves over the lane boundary and crashes at the
screen periphery.
• Stop crashes - the 'car' is brought to complete rest. If the driver does not move
off again within 10 seconds it is recorded as a stop crash.
• Truck crashes - the driver fails to reduce their speed and crash into the back of
the truck.
For these events the following periods of the EEG were analysed:
• Ten seconds of EEG at 20 seconds before the crash.
• Two-second block of EEG preceding the second of the crash.
Off road events (not leading to a crash)
Off road events are recorded when the driver crosses the lane boundary, either on the
left or right lane and travels along the grass strip situated on the outside of both lanes
for any length of time before returning back to the lane.
For these events the following periods of the EEG were analysed;
• Ten seconds of EEG at 20 seconds before the of road event.
• Two-second block of EEG preceding the second they cross onto the grass
verge.
Differences between 'drivinq-off-road crashes' and 'drivinq-off-road events not leading
to a crash'
As previously mentioned a driving-off-road crash is recorded only when the car hits the
periphery of the screen on either side of the road. However, a driving-off-road event not
leading to a crash is different in respect that the car crosses the lane boundary and
continues driving for a time before returning to the lane. In a real life situation crossing
the lane boundary is a sign that the car is not being kept under control. For both these
events the same time periods will be analysed for ten seconds, twenty seconds before
leaving the lane and again at two seconds immediately prior to leaving the lane. This is
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based on the assumption that slowing of the EEG is likely to happen in the period
slightly before the loss of ability to control steering. Therefore the period before the
initial event (i.e. the crossing of the lane boundary) is of interest, as any changes in the
EEG will have occurred before the actual crash.
Baseline EEG
Further to analysing EEG periods that are associated with events occurring on the
simulator, a block of baseline EEG was also analysed for each AusEd record, to allow
comparison with EEG associated with an AusEd event. This block of EEG was taken
at the start of the second period on the straight road. In all studies this block of EEG
was taken from between 601 seconds and 620seconds. Ideally all baseline EEG blocks
would have started at the same time. However on 11 of the studies artefact on the
EEG, most likely caused by movement of the wires, which was not possible to filter out
with the band pass filters, prohibited the use in analysis and so the first artefact free
block of EEG thereafter was used instead.
For these events the following periods EEG data were analysed:
• Ten-second block of EEG starting between 601 - 620 seconds into test.
It should be noted that all baseline times did not overlap with any events recorded by
the simulator.
Overlapping of EEG blocks
On a few occasions' crashes and off road events occurred within seconds of trucks
appearing or overlapped with each other. In a real life driving situation, if a person feels
sleepy or loses concentration whilst driving they may be more likely to have overlapping
off road events and crashes, with several near misses in a short period of time. Due to
this it was decided that all events would be analysed regardless of whether they
overlapped.
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3.9.2 Fast Fourier Transformation
Fast Fourier Transformation (FFT) is a mathematical technique that allows physiological
signals to be decomposed into constituent sine and cosine waves and was applied to
EEG signals recorded during simulator performance.
The program used for this study was designed in-house (see acknowledgements) and
used moving windows of two seconds with a resolution of one second; hence FFT data
points were generated for each second.
This FFT analysis program was derived from the program used by Martin et al (1997),
which was itself an improvement of an in-house FFT program initially used, by Rees et
al (1995) and Drinnen et al (1996).
The FFT analysis program allows the user to define the EEG frequencies used. Three
frequency bands were selected for this study,
• Theta (5) 5-7.9 Hz,
• Alpha (a) 8-11.9 Hz,
• Sigma (9) 12- 16Hz.
Frequencies of <4 Hz and >16Hz were used to limit blink artefact and muscle artefact
on the EEG.
Raw EEG signals were obtained while subjects performed the driving tasks and
downloaded from the Compumedics Replay version 5.25, on which they were acquired
as European data files (EDF). These raw data files were then processed by FFT
analysis program, which produced a power spectral density for each of the specified
EEG frequencies in microwatts per hertz (pW/Hz).
These data were then stored as text files and copied to the Microsoft Excel database
program. From here, the appropriate EEG periods (discussed in section 3.9.1) were
copied to the (Statistical Package for the social sciences) SPSS program and the mean
and standard deviation values for the EEG periods were calculated
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3.9.2 Blink frequency analysis
Blink rate analysis was also conducted for the 30-minute AusEd and Steer Clear tasks.
This was done by scoring the blinks that appeared on the EOG channels recorded
whilst subjects were on the driving simulator and SteerClear driving task.








* = indicates blink
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3.12.3.1 Intra-rater blink rate
To ensure that the scoring of the blinks was consistent I re-scored 20 of the original 105
studies. Five recordings from patient group at baseline on the AusEd drive, five
recordings from the patient's group post treatment on the AusEd drive, five recordings
from the patient groups on the Steer Clear task and five recordings from controls on the
AusEd drive. These were chosen at random by the Research Nursing Sister and I re-
scored them blind to their original score. Table 3.7 shows the mean blink rate spilt into
the 4 groups and on average.
Table3.7; Correlation co-efficient between first and second score of blinks
Record type First score Second R value * Difference mean first
mean and score mean score - mean second
SD and SD score
Patients baseline 487.2 492.6
>.99 -5.4


























*AII significant at p- 0.01 level
3.10 Driving Questionnaire Study
The second major study of this thesis was a retrospective questionnaire based survey
investigating perceived driving ability, accident rate and sleepiness.
3.10.1 Participants in the Driving questionnaire study
Patients with the obstructive sleep apnoea/hypopnoea syndrome were separated into
two groups for comparison. The "on-CPAP" group were patients who had been using
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CPAP treatment for the past two years. The "awaiting CPAP" group were patients
recently diagnosed but still awaiting CPAP.
The "awaiting CPAP" group functioned as a control group.
Inclusion criteria for both of the patient groups were the same.
Inclusion criteria: Aged18-75, holds full drivers licence, AHI >20 (AH/hr in bed, >30 if
diagnosed on a home based study), ability to complete questionnaire.
The "on-CPAP" group was identified from the sleep centre patient database and the
"awaiting CPAP" group were identified through the appointment system for patients
awaiting CPAP titration.
Patients who met inclusion criteria were mailed the driving questionnaire and invitation
letter, and were requested to return it on completion. A self addressed, stamped
envelope was included in each invitation pack.
Control subjects were also recruited for this study. These were matched to the "on-
CPAP" group by postal code and were also sent the driving questionnaire and invitation
letter. Matching of postal code to cases was done by using the first block of the
postcode characters i.e. EH12 or AB3. Matching thus has a greater chance of including
people with the same social and educational background as the patient group than by
matching people randomly around the country. It also meant that both groups would be
likely to use the same road types. For example, matching rural patients to controls in
the same rural area. This was hoped to increase the validity of comparing accidents by
road type.
Potential controls were identified using the United Kingdom British Telecom telephone
directory and as there was no way to screen for inclusion criteria prior to sending out
the questionnaire pack, only respondents meeting the following inclusion criteria were
included in analysis.
Inclusion criteria: Aged 18-75, holds full drivers licence, ability to understand and
complete the questionnaire.
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3.11 Self-Ratings in the Driving Survey Study
BACKGROUND: This postal survey was designed to gather information about
subjective perceptions of driving ability and accident rates in both patient and control
populations. These questionnaires can be seen in appendix 4
As different background information was required for the 4 sub-groups, each group
received a slightly different questionnaire. However each questionnaire contained the
same questions on driving history in the same order these being:
• How many days a week they drive,
• If they had ever felt sleepy whilst driving,
• If they had ever fallen asleep when driving,
• How they perceived their ability to drive both long and short distances
• Provide information on any accidents they had had
• Type (near miss etc)
• Time of accident
• Road type it occurred on
In-house "On-CPAP" Driving questionnaire
This questionnaire was sent to patients who had been using CPAP treatment for the
previous two years. Initial questions concerned their CPAP usage status and driving
licence status. They were asked to complete the Epworth Sleepiness Scale both for
their current situation and retrospectively for the time before commencing CPAP.
The driving history questions were split into 2 sections. Section 1 regarding the two
years prior to starting CPAP and section 2 regarding the last two years whilst using
CPAP therapy.
TIME NEEDED FOR COMPLETION: 20 minutes
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In-house "Awaitinq-CPAP" driving questionnaire
This questionnaire was sent to patients who were waiting to receive CPAP treatment for
OSAHS. They were asked to complete the ESS as well as the driving history section
which again was in reference to the 'last two years".
TIME NEEDED FOR COMPLETION: 5 minutes
In-house "community sample" driving questionnaire
This questionnaire encapsulated the driving history questions asked to all other groups
in reference to the past two years, as well as asking background information. These
questions include age, ESS, and enquire about events during sleep e.g. snoring,
breathing pauses, excessive movements of limbs, as well as a question regarding
whether they have been diagnosed with a sleep disorder or were receiving treatment for
one.
TIME NEEDED FOR COMPLETION: 20 minutes.
In-house sleep-wake Questionnaire
This questionnaire noted in section 3.7 was used here as a method of retrieving
information on events during sleep from our "awaiting CPAP" patient group. As all
recent patients to the Edinburgh sleep centre complete this questionnaire before
attending the sleep centre, it was possible to find this information from the notes rather
than asking the patient group.
The techniques described in this chapter were used in the studies whose results
comprise the following five chapters.
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Chapter 4: Treatment effects on the AusEd simulator
4.1 Introduction
The initial clinical study took the form of a parallel group, placebo-controlled,
randomised trial of CPAP therapy for OSAHS. The primary outcomes of this study were
in performance on the AusEd-driving simulator. Prospectively it was hypothesised that
no significant differences would be found between the two patient groups at baseline on
the primary outcomes of the AusEd-driving simulator. CPAP treatment was used to
investigate the sensitivity of the AusEd-simuIator and an inactive capsule was
incorporated into the trial design to control for learning and placebo effects. It was
hypothesised that significant improvement would occur in patients undergoing active
treatment (CPAP) for the OSAHS thus significant differences in the AusEd-simulator
outcomes would be found between the two patient groups after the treatment period.
4.2 Recruitment
Consecutive patients suspected of OSAHS and attending the Edinburgh Sleep centre
between February 2000 and December 2002 were contacted to participate in the
randomised controlled trial (RCT) of fitness to drive on the AusEd-simulator. Patients
were approached with a view to recruitment on the following inclusion/exclusion criteria:
Inclusion criteria: Epworth Sleepiness score (ESS) >8; an AHI of five or greater; two
major symptoms of OSAHS (Whyte et al 1989); aged between 18-70; ability to
understand the consent procedure; holds full drivers licence; no serious neurological,
cardiovascular or respiratory disease; no other co-existing sleep disorder.
Exclusion criteria: Live > 50 miles from sleep centre; driving as their occupation; not
been seen by sleep consultant; to receive treatment other than CPAP treatment;
daytime sleepiness testing (MSLT, MWT), or clinic appointment already booked for day
after polysomnography (PSG); CPAP titration night already booked by consultant.
Previous uvulopalatopharyngoplasty (UPPP) surgery
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Overall 911 patients were booked for polysomnography investigations during the study
period. Of these 127 were contacted. Table 4.1 illustrates the numbers and reasons
the other 784 patients were not contacted. Figure 4.1 demonstrates the progression of
possible participants.
Table 4.1; Reasons and number of patients not contacted regarding study.
REASON FOR NOT RECRUITING PATIENTS Number
New patients still waiting to see their consultant 243
Psychiatric/cardiovascular/respiratory disorder or other illness 99
ESS score <8 57
Did not hold drivers licence 62
CPAP night already booked (for night after PSG) 52
Recruited for other study 47
MSLT/MWT next day 39
Clinic appointment with consultant next day 38
Lived >50 miles from sleep centre 25
Older than 70 24
Flaving half PSG and half CPAP titration night 24
Driving as occupation 23
Booked for investigation other than OSAFIS 17
Receiving or to receive other treatment than CPAP 17
Diagnosed with other sleep disorder 8
English not first language 5
Previously had Uvulopalatopharyngoplasty (UPPP) surgery 4
TOTAL 784.
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Diagram 4.1; Patient inclusion/exclusion flow diagram
A comparison of age between patients who agreed to participate in the study and those
who declined showed that participants who agreed (n=54) had a mean age of 50.6 SD
(9.7) yrs and were significantly older than those who declined (n=73), mean age 45.6
(10.1) yrs, t (123)= -2.92; P<0.05.
However ESS of the participant group (n=54) was not significantly different to that of
decliners (mean ESS of 14.2 SD (3.3) vs. 13.2 SD (3.4), t (114)= -1.56; ns), there were
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no gender differences between the participant group (n=54, 7 females) and those who
declined (n=73, females 13) (x2=0.549; df=1;p=0.459)
One hundred and twenty seven patients were contacted and asked to participate in the
study and 54 patients agreed, giving a response rate of 43%. Of the 54 patients who
agreed to participate in the AusEd driving study, only 45 patients completed the study,
with nine patients excluded or withdrawing from the study. Four patients declined to
continue on treatment after their CPAP titration night, three were excluded as their
overnight PSG showed they had periodic limb movements rather than or as well as
OSAHS. One patient broke their arm and did not feel up to continuing in the study.
Another patient suffered a myocardial infarction shortly after their PSG investigation
night and was immediately commenced on CPAP therapy.
4.3 Statistics
The baseline comparisons for ordinal and continuous data for the two groups were
conducted using non-parametric Mann-Whitney U tests and dichotomous and
categorical level data were analysed with Chi square and Fishers exact non-parametric
tests. Correlational associations were assessed using Spearmans correlation
coefficients for non-parametric data. Performance changes (time on task) on the AusEd
driving simulator were assessed using a one-way ANOVA. The treatment effect
analysis was conducted using a repeated measures MANOVA test, with a repeated
within subjects factor of time (pre and post-treatment) and a between subjects factor of
treatment randomisation was also included. All tests were run on the PC statistical
package SPSS (SPSS for windows, Version 12, 2003, SPSS, Chicago, IL, USA).
4.4 Patient Group
A total of 45 patients completed this intention to treat study, 19 (3 women) had a
recruitment ESS of 13 or less and 26 (3 women) had a recruitment ESS of 14 or above.
With randomisation blocks balanced and stratified for ESS, 21 (11 from the 8-13 ESS
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group) were assigned to placebo treatment and 24 (10 from the 14-24 ESS group) were
assigned to CPAP treatment.
4.4.1 Baseline daytime schedule
Patients attended the Edinburgh sleep centre the night prior to the testing day and
under went full polysomnography. They then stayed the following day for a full day of
testing. Throughout the testing day EEG wires were checked before MWT and driving
tests. The baseline testing day schedule was as follows:
Randomisation of AusEd simulator/SteerClear order
8.30am Height, weight and neck measurements taken, questionnaires (ESS, FOSQ,
SF36, Symptom scale, Driving history, computer usage) to be completed
9.10am NART and Ravens matrices tests
10.00 MWT test 1
10.45 Blood pressure taken
10.55 AusEd / SteerClear driving simulation (randomised order). Completing the
Karolinska sleepiness scale before and after the simulation
12.00 MWT test 2
12.40 Lunch
14.00 MWT test 3
14.50 AusEd / SteerClear driving simulation (randomised order) Completing the
Karolinska sleepiness scale before and after the simulation
16.00 MWT test 4
16.50 Wires off
17.00 CPAP Education (educational video, mask fitting and CPAP trial)
18.00 Patient leaves
4.4.2 Post-treatment daytime testing
At the end of the treatment period of 4 weeks, patients were scheduled to return to the
sleep centre for a half day of testing. To reduce patient time constraints the MWT,
cognitive tests and Steer Clear were not performed and all patients underwent the
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AusEd simulator task in a morning session, regardless of whether their baseline AusEd
drive was morning or afternoon.
The revised schedule for the post-treatment-testing day was as follows;
9.00 Patients arrive at sleep centre
9.30 Patients complete questionnaires (ESS, FOSQ, SF36, symptom scale, driving
history questionnaire part2, treatment satisfaction and subjective usage, treatment side
effect)
10.00 EEG wires are applied and checked to ensure signal quality
10.40 Blood pressure taken
10.50 AusEd driving simulation
11.40 Wires off
4.5 Baseline descriptive statistics of the patient Group (N = 45)
As a group the patients were on average middle aged, overweight with an AHI (Apnoea
+ Hypopnoea Index) reflective of moderate OSAHS.
Table 4,2; Patient demographics and baseline characteristics
Variable Mean and SD Range
Gender* 39m/6f -
Age in years 50.9 (8.7) 35-68
Weight in kg 97.0 (17.1) 70-146
Height in meters 1.7 (0.09) 1.42-1.89
BMI (kg/m2) 32.6 (6.0) 23-53.5
Neck size in cm 42.1 (3.45) 31 -49.5
AHI per hour 38.9 (22.0) 8.3-97.1
Arousals per hour 33.2 (18.1) 8.8-81.5
Total Sleep Time in mins 367.7 (63.5) 159-454
Sleep efficiency %** 78.2 (13.4) 34-93
CPAP titration pressure (cmH20) 9.3 (2.1) 5-13.4
Days on treatment 35.4 (7.7) 28-59
* m=male, f=female, ** total time asleep divided by total time in bed
Overall the group demonstrated few crash and driving-off-road events during
performance on the AusEd driving simulator. Their mean lateral position was within the
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left lane (as instructed) and their mean speed was within the instructed range (60-
80km/hour).
Table 4.3; The AusEd simulator outcomes
Variable Number






AusEd truck crash 0.07 (0.33) 0-2
AusEd driving-off-road crash 0.42 (0.99) 0-5
AusEd driving-off-road incident 0.96(2.9) 0-19
AusEd stop crash 0.47 (1.5) 0-9
AusEd mean area of deviation from lane centre (cm)* 94.6 (27.5) 51 - 161
AusEd mean area of deviation from required speed
(km/h)**
11.3 (3.8) 6-27
Time outside required speed % 27.6 (16.1) 9.5-91.8
Mean road position (cm) 84.13 (31) 2-158
Mean speed (km/h) 63.8 (5) 44-71
Mean reaction time in seconds 2.8 (3.1) 0.86-17.86
Median reaction time in seconds 1.9 (1.6) o 00 1 co
* Centimetres, ** kilometres per hour
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Overall the patient characteristics reflected mean ESS and FOSQ scores in the
pathologically sleepy range and they reported generally poor health status (SF36).
Table 4.4; OSAFIS symptoms, s eepiness and quality of life outcomes
Variable Mean and SD Range
Recruitment ESS* 14.1 (2.9) 8-21
Symptom score (max 48) 25.2 (7.9) 8-44
SF36 health transition** 3.0 (0.7) 1 -5
SF36 physical functioning** 67.1 (26.6) 0-100
SF36 role physical** 46.7 (38.7) 0-100
SF36 role emotional** 58.5 (42.1) 0-100
SF36 Social functioning** 68.6 (25.8) 12.5-100
SF36 bodily pain** 63.4 (27.2) 22-100
SF36 mental health** 62.8 (16.9) 29-92
SF36 vitality** 36.6 (19.6) 0-75
SF36 general health** 51.0 (19.8) 15-90
SF36 physical** 38.0 (13.9) 12.8-62
SF36 mental** 43.1 (11.1) 21.8-65.7
FOSQ productivity*** 3.2 (0.6) 1.75-4
FOSQ social outcome*** 3.3 (0.6) 2-4
FOSQ activity level*** 2.7 (0.7) 1.22-3.89
FOSQ vigilance*** 2.8 (0.7) 1.06-4
FOSQ total*** 11.9 (2.1) 6.97-15.89
Ravens score max 60 43.4 (7.5) 22-56
NART score max 50U 32.04 (9.2) 12-47
IQ change score -0.01 (0.15) -2.34-2.13
Karolinska score before AusEd 4.7 (1.5) 1 -7
Karolinska score after AusEd 5.9 (1.9) 3-9
Karolinska score before SteerClear 4.6 (1.5) 2-8
Karolinska score after SteerClear 5.8 (1.9) 3-9
MWT SOL (mins) # 19.8 (10.4) 3.25-40
SteerClear cows hit % 7.69 (6.7) 1 -39
*ESS -Epworth sleepiness score,** SF36 - Short from 36 *** Functional outcomes of sleepiness
questionnaire, U National adult reading test, , ft Multiple sleep latency sleep onset latency in
minutes.
On average patients reported low numbers of real-world accidents and near-miss
accidents in the preceding five-year period. As a group they reported holding a drivers
licence for an average 28 years, driving most days and reported a good ability to drive
long distances (>75miles).
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Table 4.5; Driving questionnaire outcomes
Variable Number
Number of patients reporting involvement
in an accident last five years
15 -
Number of patients reporting involvement
in a near miss last five years
22 -
Mean and SD Range
No. of major accidents last 5 years 0.02 (1.5) 0-1
No. of minor accident last 5 years 0.4 (0.7) 0-2
No. of near miss accident last 5 years 3.4 (8.3) 0-50
Years held drivers licence 28.9 (10.3) 6-51
Miles driven per year 12,162.2 (8596.1) 200-50,000
Days driven per week (scale 1-4) 3.82 (0.6) 1-4
Ability to drive long distances (scale 1-5) 3.6 (1.1) 1-5
4.6 Baseline comparisons of the two patient groups
To determine if any differences were present between the placebo and CPAP group at
baseline, comparisons of the two groups on the study outcome measures were
undertaken. All baseline comparison tests were analysed with Mann-Whitney U non-
parametric tests unless otherwise stated.
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The two groups were similar in the demographic, anthropometric and clinical variables
and showed no significantly statistical differences in any of these variables at baseline.








Age in years 51.9 (8.3) 49.9 (9.2) >0.3
Education (scale 1-3) 2.2 (0.9) 1.8 (0.9) >0.2
*Sex (male or female) 21m/3f** 18m/3f** >0.9
*Smoke (yes or no) 5y/19n*** 4y/17n*** >0.9
Weight in kg 97.9 (18.9) 95.9 (15.2) >0.9
Height in meters 1.7 (0.1) 1.7 (0.1) >0.9
BMI (kq/m2) 33.2 (7.2) 31.9 (4.5) >0.9
Neck size in cm 42.4 (3.7) 41.9 (3.2) >0.5
AH I per hour 37.3 (23.4) 40.9 (20.7) >0.4
Arousals per our 31.4 (18.4) 35.2 (17.9) >0.3
Total Sleep Time in minslj 367.8 (58.7) 367.7 (70.1) >0.6
Sleep efficiency % 77.2 (12.4) 79.3 (14.7) >0.4
CPAP titration pressure (cmH20) 9.2 (2.1) 9.4 (2.1) >0.9
Days on treatment 33.7 (5.1) 37.2 (9.7) >0.4
MWT SOL 16.9 (8.8) 23.1 (11.4) >0.1
SteerClear cows hit % 7.9 (7.9) 7.4 (5.0) >0.8
Systolic blood pressure (mmHg) T 135.1 (22.3) 132.8 (18.8) >0.9
Diastolic blood pressure (mmHg) T 86.8 (10.9) 87.8 (10.2) >0.7
* Fisher's Exact test, ** m=male, f=female, *** y=yes, n=no, U total time asleep divided by total
time in bed, # Multiple sleep latency sleep onset latency in minutes, T millimetres ofmercury
There were no significant differences in the two groups on the number of crashes and
driving-off-road events recorded on the simulator. Neither were there significantly
different frequencies of patients recording crashes or off-road events. Both groups had
similar deviations in steering and speed from the required levels, and both groups
performed within required mean speed parameters. Although not significantly different
the CPAP group on average drove closer to the centre of the left lane than the placebo
group, but the mean value for each group was within the boundaries of the left lane.
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Table 4.7; The AusEd driving simulator-driving measures at baseline
Variable CPAP Placebo
n = 24 n = 21
p levelNumber Number
and % and %
Number of participants recording a crash or
off-road event*
13 (54) 8 (38) >0.2
Mean and Mean and
SD SD
AusEd stop crash 0.3 (0.7) 0.7 (2.0) >0.5
AusEd truck crash 0.8 (0.4) 0.1 (0.2) >0.9
AusEd driving-off-road crash 0.4 (0.7) 0.5(1.3) >0.5
AusEd driving-off-road incidents 0.5 (0.8) 0.7(1.6) >0.4
AusEd total number of events 1.2 (1.5) 1.9 (3.5) >0.8
AusEd mean area of deviation from lane
Centre (cm)**
93.0 (28.2) 96.5 (27.2) >0.6
AusEd mean area of deviation from required
speed (km/h)***
10.9 (2.8) 11.8 (4.81) >0.9
Time outside required speed % 26.1 (10.8) 29.3 (20.78) >0.7
Mean road position (cm)** 78.1 (33.5) 91 (26.9) >0.2
Mean speed (km/h)*** 64.1 (3.5) 63.4 (6.4) >0.8
Mean reaction time in seconds 2.7 (3.5) 2.8 (2.6) >0.5
Median reaction time in seconds 1.8 (1.2) 2.1 (1.9) >0.8
90th centile reaction time in seconds 0.39 (0.78) 0.41 (0.74) >0.8
*
Chi-square, ** Centimetres, *** Kilometres per hour
There were no differences in the two groups in their level of subjective sleepiness,
OSAHS symptoms, general health status and IQ decrement at baseline.
138








Recruitment ESS* 14 (2.9) 14.2 (3.1) >0.8
Symptom score (max 48) 24.7 (6.9) 25.9 (9.1) >0.6
SF36 health transition** 3.1 (0.7) 2.9 (0.8) >0.5
SF36 physical functioning** 67.9 (29.6) 66.2 (23.4) >0.6
SF36 role physical** 51 (42) 41.7 (34.8) >0.5
SF36 role emotional** 56.9 (43.4) 60.3 (41.7) >0.9
SF36 Social functioning** 70.3 (27.8) 66.7 (23.8) >0.5
SF36 bodily pain** 63.5 (29.3) 63.1 (25.2) >0.9
SF36 mental health** 65 (12.8) 60.2 (20.7) >0.2
SF36 vitality** 40 (19.9) 32.6 (18.9) >0.2
SF36 general health** 50.5 (21.9) 51.5 (17.5) >0.9
SF36 physical** 38.4 (15.2) 37.5 (12.8) >0.8
SF36 mental** 44 (8.7) 42.1 (13.4) >0.5
FOSQ productivity*** 3.2 (0.6) 3.1 (0.6) >0.4
FOSQ social outcome*** 3.3 (0.6) 3.3 (0.6) >0.6
FOSQ activity level*** 2.8 (0.7) 2.7 (0.6) >0.3
FOSQ vigilance*** 2.8 (0.6) 2.7 (0.8) >0.9
FOSQ total*** 12.1 (2.2) 11.8 (1.9) >0.5
Ravens score max 60 43.5 (8.0) 43.4 (6.9) >0.8
NART score max 50]j 33.6 (9.1) 30.3 (9.3) >0.3
IQ change score 0.15 (0.99) -0.2 (1.3) >0.4
Karolinska score before AusEd 4.3 (1.6) 5.1 (1.3) >0.1
Karolinska score after AusEd 5.8 (2.1) 6.2 (1.8) >0.6
Karolinska score before SteerClear 4.5 (1.4) 4.7(1.7) >0.8
Karolinska score after SteerClear 5.9 (1.9) 5.7 (1.8) >0.8
*ESS -Epworth sleepiness score," SF36 - Short from 36, *** Functional outcomes of sleepiness
questionnaire, U National adult reading test
The CPAP and placebo group reported no statistically significant differences in the
number of accidents reported and there were no differences in the frequency of patients
reporting accidents and near misses. Further, the number of days driven per week and
their ability to drive long distances were not different, however the placebo group
showed trends towards higher numbers of near miss accidents and higher mileage than
the CPAP group.
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Table 4.9; Driving questionnaire ou tcomes
Variable CPAP n = 24 Placebo n = 21 P
levelNumber and % Number and %
No. of patients reporting accidents * 7(29) 8(42) >0.5
No. of patients reporting near-misses* 14 (58) 8(42) >0.2
Mean and SD Mean and SD
No. major accidents last 5 years 0(0) 0.1 (0.2) >0.3
No. minor accidents last 5 years 0.33 (0.57) 0.5 (0.8) >0.6
No. near miss accidents last 5 years 2.7 (3.9) 4.1 (11.6) >0.07
Years held drivers licence 31.3 (8.6) 26.4 (11.7) >0.1





Days driven per week (scale 1-4) 3.88 (0.5) 3.76 (0.7) >0.5
Ability to drive long distances
(scale 1-5)
3.5 (1.1) 3.62 (1.2) >0.7
*Chi-square
This indicates that the baseline characteristics of the two treatment groups were not
significantly different.
4.7 Correlation associations between AusEd outcomes and PSG,
sleepiness, quality of life and cognitive variables.
As would be expected with the large number of variables, there were several significant
correlations found between some of the AusEd outcome variables and some of the
anthropometric, sleepiness, quality of life and cognitive variables, table 4.10 displays
the correlation co-efficient data. Indeed 7 of the 84 correlations were significant, only
slightly more than the 4 that would have been expected by chance alone at p<0.05.
The ESS was positively associated with both time-spent out with the required speed
zone (%) and with the mean RT. The physical summary score of the SF36 was
negatively correlated with cumulative speed deviation and time-spent out with the
required speed zone (%) and positively with mean RT. The FOSQ domain of activity
level was negatively correlated with mean RT, as was the FOSQ domain of vigilance
that was also negatively associated with time spent out with the required speed (%).
The estimate of computer experience was negatively associated with mean RT and the
percentage of steers hit during the SteerClear vigilance task was negatively associated
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with mean RT. All of these associations were weak in magnitude but all were in the
anticipated direction.
Table 4.10; Correlation Results between AusEd variables and PSG, sleepiness and
quality of life variables
Cumulative Cumulative Time spent Mean Mean Mean
Steering speed out with lateral speed. reaction
deviation. deviation. required road r± and time
Correlation r± and p speed position p level (sec).
co-efficient level zone (%). r± and r± and p
(r±) and p r± and p p level level
level level
AH I 0.2 0.1 0.03 0.2 0.05 0.1
NS NS NS NS NS NS
Arousals 0.06 0.09 -0.004 0.007 -0.07 -0.03
NS NS NS NS NS NS
Mean 0.2 -0.8 -0.1 0.2 0.2 0.004
desaturation NS NS NS NS NS NS
BMI 0.001 0.1 0.2 0.06 -0.2 0.1
NS NS NS NS NS NS
ESS 0.4 0.1 0.3 0.1 0.01 0.4
NS NS 0.04 NS NS 0.002
Mean MWT -0.1 -0.2 -0.2 0.01 0.3 -0.1
SOL NS NS NS NS NS NS
MCS (SF36) 0.09 0.7 -0.02 0.1 0.02 -0.2
NS NS NS NS NS NS
PCS (SF36) 0.07 -0.3 -0.3 0.1 0.3 -0.2
NS 0.008 0.006 NS 0.02 NS
Activity level 0.2 -0.03 -0.1 0.2 0.1 -0.3
(FOSQ) NS NS NS NS NS 0.04
Vigilance 0.1 -0.1 -0.3 0.1 0.08 -0.2
(FOSQ) NS NS 0.03 NS NS 0.03
FOSQ total 0.2 -0.2 -0.2 0.1 0.1 -0.3
NS NS NS NS NS 0.04
SteerClear 0.01 0.3 0.39 -0.03 -0.1 0.2
% Steers hit NS NS 0.009 NS NS NS
IQ change -0.14 -0.01 0.03 -0.2 -0.2 -0.4
scores NS NS NS NS NS NS
Computer -0.13 -0.3 -0.2 0.1 -0.3 -0.3
experience NS NS NS NS NS 0.038
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4.8 Time on task analysis on the AusEd-driving simulator
Because of suggestions that driving performance may be impaired progressively the
longer one is driving on a monotonous road, we have examined the relationship
between driving time (time on task) and the error measures from the AusEd simulator.
As the two patient groups showed no significant differences in the error measurements
of the AusEd driving simulator at baseline, time on task effects were analysed for the
whole patient group (n=45). This was undertaken by analysing the alternating types of
road (straight or chicane) within their own set;
• Blocks of straight road - four blocks of 5 minutes duration's
• Blocks of chicane road - five blocks of 2 minutes duration's
The driving task starts with a two-minute block of a twisting chicane road that in turn
becomes a five-minute block of straight road. The road layout alternates between these
two road types for the duration of the 30-minute task.
A one-way ANOVA was performed to establish if changes in the mean area of deviation
from lane centre, mean area of deviation from the required speed, mean road position
and mean speed were different over time. As one might expect the road position and
speed to be different between straight and chicane periods of road, time-on-task
changes were analysed separately for the two road types.
Straight Road
There were no significant differences over time in the mean area of deviation from the
lane centre and the mean road position. Both the mean area of deviation from required
speed and mean speed showed significant differences. Table 4.11 shows the means
and standard deviations of the four error measures.
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Table 4.11; Time on task performance - Straight b
Block 1 Block 2 Block 3 Block 4 F-value P
Mean Mean Mean & Mean & Level
(SD) (SD) (SD) (SD)
Mean area of


















Mean road 75.3 73.3 72.3 73.5
2.91 >0.8













Cm centimetres, km/h kilometres per hour
Figures 4.1 to 4.4 graph the time changes over the four straight road blocks for the
AusEd error measurements. Figures 4.2 and 4.4 would suggest that participants
recorded greater variability in speed and a lower mean speed in blocks one and four,
than blocks two and three. Although each patient was given a 10-minute practice run
before commencing the 30-minute drive, the first block of straight road showed the
highest mean area of deviation from the required speed and the lowest average speed
that may suggest a learning effect. The fourth block again sees a rise in the variability
of speed and a reduction in mean speed. This may represent impairment in
performance, however one should note that the mean speed was 65.5 (SD 5.6) and





























Figure 4.1; Straight road
Steering deviation
Block Block Block Block
One Two Three Four
Block number (5 minutes per block)
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Chicane Road
The chicane road layout yielded significant time-on-task differences in performance on
all four of the driving measures, Table 4.12 shows the means and standard deviations
of the four performance outcomes. The measures of steering (mean area of deviation
from lane centre and road position) showed a similar pattern of trends over the five
blocks, with the highest steering deviation and farthest mean road position from lane
centre occurring in the first two-minute block. As the mean and standard deviations of
the five blocks reduce over time, the significant differences obtained in the ANOVA are
in the direction of an improvement in performance. Figure 4.5 to 4.8 graph the changes
over time in the chicane road time segments.
The highest mean deviation in speed from the required speed and the lowest mean
speed were found in the first chicane block. The mean speed deviation showed a
reduction during second and third blocks before a slight increase in the fourth block and
levelled off for the fifth and final block. The time-on-task changes in mean speed
appeared to resemble an inversion of this pattern.



















































































*cm - centimetres, ** km/h - kilometres per hour
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Figure 4.5; Chicane road
Steering deviation
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4.9 Results of treatment effects for the two patient groups
To determine if CPAP had a significantly different effect on both the primary (AusEd
driving measure outcomes) and secondary outcome measures a repeated measure
MANOVA was employed.
Demographic and anthropometric measures
There were no significant differences in BMI, neck size and blood pressure with
treatment (table 4.13).















































T millimetres of mercury
Primary Outcomes
No outcome of the AusEd driving simulator program was significantly different after
CPAP compared with after placebo. As can be seen in table 4.14, mean scores for the
outcomes of area of deviation from lane centre, area of deviation from required speed,
and both mean and median reaction time reflected improvement in both the placebo
and CPAP treatment groups.
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No. of patients recording
crash/off-road incident
12 (50) 9(43) p>0.4
Secondary outcome measures
CPAP treated patients tended to have better improvement in ESS and had significantly
better improvement in OSAHS symptoms. The CPAP treated group also showed
significant improvement in the SF36 mental component summary, as well as on the
FOSQ domains of productivity, activity level and vigilance and the FOSQ total score. A
significant reduction in SF36 bodily pain subscore, linked CPAP with an increase in
pain. Placebo treatment was associated with deterioration in health status from the
SF36 health transition score.
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* Showed significant time effect at p=0.
form 36, ± functional outcome of sleep
02, ** Showed significant time effect at p=0.001 fShort
questionnaire
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Previous research has suggested that pre-treatment patients may under-report MVAs
until treatment has been established (Engleman 1997). In the current study, patients
were asked at their baseline visit to report the number of accidents they had been
involved with in the previous five years, and they were asked this again after their
treatment period. Both patient groups reported significantly changed values in minor
accidents between baseline and post-treatment. One person from each treatment
group reported a minor accident during their treatment period. This may account for the
rise in accident reports from the placebo group, but would not account for the reduction
reported by the CPAP group. Further, although the two groups at baseline did not report
significant differences in the frequency of involvement in accidents and near misses,
post-treatment, more CPAP patients reported having near misses in the previous five
years.
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17 (71) 6 (29) 0.05
153
Perceived benefit of treatment
CPAP treatment was rated as significantly less acceptable than the placebo treatment,
but was significantly more effective. Although patients were more satisfied with CPAP,
there were also significantly more side effects associated with it. Compliance was
higher in the placebo and was trending towards significance.










Compliance %* 76.5 (29.2) 91.9 (13.2) >0.08
Acceptability of treatment (Scale 1-10) 6.0 (2.5) 7.4 (2.8) 0.05
Satisfaction of treatment (scale 1-10) 6.8 (2.6) 4.0 (2.8) 0.002
Effectiveness of treatment (scale 1-10) 6.0 (2.6) 2.8 (1.7) 0.001
Side effects of treatment % 17.9 (14.0) 10.3 (8.3) 0.036
* Number of night's treatment used divided by number of possible nights usage.
4.10 Summary of results
As hypothesised there were no differences in baseline demographic,
polysomnographic, clinical or symptomatic characteristics and no differences in
baseline performance on intellectual tests, driving reports or driving simulation scores
between the placebo and CPAP treated patient groups.
Weak, yet significant correlation co-efficients were found between several of the AusEd
driving simulator outcomes and subjective sleepiness, sub-domains of the SF36 and
FOSQ, vigilance task and subjective rating of computer experience.
The primary outcomes of driving performance as measured by the AusEd simulator on
several driving performance measures including steering deviations, lane position,
speed and speed variability and a brake reaction time task yielded no significant
differences between the two treatment options. Hence, these outcomes do not support
the hypothesis that the AusEd simulator would be sensitive to changes in driving
performance associated with treatment.
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However, the results from the repeated measures MANOVA do indicate a significant
improvement in several of the secondary, non-simulator outcome measures with CPAP.
The SF36 subscales of health transition and the mental component summary, as well
as the scales of productivity, activity level, vigilance and total score from the FOSQ
questionnaire, all showed significant improvement with CPAP treatment. Inversely, the
SF36 scale of bodily pain was improved in the placebo patient group but declined in the
CPAP patient group. Symptoms of OSAHS were also significantly reduced by CPAP
treatment, and the ESS scale shows a trend towards a CPAP treatment effect.
For a discussion of these results please see chapter 6.
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Chapter 5: Case control comparisons on the AusEd driving
study
5.1 Introduction
In addition to the placebo-controlled treatment aspect of the study, healthy community
controls were recruited and matched to the CPAP patient group for gender and age,
with the aim of identifying differences in performance on the driving simulator between
the OSAHS patients and healthy subjects. The primary outcomes of this study were the
case-control comparisons of and changes in performance on the AusEd-driving
simulator.
Prospectively it was hypothesised that the healthy non-OSAHS control group would
show significantly different results on the outcomes of AusEd driving simulator when
compared to the pre-treatment CPAP patient group. It was also hypothesised a priori
that subjective sleepiness, OSAHS symptomology and perceived health status would
be poorer in the patient group. It was further hypothesised that these significant
differences might no longer be found when comparison was made between the control
group and the CPAP treated patient group.
5.2 Control subject recruitment
Volunteers were matched with patients randomised to CPAP, for their age (±5years)
and gender, and inclusion/exclusion were as follows;
Inclusion criteria: ESS <11; holds full drivers licence; no serious neurological,
cardiovascular or respiratory disease; aged between 18-70; ability to understand
consent procedures;
Exclusion criteria: symptoms of sleep apnoea, frequent snoring, witnessed breathing
pauses, regular napping in day or evening; symptoms of other sleep disorders.
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Over all 64 people responded to the adverts and contacted me for further details. Fifty
people then agreed to complete the inclusion questionnaire. At this point, an
information sheet, inclusion questionnaire and consent form were sent to the volunteers
and a prepaid envelope was included for their return. Of the 50 sent, 42 were returned.
Of the 42 questionnaires returned, 13 (2 females) volunteers were excluded due to their
ESS (^11) or symptoms compatible with OSAHS. Twenty-nine volunteers were then
contacted and a telephone interview conducted to further ensure all possible volunteers
were suitable. All 29 met inclusion criteria however only 19 (2 females) of these
volunteers were an age and gender match to CPAP patients, and therefore included.
Diagram 5.1 demonstrates the progression of volunteers.
Diagram 5.1; Progression of volunteers in the AusEd study
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Mann Whitney U tests were conducted and showed that the 19 controls subjects
included in the study (mean age 52.4 SD 10.2) were neither older than the 13 excluded
control subjects (mean age 53.7 SD 10.1) z=-0.386, p>0.1 nor sleepier as measured by
the ESS, z—1.588, p>0.1 (ESS 4.9 SD 2.1 versus 7.5 SD 4.5 for used and excluded
control groups respectively). The Fisher's exact test showed that there were no
significant differences in the distribution of gender in the two groups, p >0.1.
5.3 Statistics
Between groups comparisons were conducted using the non-parametric Mann-Whitney
U test and categorical level data were analysed with Fisher's Exact Test.
All tests were performed on the PC statistical package SPSS (SPSS for windows,
Version 12, 2003, SPSS, Chicago, IL, USA).
5.4 Testing schedule
Control subjects matched to CPAP patients for age and sex completed the driving
simulator task at the same time (morning or afternoon) as their matched CPAP patient's
baseline drive. The control group also had a familiarisation trial of the AusEd driving
simulator.
Therefore patients matched to CPAP patients whose baseline AusEd simulator drive
was in the morning were asked to attend the sleep centre for 8.45am and their daytime
schedule was as follows:
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9am Introduction, Height, weight and neck measurements taken
9.15 questionnaires (ESS, FOSQ, SF36, Symptom scale, Driving history, computer
usage) to be completed
9.45 NART and Ravens matrices tests
10.10 EEG wires on
10.45 Blood pressure taken
10.55 AusEd driving simulation. Completing the Karolinska sleepiness scale before and
after the simulation
11.50 wires off
Patients matched to CPAP patients whose initial drive was in the afternoon were asked
to attend the sleep centre for 1pm, as follows:
1pm Introduction, height, weight and neck measurements taken
1.15 questionnaires (ESS, FOSQ, SF36, Symptom scale, Driving history, computer
usage) to be completed
1.45 NART and Ravens to be completed
2.10 EEG wires on
2.45 Blood pressure taken
2.55 AusEd driving simulation. Completing the Karolinska sleepiness scale before and
after the simulation
3.50 wires off
All control subjects were asked to avoid alcohol and caffeine from 8pm the previous
evening. Controls subjects were also questioned regarding when they went to bed,
how long they felt they took to fall asleep and when they woke up in the morning.
159
5.5 Comparison between baseline OSAHS patients randomised to CPAP
and Control volunteers
All baseline comparisons were analysed with Mann-Whitney U non-parametric tests
unless otherwise stated.
As can be seen from table 5.1 there are several significant differences between the
control group and the CPAP patients at baseline.
Anthropometrical data shows the control group were thinner and had a BMI in the
normal range, compared to the CPAP patient group. They also had smaller neck sizes
and were better educated
Table 5.1; Patient and control demographics results
Variable CPAP Controls p level
Mean and SD Mean and SD
n = 24 n = 19
Age in years 51.9 (8.3) 52.4 (10.2) >0.1
Education (scale 1-3) 2.2 (0.9) 2.7 (0.5) 0.038
*Sex (male or female) 21m/3f 17m/2f >0.1
*Smoke (yes or no) 5y/19n 1 y/18n >0.1
Weight in kg 97.9 (18.9) 80.5 (11.9) 0.001
Height in metres 1.7 (0.1) 1.8 (0.1) >0.06
BMI (kg/m2) 33.2 (7.2) 25.6 (3.6) 0.001
Neck size in cm 42.4 (3.7) 38.4 (5.4) 0.004
Systolic blood pressure (mmHg)U 135.1 (22.3) 134.9 (14.8) >0.1
Diastolic blood pressure (mmHg) H 86.8 (10.9) 88.8 (9.9) >0.1
*Chi-square, U millimetres ofmercury
Primary outcomes
The median reaction time on the AusEd simulator was significantly faster in the control
population than the OSAHS population at baseline. However all other driving
performance measures were similar between the 2 groups.
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Table 5.2; Baseline AusEd simulator outcomes
Variable CPAP Controls
n = 24 n = 19
P level
Number Number
and % and %
Number of participants recording a crash or
off-road event*
13 (54) 9(47) p>0.6
Mean and Mean and
SD SD
AusEd stop crash 0.3 (0.7) 0.7 (1.7) >0.6
AusEd truck crash 0.1 (0.4) 0 >0.3
AusEd driving-off-road crash 0.4 (0.7) 0.2 (0.4) >0.2
AusEd driving-off-road incidents 0.5 (0.8) 0.3 (0.9) >0.3
AusEd total number of events 1.2 (1.5) 1.2 (1.9) >0.6
AusEd mean area of deviation from lane
Centre (cm)**
93.0 (28.2) 94.1 (24.2) >0.1
AusEd mean area of deviation from required
speed (km/h)***
10.9 (2.8) 9.9 (2.5) >0.1
Time outside required speed % 26.1 (10.8) 20.9 (9.7) >0.1
Mean road position (cm)*** 78.1 (33.5) 84.4 (28.1) >0.1
Mean speed (km/h)** 64.1 (3.5) 65.2 (4.5) >0.1
Mean reaction time in seconds 2.7 (3.5) 1.7 (1.3) >0.1
Median reaction time in seconds 1.8 (1.2) 1.1 (0.3) 0.017
90th centile reaction time in seconds 0.39 (0.78) 0.1 (0.1) >0.1
*Chi-square, ** Centimetres, *** kilometres per hour
Secondary Outcomes
As anticipated, because of the selection criteria the control group reported fewer
symptoms of OSAHS, were less sleepy in both trait (ESS) and state (Karolinska)
measured sleepiness scales and reported better health status both generally (SF 36)
and regarding sleepiness (FOSQ). The control group showed higher intellectual
function than the patient group, but there were no significant differences in the IQ
change scores of the two groups.
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Recruitment ESS* 14 (2.9) 4.9 (2.1) 0.001
Symptom score (max 48)** 24.7 (6.9) 8.2 (4.1) 0.001
SF36 health transition** 3.1 (0.7) 2.8 (0.6) >0.1
SF36 physical functioning** 67.9 (29.6) 95.5 (7.6) 0.001
SF36 role physical** 51 (42) 89.5 (28.0) 0.001
SF36 role emotional** 56.9 (43.4) 92.9 (23.7) 0.002
SF36 Social functioning** 70.3 (27.8) 86.8 (19.3) 0.045
SF36 bodily pain** 63.5 (29.3) 85.1 (21.5) 0.02
SF36 mental health** 65 (12.8) 76.8 (14.9) 0.016
SF36 vitality** 40 (19.9) 73.9 (13.8) 0.001
SF36 general health** 50.5 (21.9) 78.8 (15.2) 0.001
SF36 physical** 38.4 (15.2) 52.2 (7.4) 0.004
SF36 mental** 44 (8.7) 52.7 (7.6) 0.002
FOSQ productivity*** 3.2 (0.6) 3.9 (0.1) 0.001
FOSQ social outcome*** 3.3 (0.6) 4.0 (0) 0.001
FOSQ activity level*** 2.8 (0.7) 3.9 (0.1) 0.001
FOSQ vigilance*** 2.8 (0.6) 3.7 (0.3) 0.001
FOSQ total*** 12.1 (2.2) 15.6 (0.4) 0.001
Ravens score max 60 43.5 (8.0) 49 (7.9) 0.021
NART score max 50fl 33.6 (9.1) 41.2 (5.8) 0.006
IQ change score 0.15 (0.99) 0.0 (1.1) >0.1
Karolinska score before AusEd 4.3 (1.6) 2.7 (1.0) 0.001
Karolinska score after AusEd 5.8 (2.1) 3.2 (1.6) 0.001
*ESS -Epworth sleepiness score,** SF36 - Short from 36, *** Functional outcomes of
sleepiness questionnaire, National adult reading test
Both groups reported holding their driving licenses for similar periods of time and
reported similar distances driven annually. However the CPAP group drove more
frequently per week (scale 1-4), but reported a reduced level of ability to drive long
distances (scale 1-5) compared to the control group. Accident frequency was not
significantly different in the two groups for the preceding five years, although more
patients reported significantly more near miss incidents than controls.
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Table 5.4; Baseline driving questionnaire outcomes
Variable CPAP Controls
n = 24 n = 19 p level
Number and % Number and %
Frequency of participants
reporting accident last 5 years* 7(29)
6 (32) >0.9
Frequency of participants
reporting near accidents last 5 14 (58) 6 (32) 0.03
years*
Mean and SD Mean and SD
Major accident last 5 years 0(0) 0.1 (0.2) >0.1
Minor accident last 5 years 0.33 (0.57) 0.4 (0.8) >0.1
Near miss accident last 5
years
2.7 (3.9) 0.9 (1.6) >0.06
Years held drivers licence 31.3 (8.6) 30.8 (13.1) >0.1
Miles driven per year 9754.2 (5271.6) 8789.5 (4366.3) >0.1
Days driven per week
(scale 1-4)
3.88 (0.5) 3.47 (0.8) 0.05
Ability to drive long distances
(scale 1-5)
3.5 (1.1) 4.5 (0.7) 0.001
*
Chi-square
5.6 Comparison between post-treatment OSAHS patients randomised to CPAP
and Control volunteers
All comparison were analysed with Mann-Whitney U non-parametric tests unless other
wise stated.
The outcomes from the control group were also analysed in comparison to the CPAP
group after the treatment period.
Demographic and anthropometric data
There were no improvements changes in the patient's weight, BMI or neck size during
the treatment period and as such, these outcomes remained significantly different from
the control group.
163
Table 5.5; Post-treatment Patient and control demographics
Variable CPAP Controls p level
Mean and SD Mean and SD
n = 24 n = 19
Weight in kg 99.1 (19.5) 80.5 (11.9) 0.001
Height in meters 1.7 (0.1) 1.8 (0.1) >0.06
BMI (kg/m2) 33.3 (6.6) 25.6 (3.6) 0.001
Neck size in cm 42.3 (3.7) 38.4 (5.4) 0.05
Systolic blood pressure (mmHg)* 134.8 (22.8) 134.9 (14.8) >0.1
Diastolic blood pressure (mmHg)* 87.1 (10.9) 88.8 (9.9) >0.1
* millimetres of mercury
Primary outcomes
As with the baseline results, there were no significant differences in the two groups in
the crash/off-road events, steering and speed outcomes. However the significant
difference between the groups at baseline regarding the median brake reaction time
was not present in the post-treatment/control analysis, signifying an improvement in the
CPAP group.
Table 5.6; Post-treatment AusEd driving simulator outcomes
Variable CPAP Controls
n = 24 n = 19
P level
Number Number
and % and %
Number of participants recording crashes* 12 (50) 9(47) >0.9
Mean and Mean and
SD SD
AusEd stop crash 0.5 (1.1) 0.7 (1.7) >0.9
AusEd truck crash 0 0 >0.9
AusEd driving-off-road crash 0.8 (2.1) 0.2 (0.4) >0.3
AusEd driving-off-road incidents 1.4 (3.9) 0.3 (0.9) >0.1
AusEd total number of events 2.7 (6.1) 1.2 (1.9) >0.6
AusEd mean area of deviation from lane
Centre (cm)*
87.5 (28.1) 94.1 (24.2) >0.1
AusEd mean area of deviation from reguired
speed (km/h)**
10.6 (5.0) 9.9 (2.5) >0.8
Time outside reguired speed % 25.1 (15.7) 20.9 (9.7) >0.4
Mean road position (cm)* 71.6 (29.3) 84.4 (28.1) >0.4
Mean speed (km/h)** 64.1 (5.5) 65.2 (4.5) >0.7
Mean reaction time in seconds 2.1 (1.3) 1.7 (1.3) >0.1
Median reaction time in seconds 1.4 (0.6) 1.1 (0.3) >0.1
90th centile reaction time in seconds 0.8 (1.9) 0.1 (0.1) >0.2
* Chi square, ** Centimetres, *** kilometres per hour
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Secondary Outcomes
As would be expected after treatment the CPAP patients reported fewer OSAHS
associated symptoms and this abolished the significant difference from the controls
found at baseline. However this result was not mirrored by the ESS outcome, which
remained significantly higher than the control group, however there was a reduction in
the mean ESS score of the patients from baseline to post-treatment. The Karolinska
sleepiness scale score also remained significantly different between the two groups
both before and after the simulated drive.
As with baseline the two groups remained significantly different in all domains of the
FOSQ. However, the SF36 domains of health transition the SF36 health transition
remained non-significantly different as at baseline, mental health and the mental health
summary score were not significantly different post-treatment, showing an improvement
in this area associated with depression and tension.
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ESS* 9.9 (5.2) 4.9 (2.1) 0.001
Symptom score (max 48) 14.2 (11.5) 8.2 (4.1) >0.1
SF36 health transition** 3.1 (0.9) 2.8 (0.6) >0.1
SF36 physical functioning ** 66.1 (33.3) 95.5 (7.6) 0.001
SF36 role physical** 57.3 (38.6) 89.5 (28.0) 0.002
SF36 role emotional** 73.6 (38.0) 92.9 (23.7) 0.029
SF36 Social functioning** 75.9 (23.9) 86.8 (19.3) 0.074
SF36 bodily pain** 56.9 (27.7) 85.1 (21.5) 0.001
SF36 mental health** 70.3 (15.2) 76.8 (14.9) >0.1
SF36 vitality** 50.2 (20.4) 73.9 (13.8) 0.001
SF36 general health** 49.4 (21.5) 78.8 (15.2) 0.001
SF36 physical summary score** 36.3 (13.6) 52.2 (7.4) 0.001
SF36 mental summary score** 49.5 (9.8) 52.7 (7.6) >0.1
FOSQ productivity*** 3.4 (0.5) 3.9 (0.1) 0.001
FOSQ social outcome*** 3.5 (0.7) 4.0 (0) 0.001
FOSQ activity level*** 3.0 (0.7) 3.9 (0.1) 0.001
FOSQ vigilance*** 3.2 (0.6) 3.7 (0.3) 0.002
FOSQ total*** 13.2 (2.4) 15.6 (0.4) 0.001
Karolinska score before AusEd 3.8(1.5) 2.7 (1.0) 0.04
Karolinska score after AusEd 5.3 (1.9) 3.2 (1.6) 0.001
*ESS -Epworth sleepiness score,** SF36 - Short from 36, *** Functional outcomes of
sleepiness questionnaire,
After treatment the CPAP patient group were also asked to re-estimate the number of
major, minor and near miss accidents they had had in the preceding five years. As
baseline, the two groups reported no significant differences in the major and minor
accidents, the CPAP patient group reported significantly more near miss incidents.
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n = 19 p level
Number and % Number and %
Frequency of participants
reporting accident last 5 years* 5(21)
6 (32) >0.4
Frequency of participants
reporting near miss accidents last
5 years*
17 (71) 6 (32) 0.01
Mean and SD Mean and SD
No. of Major accidents last 5 years 0(0) 0.1 (0.2) >0.1
No. of Minor accident last 5 years 0.2 (0.4) 0.4 (0.8) >0.1
No. of Near miss accident last 5
years
2.5 (3.1) 0.9 (1.6) 0.008
*
Chi-square
5.7 Summary of results
Contrary to the hypothesis the baseline comparisons of the two groups on the AusEd
driving measures showed no significant differences in the number of crashes/off-road
events, steering and speed outcome measures, however the control group did show
higher median brake reaction time than the CPAP group. The lack of differences in the
crash/off-road events, steering and speed measures was replicated when post-
treatment CPAP and controls were compared. However, there was no longer a
difference between the two groups in the median brake reaction time, signifying an
improvement in the CPAP group with treatment.
As hypothesised there were differences at baseline in the anthropometric, symptomatic,
sleepiness and quality of life outcomes between the CPAP group and the matched
controls. Significant differences were also found in the scores of intellectual tests
although no differences were found in the IQ change scores, and the CPAP group
reported higher number of near miss accidents. Although CPAP treatment did not
significantly reduce subjective sleepiness by ESS or FOSQ outcome, there were no
longer differences in the two groups in relation to OSAHS symptomology, and the
mental health and mental component summary scores of the SF36 also showed no
significant differences.
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The improvement in the median reaction time seen in the CPAP group post-treatment
has real life implications, as a slow or reduced reaction time could be fatal especially
when travelling at high speeds. However as the simulator did not detect differences in
any of the other driving measures between the two groups, either before or after CPAP
treatment the outcomes do not support the hypothesis that the AusEd simulator would
be sensitive to differences in performance between OSAHS patients and healthy
volunteers.
For a discussion of these results please see chapter six.
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Chapter 6: Discussion of results for the treatment effects and
case-control outcomes of the AusEd driving simulator.
This chapter will address the results and outcomes of the main AusEd driving simulator
study.
6.1 Summary of the treatment effect of the AusEd driving simulator study
Forty-five OSAHS patients with mean AHI 38.9 completed the laboratory-based AusEd
driving simulator study. Patients were randomised to a low (8-13) or high (14+) ESS
group and within block stratification was used to assign them to receive placebo (n=19)
or CPAP treatment (n=24). In addition to nocturnal polysomnography and the AusEd
simulator driving measures, patients were tested on objective and subjective daytime
sleepiness, intelligence tests, quality of life measures, OSAHS symptomology, a
vigilance task and perceived driving ability.
Baseline comparisons of the anthropometric and demographic data between placebo-
and CPAP-treated patients showed the groups were similar in age, weight, BMI, and
educational status. The two groups were not statistically different in any of the
nocturnal variables of AHI, arousals, sleep efficiency or total sleep time. Further, the
two groups showed no statistical differences in their level of objective daytime
sleepiness, although the placebo group had higher mean sleep onset latency. This
coupled with the fact that no differences were found between the two groups in
subjective reports of sleepiness, general health, driving ability, OSAHS related
symptoms, and their level of objectively measured vigilance (SteerClear), suggests that
the randomisation process produced two similar groups.
AusEd driving measure outcomes
The two patient groups recorded no significant differences in any of the baseline driving
measurements of steering deviation, road position, speed deviation and mean speed.
169
Neither were they different in the number of crashes and driving-off-road events
recorded by the simulator, further there were no differences in any of the reaction time
variables.
However, both groups recorded a mean lane position which was congruent with them
driving within the left lane boundary, and both groups also had a mean speed which
was within the task instructions to maintain speed in the range 60-80 km/h.
Post Treatment outcomes
Treatment effects on the AusEd driving simulator were analysed using a repeated
measures MANOVA. The post treatment drives on the simulator yielded no significant
differences between the two groups in any of the driving measured outcomes, returning
the null hypothesis.
Some treatment effects were found. The CPAP group reported fewer OSAHS
symptoms compared to the placebo group. ESS was not significantly improved in the
CPAP group over placebo, but there was a time effect in this variable, with both groups
improving from the baseline value. QOL of life measures were significantly improved in
the CPAP group, this is especially evident in the FOSQ questionnaire in which all but
one of the domains showed a significant improvement over the placebo group.
6.2 Summary of the case control aspect of the AusEd driving simulator
study.
Nineteen OSAHS symptom free control subjects, matched to the CPAP treated group
for age (±5 years) and gender, and the 24 CPAP treated OSAHS patients completed
this aspect of the AusEd driving simulator trial.
The control group was significantly thinner, and had higher intellectual functioning,
although the IQ change scores of the two groups were not significantly different. Both
groups reported similar driving habits, and reported similar number of accidents for the
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preceding five-year period. However, the CPAP group did report a significantly reduced
ability to drive long distances compared to control subjects.
Baseline AusEd driving outcome measures
In contradiction to the hypothesis, the two groups showed no significant differences in
the steering, speed and off-road/crash driving measures. However the control group
recorded a significantly faster median reaction time than the patient group.
CPAP post treatment comparisons
Post-treatment CPAP patients' scores from the AusEd driving simulator and their
secondary outcome measures were also compared to the outcome measures of the
control group.
AusEd driving simulator outcome measures.
There were no significant differences in the two groups on any of the steering, speed
and crash/off-road events. The significant difference in the median reaction time seen
at baseline was not found in the post treatment drive.
Secondary outcomes
CPAP treatment reduced OSAHS related symptoms and these were not significantly
different from the control group post treatment. ESS remained significantly higher than
the control group but was lower than pre-treatment. Two domains of the SF36 were no
longer significantly different from the control group, although the significant differences
found in the FOSQ scores remained evident post-treatment.
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6.3 Discussion of the AusEd driving simulator and secondary outcome
measures
AusEd outcomes
The AusEd driving simulator was designed as a portable laboratory based tool to
assess fitness to drive in OSAHS patients. The results of the parallel-limb placebo
controlled and case-controlled trials could not support the validation of this simulator as
an effective tool for distinguishing OSAHS patients with poor driving performance either
from other patients or healthy controls. No significant differences were found between
the CPAP and placebo treated patients groups on the driving outcome measures of the
simulator, either before or after the treatment period. The only driving outcome measure
to discriminate between untreated and control subjects was median reaction time during
braking to the stimulus of a vehicle ahead. However, the lack of differences may not be
due to the insensitivity of simulator.
The driving simulator aimed to assess tracking, visual search and speed control, three
aspects of real life driving. For these three areas participants were instructed to drive
along the centre of the left lane, bring the car to an immediate stop when a truck
appeared on the horizon (to assess reaction time) and to keep their speed between 60-
80km/h. Outcome measures for the tracking task were; the mean deviation from lane
centre (to assess steering deviation) and mean road position (to assess where
participants positioned themselves laterally on the road). The visual search component
was measured by brake reaction time recorded when drivers reacted to a truck
appearing on the horizon. Speed control was measured by the mean deviation from the
required speed and the percentage of time out-with the required speed (to assess if
participants were driving above or below the speed guidelines), and mean speed was
also recorded.
As this was a validation study no normative values for each of these outcomes exist.
Therefore it is not possible to determine if the outcome measures of mean deviation
from both the lane centre and required speed were within an acceptable margin.
However, it is possible to determine whether the groups had a mean lateral position
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within the left lane and a mean speed between 60-80kph. In fact all three groups (on all
drives) recorded a mean speed over the 30-minute drive that was within the 60-80kph
limits. Further, both patient groups (pre and post treatment) and the control group
recorded a mean road position between -180 and 180cm. This is the centimetre range
of the left lane of the AusEd simulated road. As these measures (on average) were
within the task parameters on the patients' baseline drives, one might speculate that the
lack of significant differences were not as a result of the insensitivity of the simulator,
but because the groups as a whole, were not impaired in these task areas. There is
further support for the sensitivity of the simulator as the median reaction time was
significantly slower in the pre treated CPAP group compared to the controls and this
difference was abolished with CPAP treatment.
Only one other study comparing OSAHS patients and control subjects utilised a brake
reaction time (BRT) task. Control subjects in the Haraldsson study (1991) recorded a
mean BRT of 1.3 seconds, which is similar to the BRT of 1.7 seconds in the current
study, suggesting the RT task might be potentially accurate and useful.
In the present study the baseline vigilance task SteerClear was run at a different speed
from the Findley studies (1995) due to improvements in computer processor speeds.
Hence, although it is possible to report that the performances on the vigilance task of
the two patient groups at baseline were not significantly different, it is not possible to
report if their scores would be classed within the normal range (Findley et al 1995).
This inhibits one from providing objective evidence that the pre-treatment patient groups
showed no vigilance decrements at baseline. Therefore, it is not possible to speculate
if the patient group were likely to have a reduced RT. The baseline sleep onset
latencies on the MWT of the two groups were 20 minutes. This may be considered
pathological, indicating the groups were sleepy. As sleepiness is linked with a
reduction in vigilance this may support the increased RT of the patient group compared
to control subjects. However as discussed in section 2.7 the inability to remain awake
for 40 minutes does not automatically mean one cannot safely control a vehicle.
The patient population in the current study would be classed as having moderate
OSAHS. Some evidence exists that it may be patients with severe OSAHS who are at
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increased risk. Aldrich (1989) reported those patients with an AHI greater than 60 were
twice as likely to have an MVA than those with an AHI <60. While Findley reported that
only the severe patients reported higher MVAs than all licence holders on a state
registration, they do not report the AHI of this OSAHS group. However George et al
(1999) reported that significantly more MVAs were reported in an OSAHS group
AHI>40 as compared to a control population. This level of disease severity is similar to
the current patient population.
Perhaps the moderate degree of OSAHS in this patient population may not produce
severe driving impairment on a driving simulator and as such only BRT and not tracking
and visual search were affected. However, the driving history elicited from the groups
would also suggest that the patient groups and controls were similar in MVA
involvement for the previous five years. Although there is a discrepancy in the number
of minor accidents in the patient group between baseline and post treatment, overall the
two groups reported similar numbers of actual accidents and the frequency of
participants reporting accidents was similar. The control group and CPAP treated
group also did not differ in actual crash rate and frequency of participants reporting
accidents. Evidence that actual MVA rate in OSAHS patients is linked to poor
simulated driving performance has been reported (Findley 2000, Turkington 2001). If
simulated driving were an accurate reflection of real life driving one would expect this
association. However as the frequency of participants reporting actual MVAs and the
number of MVAs reported is not significantly different in the patient and control group in
the current study, one would not necessarily expect to find a difference in performance
on the simulator.
OSAHS and other driving simulators
The studies cited in section 2.10.2 are not congruent with the current study in that both
the DADT (George et al 1997, 1996a) and Swedish Road and Traffic Research
Institute's driving simulator (Haraldsson et al 1990) recorded significantly poorer
tracking and visual search outcomes in pre-treated OSAHS patients, compared to
controls. However the studies cited in section 2.10.2 did not utilise a parallel OSAHS
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patient group free from active treatment, and therefore it is not possible to directly
compare the treatment-effects trial of the current study with these.
However driving simulator studies published since the inception of the AusEd validation
study are also not congruent with the results from this study. The PC based Divided
Attention Steering Simulator (DASS, Stowood scientific instruments 1999) assesses
tracking and visual search. This task utilises the steering wheel configuration of the
DADT and does not employ a speed task. The tracking task is based on a screen view
of a single track winding road with a car bonnet in the foreground, during which one
must steer the 'car' down the road maintaining one's position in the lane. The visual
search task is similar to the DADT simulator. Digits are displayed in the four corners of
the monitor and subjects must press buttons mounted on the steering wheel,
corresponding to each corner, when the target number is displayed. The drive lasts 30
minutes and the program allows the administrator to select a road view from three
options. The standard view shows the car bonnet and the full road layout to the
horizon. The other views show only the car bonnet and near road (as in fog) or the car
bonnet and far road (the aspect just in front of the horizon). The outcome measures
included deviation from the lane, reaction time and the number of off-road-events. Off-
road-events were categorised as crashes if they remained out with the lane for 15
seconds. Several studies (Juniper et al 2000, Hack et al 2000, 2001, Turkington et al
2001, 2003) have used the DASS and found that untreated OSAHS patients perform
poorer on all aspects of the steering simulator than treated OSAHS and controls
subjects.
Juniper et al (2000) compared the performance of 12 OSA patients diagnosed with
oximetry and 12 healthy matched controls on all three road-types in a randomised
order. Overall, the OSA patients had slower reaction times, greater steering deviations
and higher numbers of off-road events. Although the OSA group showed performance
decrements on all drives compared to the controls, the near drive (fog like conditions)
had the greatest magnitude of difference in the three driving outcomes. This suggests
that not only could OSA patients have poorer driving performance than controls, but
also this decrement in driving performance could be worsened by poor driving
conditions. The authors, however, did not gather information on the MVA rate of the
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participants, so it is not possible to elicit a judgement as to whether the OSA group
were at increased involvement in MVAs in real driving.
A similar protocol was used by Hack et al (2001) to establish if the simulator could
detect differences in driving performance in several conditions. Driving performance
was compared in 26 OSA patients before and after four weeks of CPAP treatment.
Further driving performance was compared in 12 controls that drove in a pseudo
randomised condition of alcohol consumption or a non-alcohol consumption drive. A
second control group (n=12) was also employed and their driver performance was
compared after a night of normal sleep or after 24 hours of sleep deprivation. All the
groups completed the three road-view conditions in a randomised order and the total
drive time was 90 minutes in each driving session. The untreated OSA group showed
significantly poorer steering control, longer RT and more drive-off the road events
compared to after CPAP treatment. This pattern was mirrored by both the alcohol and
sleep deprivation groups, with their driving performances' being significantly poorer
when compared to their 'normal' drives.
Hack et al also compared steering error at the start of each drive within each condition
and its progress over the 90-minute driving sessions. The alcohol group started poorly
and remained poor over the course of the drive, compared to their normal (alcohol free)
drive. The pattern was different in the sleep deprived and untreated OSA group.
Compared to their own 'normal' drives these two groups showed little steering error
initially when they were new to the task, but performance degraded with time-on-task.
This indicates that not only can PC based simulators detect differences in performance,
but that they can detect differences in the pattern of performance also.
Hack et al (2000) also compared driving performance in 59 male OSA patients, with
>10 4% dips in arterial oxygen saturation per hour. Patients were randomised to
receive either active CPAP (n=33) or sham CPAP (n=26). Baseline drives on the DASS
(road conditions and RT task as described above) were compared to post treatment
drives after one month of treatment. In the baseline drive, the two groups did not differ
in any of the driving measure outcomes of the steering simulator and were not
significantly different in age, weight or BMI.
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Post treatment drives showed a significant improvement in the therapeutic CPAP group
in all driving measure outcomes including RT, steering deviation and the number of off-
road events. They also reported significantly improved objective and subjective
sleepiness. However the sham CPAP group also recorded significant improvements in
subjective sleepiness (the ESS) and in the number of off-road events. To compare
between the groups, the authors compared the change scores in the driving outcome
measures by subtracting pre-treatment scores from post-treatment scores. All driving
measures showed a greater magnitude of change in the therapeutic CPAP group. This
was the first placebo-controlled parallel limb study to compare driving performance on
OSA patients. It further supports the hypothesis that driving simulators can indeed
separate driving performance between treated and untreated OSA patients, but
highlights the important issue of placebo effects. The decrease in the number of off-
road events as well as the subjective improvement in sleepiness shown in the sham
CPAP treated patients in this study may limit the conclusions that can be drawn from
the previous studies that have not included a control population.
Despite lacking a placebo controlled patient group, Risser et al (2000) used the
Systems Technology, Inc. Driving simulator (STISIM) to assess differences in
performance between 15 OSAHS patients (mean AHI 47/hour) and matched control
subjects. This is a PC based, fully interactive driving simulator. Like the AusEd
simulator it assesses steering deviation, speed control and the number of of-road
crashes but contains no measure of reaction time. Unlike the AusEd set-up, subjects
sit in a fully adjustable mini-van seat, and engine and tyre noises reflect the speed of
the vehicle. The road layout was of a two-lane road with both bends and straight
periods, with on-coming vehicles. Subjects were required to drive at 55mph for 60
minutes. OSAHS patients performed significantly more poorly than the controls in the
aspects of steering variability, speed variability, number of crashes and lane position
variability. Both groups showed a time-on-task decrement in lane position, but the slope
of this was higher in the untreated patients. Further the OSAHS groups also showed a
time-on-task performance decrement in the number of crash events, with the peak
number of crashes occurring in the last ten minutes of the drive. Unlike the AusEd
simulator, the simulator studied here demonstrates that a measure of speed can show
significant differences in OSAHS and controls, however this study did not measure RT,
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which is an important resource required while driving. The severity of patients in this
study was similar to the current study, indicating that driving performance decrements
do occur in groups with a moderate disease severity. The simulator was slightly more
sophisticated than AusEd and also one should note that the driving task was longer in
the STISIM study (60 minutes vs. 30 minutes) and the peak difference in crash events
occurred in the last block of driving, a full 20 minutes after the AusEd drive at its
assessed duration would have finished.
These studies illustrate the possibility of separating driving performance between
treated and untreated OSAHS patients and community controls, at least in some
aspects of driving. However, these studies generally did not enquire about real life
driving accidents and near miss incidents. This is crucial in deciding if the simulator
performance is indeed a reflection of real life driving. Although the AusEd driving
simulator only discriminated untreated OSAHS patients and controls by RT, the lack of
differences in real life driving (as measured by self-reported accident levels) were also
not different between the two groups. However, as only RT (from visual search)
showed decrements in performance, one cannot accurately determine whether the lack
of differences in the other driving outcome measures were due to the fact that the
OSAHS patients did not have global driving performance problems (i.e. all three areas
driving of tracking, visual search and speed control).
To try and detect a relationship between simulated driving performance and real life
MVAs, Turkington et al (2001) used a logistical regression technique on data obtained
from a twenty-minute version of the DASS with subjective reports of driving ability and
accident frequency from 150 OSAHS patients. The mean RDI of the group was 26.1,
but 20% of the group had a RDI less than 15/hour. 25% reported having an accident in
the past 3 years, 35% reported a near miss and 15% admitted falling asleep at the
wheel. Using results from previous simulator studies Turkington et al defined poor
performance as a tracking error >0.2, RT >2 seconds and 10 or more off-road events
an hour. The median tracking error, RT and the number of off-road events in the sample
were all higher than the defined impairment cut-offs the authors defined as a poor
performance. Results indicated that factors not directly associated with both driving
and OSAHS (age, gender, and alcohol intake) were better indicators of performance on
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the driving simulator than driving-related variables. However, the number of near
misses in the previous 3 years was associated with both poor tracking error and the
number of off-road events. Further the number of off-road events predicted the
reported number of accidents in the previous year, but the statistical method employed
only correctly classified 10% of the population who had experienced an accident in the
previous year. Both falling asleep at the wheel and the number of near-miss accidents
were associated with the ESS. There were no other factors associated with poor driving
performance. Although this study identified near miss accidents as predictor of tracking
error, the results from this study highlight the issues with driving simulators as a method
for screening OSAHS patients for driving ability, especially with a view to suspending
patients' driving licences. Although the patients who performed well on the simulator
were unlikely to have had an accident in the previous year, no relationship was found
between those who performed poorly and previous accident rate. Further, no patients
recording less than 10 off road events per hour reported an accident in the preceding
year, while only 10% of those who had 10 or more drive off-road events reported any
accidents in the previous year.
These results may have been partially due to the self-report methods for establishing
previous accident rate and, as reported in section 2.10.2, PC based driving simulators
which do not asses all three areas of driving (tracking, visual search and speed control)
lack both face validity and an adequate measure of all areas of actual driving
performance. Therefore the lack of associations between actual driving ability and
simulated performance may also stem from the fact that not all facets of driving ability
were measured in this simulator.
Other simulator tasks have shown differences in performance in only 20-30 minute
trials. One may speculate that although AusEd was designed to be monotonous and
was run in darkness to make it soporific. As it incorporates tracking, visual search and
speed control tasks the simulator may be more stimulating, initially than the others, and
as such a longer period of time may have been required to show a time-on-task
decrement in driving performance. However, it must be noted that in the current study,
time-on-task results for the patient group baseline drives (section 4.10) may suggest a
learning effect. Although each group were given a 10 minute practice run before
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commencing the 30 minute drive, steering and speed outcomes showed a change over
the 30minute drive, with the first block of 7.5 minutes showing the highest level of
deviation from test requirements. If a learning effect was present during the initial part
of the main drive this may have inhibited a true effect of deterioration in driving
performance from presenting during the 30-minute task. Therefore studies utilising
simulators must ensure that practise periods are both long enough and cover all
aspects of the driving task to ensure that learning effects are adequately controlled for,
prior to the main drive.
Hack et al (2001) reported the steering deviation at the start of the drives were similar in
both treated and untreated OSA patients, but worsened with time on the task in the
untreated group, over three 30 minutes drives. The Swedish transport simulator is state
of the art and is fully interactive, and Haraldsson reported that although patients were
instructed to drive for 90 minutes several stopped driving after one hour due to
sleepiness. Risser (2000) et al reported a time-on-task effect in their driving study with
the greatest number of crashes occurring in the last 10-minute block. These results
may indicate that if sleepiness is a causal factor in driving impairments one must
provide a long enough period for it to manifest itself and as a consequence impair
driving.
Despite the minor limitations of these studies, they consistently show differences in
driving performances in untreated OSAHS patients from treated patients and controls,
an association that the AusEd driving simulator was unable to replicate. The lack of
differences in both tracking (which has been shown to be consistently poorer in
untreated patients in the studies cited previously) and speed may be partly due to
methodological issues with the study design. These include study power, patient
selection, CPAP use, driving simulator malfunction and software faults.
Methodological issues with the AusEd driving study
Firstly the sample size of the study population was lower than we had sought. At study
inception a sample of 60 patients (30 to each treatment) and 30 control subjects was
anticipated to give a power of 0.8 at the 5% level. In fact we recruited only 45 patients
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and 19 controls. Nevertheless studies on other simulators (Haraldsson 1990, George
1996a + 1997, Juniper 2000, Hack 2001, Turkington 2003,) have shown differences in
OSAHS and control subjects' performance with numbers of participants similar to the
current study, suggesting that the simulator may not have been as discriminating as
other devices.
The low acceptance rate in the treatment effects trial may have been a product of the
recruitment method. OSAHS patients were contacted and asked to participate in the
study prior to their polysomnography investigation. Hence, they were being asked to
participate before they were diagnosed with the condition. On telephoning patients to
establish if they would be willing to participate, many communicated their hesitation in
committing to taking two days of off work. This recruitment method was chosen to
ensure that all daytime testing of patients was completed on the day after their
polysomnography night. Despite heavily advertising for control subjects there was a
low level of recruitment, and this may have been due to the time required to complete
the study.
Other factors which may have contributed to the lack of major differences in our study,
include the poor correlations between nighttime variables and daytime testing
(Kingshott 1999b). Due to financial constraints and waiting time for polysomnographic
investigations, it was not practical to ask patients already diagnosed to undergo a
further PSG night. Hence, to limit the time participants would require to take of work,
the follow-up investigation day was limited to one morning. This in itself may have
limited the conclusions one can draw from the current study. Restriction to a morning's
testing required dropping of the MWT and SteerCiear. Both these instruments have
shown improvement with CPAP (Findley et al 1989b, 1991 + 1999, Sangal 1992a,
Engleman et al 1994a, Jenkinson et al 1999 + 2001, Kingshott et al 2000). Their use in
this study would have helped to clarify by objective methods if the CPAP group had
improved on both sleepiness and vigilance over the treatment month.
The treatment issued for this treatment effects study was either auto-titration CPAP or
an oral placebo. The use of auto-titration CPAP has been show to be at least as
effective as fixed-pressure CPAP (section 1.9.3.2), and previous studies have
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employed an oral placebo for comparison with a mechanical treatment (Barnes 2002,
Faccenda 2002, Engleman 1999).
Issues in the use of placebos in medical research have been raised (Karlawish and
Pack 2001). It has been argued that placebo-controlled trials result in patients being
denied active treatment. However, in the current study patients were started on the
treatment limb between one and two months after their polysomnography study. At the
start of the study the local waiting time for a CPAP titration appointment and CPAP unit
issue after diagnosis was made was around 6-8 months. As patients would not be
denied active treatment for prolonged periods of time, I felt justified in using a placebo.
At study inception, concerns of safety and acceptability existed concerning sham CPAP
(Kreiger et al 1983, Loredo et al 1999) and this coupled with the fact that the early use
of CPAP predicts long term CPAP use (Mcardle 1999, Weaver 1997b) provided
grounds for caution in using sham CPAP. Although it is essential to ensure treatment
effects are the result of active treatment, the issues concerning sham and the long-term
benefits patients can receive from CPAP an oral placebo was selected. As such, the
oral placebo was actively sold to patients, with the approval of the local ethics
committee, as a potential treatment for OSAHS. I believe this is the reason that
subjective ESS was significantly improved in the placebo group, although it was not
within the normal range (usually <10). Compliance in the oral placebo group was
based on the number of capsules returned at the end of the treatment limb.
Compliance expressed as the number of nights used divided by the total number of
nights on the treatment limb was similar in both groups. A statistical trend towards
higher nights of use of placebo was observed. The mean CPAP use was 76% of the
nights issued, with an average usage of 4.2hours/night. Five people used CPAP for
less than 50% of the days on treatment and 12 people used it for less than an average
4 hours per night. As the number of participants in the CPAP group was small, the
small numbers of patients not using CPAP regularly or for at least four hours per night
may have been a major reason that more of the subjective secondary outcomes were
not significantly different between the CPAP treated patients and those on the placebo.
A longer period of treatment may have given patients more time to adjust to wearing
CPAP and settle into a routine. Given the issues with delaying treatments for those
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patients on placebo and the fact that other studies have shown significant
improvements in both subjective and objective outcomes after a similar period of time
(Engleman 1999, Jenkinson 1999, Stradling 2000, Montserrat 2001), one month of
treatment seemed justifiable. Turkington et al (2004) reported significant improvements
in performance (including steering error, reaction time and the number of off-road
events) on a 20-minute DASS trial in 18 OSAHS patients after only 7 days of treatment
compared to 18 OSAHS patients who were not treated. The CPAP treated patients
then stopped using CPAP for one week. The significant differences in driving
performance were still evident in these areas between the two groups at 7 days,
although the magnitude of the differences were lower than had been found while using
CPAP. Although the control group were not given a placebo treatment it does suggest
that driving performance can improve quickly with CPAP. Subjective improvements in
the Stanford Sleepiness Scale (SSS) also showed significant improvement in the CPAP
treated group compared to the controls, and this unlike DASS performance deteriorated
quickly with the removal of CPAP. Although, this serves to suggest the insensitivity of
the AusEd simulator, one should note that the DASS-tested patients were all clinically
severe (>50 apnoeas/hypopnoeas per hour) and used CPAP on average for
4.9hrs/night.
Most patients in the current study could be considered to have moderate OSAHS, but
15% of the patient group had an AHI less than 15. Although previous studies have
indicated that mild OSAHS patients experience subjective improvements with CPAP
(Engleman 1999) others have reported that increased MVA rate in untreated OSAHS
patients may be highest in severe cases (Findely 1989a, Adrich 1989, Cassel 1990).
Therefore the moderate disease severity may have reduced the possibility of the patient
sample having driving impairment. Conversely, although the control subjects were
vigorously screened (both by questionnaire and a telephone interview) for lack of
snoring and sleepiness before participating in the case control study, no objective
monitoring, to detect OSAHS and no objective measure of sleepiness were undertaken.
Although unlikely, it is not possible to exclude entirely the possibility that some of the
control group may have had OSAHS. Further the baseline characteristics of the control
group (lower mean BMI, mean higher IQ, mean lower weight, higher education level)
would have served to discriminate the controls from the patients. It should also be
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noted that the level of subjective sleepiness inclusion criteria was different between the
patient and control groups. An ESS of 8 or greater was used as inclusion criteria for the
patient groups however controls were accepted with an ESS of up to 11. This overlap
of ESS between the 2 groups served to increase the possible numbers of participants.
As no objective measures were used to assess the presence of OSAHS in the control
group ESS was used in this group as a possible indication of OSAHS symptomology.
Within the Department an ESS of 11 or over is classed as pathological sleepiness and
therefore this was the level was used as the cut-off for subjective sleepiness. However
an ESS of 8 was used with the patient group to inhibit the exclusion of patients who
may not have recognised their level of sleepiness. Further although sleepiness most
likely plays a large part in MVAs in the OSAHS population, one did not wish to exclude
patients solely on ESS, as a lack of subjective sleepiness does not necessarily exclude
these patients from the risk of MVAs.
However if these discrepancies had effects on the simulator performance, one might
presume this would, overall, increase the performance differences between the two
groups with the control group performing better. It is unfortunate that the control group
were not tested on the SteerClear task, this could have provided further indication if the
patients and control group were similar in their performances. This may have helped
clarify if the AusEd simulator was not sensitive enough to discriminate differences in
performance. Further, although the performance of the placebo treated patients did not
change significantly over the one-month period suggesting that the AusEd does have a
level of test-retest reliability, the reproducibility was not tested in the control group who
would have been free from possible placebo/nocebo effects. Therefore it is not possible
to conclude that the lack of performance differences between the three groups was due
to real measures of actual performance as opposed to poor reproducibility of the
simulated tasks.
Several factors built into the AusEd driving simulator may have reduced the sensitivity
of the program. A problem concerning the recording of RT was noted on several drives.
On each drive 10 trucks were requested to appear, but on occasions the simulator did
not record one or more of the actual reaction times. This may have been due to a
software 'bug' in the original base programming, but due to copyright restrictions, our in-
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house programmer was unable to have access to this part of the program to investigate
or repair this. We have speculated this could have been a consequence of the program
only recording a RT when the brake was depressed by 90%, when it was therefore
possible to reduce speed without recording a reaction, and as such several people
'tailgated' the truck (despite strict and clear instructions to stop immediately when a
truck appeared). As this was both a validation study and an intention to treat study no
data were filtered or removed. A second 'bug', also on occasion, caused 'time-outs' in
which the computer would close down the driving simulator program. This occurred
several time during the practise runs but only once during the 30-minute drive. To limit
this problem, the PC the AusEd program was run on was used only for the AusEd and
SteerClear programs, and was only switched on immediately prior to the running of the
tasks, which appeared to help. Further, the AusEd output program only measured
driving-off road events when the periphery of the outside lanes was crossed, and
therefore any drifting across to the on-coming lane was not recorded. These incidents
could prove fatal in real life, and information on these events, if they occurred, may
have shown differences between the patients and control groups. It was extremely
unsatisfactory that we were unable to access and improve the software for the device
which we had jointly designed. This had a major deleterious effect on this study.
The outcome measures of the simulator were recorded as means and no standard
deviations were recorded for steering and speed performances, as has been
incorporated in some other simulators. As the outcome data for the steering and speed
deviations for each individual drive were reported as a mean value, it did not make
sense to report the group outcomes as a median value.
Although the data were non-parametrically distributed, a repeated measure MANOVA
was used to assess treatment effects between the patients groups. If non-parametric
statistics had been used, due the number of comparisons being made, a correction for
multiple comparisons would have been required. Hence the loss of power in the
parametric test would be similar to that of the multiple comparisons with correction and I
felt justified in using the parametric tests. I do not believe the choice of statistical tests
used produced a type two statistical error. MANOVA analysis has been commonly used
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in psychological performance research, so this was not a methodology avoided by
others.
OSAHS and professional drivers
OSAHS patients who were professional drivers were excluded from this study, due to
the nature of the placebo and the ethics of withholding treatment. However, one should
not forget this population. Previous reports on this population have shown high
prevalence of snoring and SDB in bus drivers (Hui 2002) and in a self report survey
Engleman (2005) reported weak correlations between ESS and work related accidents
in Scottish bus drivers. Truck drivers with SDB were twice as likely to be involved in an
MVA than those without OSAHS (Stoohs 1994). This population may be at increased
risk to OSAHS due to the sedentary lifestyle associated with professional driving, as
BMI and obesity are risk factors in OSAHS.
6.4 Conclusion
In summary, the AusEd driving simulator did not produce outcome measures congruent
with other driving simulators assessing performance in an OSAHS patient population.
Reasons that the simulator may have failed to find a difference between treated and
untreated patients and also controls have been discussed above. The AusEd driving
simulator was designed as need for a clinical tool to assess driving was required and
previous simulators did not appear to measure all areas of driving (section 2.10.2). As
such, further research is much needed to find a tool that can assist in discriminating
OSAHS patients who may be at increased risk of MVAs.
Several issues regarding driving simulators as a method to assess driving performance
exist. Despite most published simulator studies showing that driving performance is
poorer in untreated compared to treated OSAHS patients and controls, there is still the
issue of poor correlations between simulator outcomes and real world driving. Before
any type of simulator can be used as a discriminative and valid guide to suspend driving
in sub-populations, a clear and justifiable correlation between real world driving and
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simulated driving must be shown. Although limited evidence exists that simulated
performance predicts past actual MVA rate (Turkington et al 2004, Findley et al 2000),
further research is essential before driving simulators can be used in day-to-day clinical
settings. Further, although simulator studies have shown an improvement in driving
performance after CPAP, the outcome measures for treated OSAHS on the majority of
simulators do not return to the same levels as controls, which raises the issue as to
what level of impairment is actually clinically relevant. Some authors have suggested
cut-off levels of impairments (Turkington et al 2001) on steering deviations, RT and
number of drive off- the road events, based on results from control populations and
treated CPAP patients. For example a steering deviation of 2cm or over and more than
10 off-roads an hour has been suggested as equating to poor performance. However
one might argue that any off-road events are 'pathological' as this should not occur with
any real regularity in real life driving.
A second issue would concern which areas of driving would require to be 'pathological'
before driving is suspended. In any given individual, if steering deviation was regarded
to be higher than normal but all other outcomes were not, would one be considered
dangerous to drive? Further, if a patient was considered to be impaired in their driving
abilities but had never previously been involved in an MVA, would one be justified in
suspending their licence? Although, the fact that an event has not happened previously
does not inhibit one from happening in the future, any method of limiting person actions
should be based on strong evidence to support this. At this time strong evidence does
exist that as a population OSAHS patients are at a higher risk of being involved in an
MVA. However, most driving simulator studies as well as studies investigating numbers
of actual MVAs in OSAHS samples report large degrees of variability within this
population. Further, as poor correlations exist between the indicators of disease
severity, simulated driving performance and accidents rates, one cannot report that it is
only severe OSAHS patients who are at increased risk. At this time our level of
understanding as to why sub-populations of OSAHS have higher number of MVAs is
poor, but this is coupled with limited evidence to support the fact that simulated driving
performance is an actual reflection of real life driving. As such driving simulator
research in the OSAHS population has not developed to a point where these
instruments would be reliable tools to assess fitness to drive.
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OSAHS patients appear to be at an increased risk of MVAs. Hence further extensive
research should be under taken to assess if a PC based simulator such as the AusEd
can discriminate driving performance using the tracking, visual search and speed
outcome measures. This safe, economic and portable, potential method for screening
drivers and in turn reducing the number of potential accidents and fatalities as a
consequence of OSAHS, would be desirable
However, on the basis of the data presented in this thesis, the AusEd simulator as
available to us is not the ideal device to use in further studies, unfortunately.
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Chapter 7: Secondary Methods of Analysis from the AusEd
Driving Study
7.1 Introduction
Motor vehicle accidents (MVAs) associated with sleepiness or falling asleep at the
wheel may be implicated in up to 16-23% of accidents involving the general driving
population. As previously reviewed, research concerning MVA rates in OSAHS patients
has also indicated that this population may be at increased risk, with estimates ranging
from 2-7 times that of healthy matched controls (George et al 1987, Young 1995,
Findley et al 1988).
Brown (1994) defined fatigue (which is often used interchangeably with sleepiness) as a
subjective experience of diminished inclination to continue performing the current task.
During driving this may manifest itself as an increasing need for sleep that is often
described as a feeling of sleepiness. Sleepiness may reduce mental alertness which in
turn increases the likelihood of an MVA by reducing one's attention available to the
driving task, by slowing responses to external stimuli (i.e. other road traffic) or as a
result of falling asleep at the wheel.
However, investigating the cause of accidents after the fact may be unreliable,
especially in sleep-related accidents. Bonnet and Moore (1982) concluded that healthy
adults who fell asleep unexpectedly tend to deny having fallen asleep if the sleep period
is less than two minutes. This may be coupled with the evidence that although drivers
(free from sleep disorders) are aware of their level of sleepiness during driving, they
may underestimate their likelihood of actually falling asleep. When subsequently asked
about levels of sleepiness, they have a poor recollection of it (Reyner and Home
1998a, Home and Reyner 2004). Hence, drivers may not attribute any accidents to
feeling sleepy or actual sleep periods.
Therefore research investigations into sleepiness and sleep periods, as precursors to
accidents may be best suited to prospective studies. One method of measuring driving
performance is to monitor vehicular events such as crashes, near misses, and lane
189
drifting and speed deviations. The frequency of these events may establish that sleep
deprived or OSAHS individual may have greater numbers of these events, but will not
necessarily establish their cause. Therefore, such a metric may be complimented by
investigating a further aspect of performance, for example physiological measures, i.e.,
analysis of EEG, heart rate variability and eye activity measures, or behavioural
measures i.e., verbal reports of subjective sleepiness. In addition it is not clear whether
the increased rates of accidents in sleepy drivers relates to falling asleep or to delayed
responses when awake. Recording of EEG during driving simulation may help clarify
this.
Electroencephalograms record the electrical activity of the brain and although any one
frequency of activity may be dominant (i.e. theta whilst in stage two of sleep) other
frequencies are also present albeit at very small thresholds. Recordings of
electroencephalograms (EEG) during driving can be used to assess whether periods of
sleep (for example, 15 seconds or more of any sleep stage in a 30 second epoch as
defined by R&K (1968)) or micro-sleeps (defined as an intrusion of alpha or theta for
greater than 3 seconds) are occurring. Fast Fourier transformation (FFT) can also be
applied to the EEG trace. This is a method for dividing biological signals into its
constituent parts. FFT analysis gives one the absolute power or spectral density power
of each frequency band. Time changes in these bands can be used to speculate on
changes in cortical arousal, for example increases in delta and theta spectral density
power could indicate increased levels of sleepiness and in turn a reduction in vigilance.
Mitler et al (1997) conducted physiological sleepiness monitoring, including EEG
recordings during real world driving on a group of 80 male long-haul truck drivers, who
were monitored as they performed evening/night shifts for work. Two of these drivers
were polysomnographically diagnosed with OSAFIS. In addition, the authors found that
as a group these drivers were sleep deprived, and that their actual hours of sleep were
lower than their subjective reports of ideal hours of sleep. On analysis of concurrent
EEG monitoring obtained during driving, two drivers (not those diagnosed with
OSAFIS) exhibited seven episodes of stage 1 sleep during evening and early morning
driving, with one episode of stage 1 sleep lasting for 80 seconds. Further behavioural
signals obtained from video recordings of the drivers faces, were sampled every 30
190
minutes (in six minute blocks) and of 29,310 video segments. 7% of these showed the
driver to be drowsy, determined by drooping eyelids and a bobbing head.
During this study none of the drivers were involved in any accidents, suggesting that
sleepiness and sleep periods do not always result in MVAs. However the end result of
sleepiness is often sleep and it is not ethical to sleep deprive or withhold treatment of
OSAHS to determine if drivers will eventually show EEG changes prior to driving
incidents. Therefore, several studies have been conducted more safely on driving
simulators and vigilance tasks to assess changes in EEG and performance.
Kingshott and Douglas (1999a) recorded concurrent EEG whilst participants underwent
the sustained vigilance task SteerClear. They reported that only 3 of a possible 71
OSAHS patients and none of the 9 normal controls had microsleeps (theta for >3
seconds). This is congruent with results of Mitler, however, SteerClear does not
realistically assess driving performance and due to the nature of the SteerClear task it
would not necessarily be possible to relate these microsleeps to actual events. Risser
et al (2000) recorded driving performance (lane drifting, speed variability, steering rate
and crash frequency) on a driving simulator in a 60-minute drive with concurrent EEG
recordings in 15 OSAHS and 15 control patients. Overall lane position showed more
variability in the OSAHS patients than controls and the OSAHS patients experienced
more crashes. Both these measures of driving-based performance showed
deterioration over time in the patient group. Steering rate and speed variability were
also significantly different between the two groups although these did not worsen with
time. Overall the OSAHS group had greater number and longer durations of EEG
defined microsleeps (alpha or theta >3seconds) and both of these EEG measures
showed a time-on-task effect for the patient group. Strong correlations were found
between EEG measures and lane position and crash rate, further supporting the
hypothesis that as sleepiness increases measures of driving performance deteriorate.
Kinnari et al (2000) conducted a simple visual reaction time task in 21 male patients
with moderate OSAHS, who underwent concurrent EEG recordings during the task.
The 90-minute EEG recordings were divided into segments of 0.5-2seconds using an
automated computer program and these segments were classified (initially by a
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validated computer program and then checked manually) as one of seven stages,
including; alert eyes open; alert with alpha; sleep stage one and sleep stage two. The
authors report that duration of the reaction time was linearly correlated with the
vigilance state and that RT increased as alertness deteriorated. However they also
reported that the presence of slow eye movements was more consistently related to
changes in performance than changes of the EEG.
Therefore, if driving performance can also be affected by sleepiness as opposed to
actual sleeping at the wheel, overt changes in EEG i.e. microsleeps may not always be
seen. Researchers from the Sleep Research Centre in Loughbourgh University (UK),
have undertaken a variety of studies investigating driving performance in healthy young
drivers in sleep deprived states to investigate drivers' awareness of sleepiness (Home
and Baulk 2004), and a range of possible sleepiness reducing (Home et al 1996,
Reyner and Home 1998b, Reyner and Home 2002) and enhancing measures (Reyner
and Home 2000, Baulk et al 2001, Home et al 2003). Within these experimental
protocols utilising a real-world driving simulator, subjects undergo a thirty-minute
practise run before commencing a two-hour drive. During these studies concurrent EEG
recordings were produced. Instead of manually scoring these EEG traces for the
intrusion of alpha or theta frequencies, these EEG recordings are subject to Fast
Fourier transformation (FFT), a process that can transform a single biological signal into
its component parts, and give the absolute power/spectral density power for a
frequency range. The Loughbourgh University team used the standardised values from
the frequency band of 4-11 Hz (theta + alpha) and averaged this band over every one-
minute period during the total two-hour drive. To standardise these frequencies, they
used the difference of each minute epoch from the average power from the thirty-
minute baseline value and then divided by the standard deviation of the baseline power.
Using concurrent video footage of driver and road, sleep related driving incidents and
incidents caused by other factors, are distinguished using signals of sleepiness (eye
rolling, staring or eyes closed).
This research team have shown that in sleep deprived young adults, time-on-task
increases in sleepiness occur, both through verbalisation of sleepiness (using the
Karolinska sleepiness scale) (Reyner and Home 1998b, Home et al 2003) and with
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increases in the standardised FFT alpha/theta power (Reyner and Florne 1998b, Florne
et al 2003). These are often associated with a time-on-task decrement in sleep-related
incidents as recorded by the driving simulator (Reyner and Home 1998b, Home et al
2003). These findings are consistent with those of Kecklund and Akerstedt (1993) who
found positive correlations between subjective reports of sleepiness (reported hourly)
and EEG alpha plus theta power increases in nighttime long distance truck drivers.
However Home and Baulk (2004) have also reported that after a normal night of sleep
there is still a time-on-task decrement in sleep-related driving incidents, but is not
accompanied by the same time-on-task decrement in the standardised FFT alpha/theta
power.
Lai and Craig (2002) recorded EEG from 19 bipolar channels on 35 healthy but sleep
deprived participants during a simulated driving task. Participants had a 10-15 minute
baseline drive and then a further drive lasting for up to two hours. The EEG was first
classified as one of four stages depending on the presence or absence of alpha, and
theta. The authors described the cycle through these phases as a cycle of micro-sleep
to arousal. The first full cycle of each of these phases and the baseline EEG of the 19
channels was subject to FFT. The EEG was defined into four frequencies; delta (2-4hz),
theta (4-8Hz), alpha (8-13Hz) and beta (13-20Hz). The power for each frequency was
an average of each band over the 19 channels and was averaged over 30s. Each
frequency band (delta, theta, alpha and beta) showed increases in mean power from
the baseline EEG during the transition to fatigue. Delta and theta showed greater
changes in magnitude (22 and 26% respectively) than the alpha and beta bands (9%
and 5%). This study demonstrates that changes in the EEG can be seen during driving
and that these changes are accompanied with individual increases in each of the
component frequencies of the EEG, with delta and theta showing the largest increases.
However although the authors comment that increased levels of fatigue were
accompanied by increasing numbers of participants having "driving related errors and
accidents," they do not report if these changes in driving performance were significantly
different from that of baseline or throughout the drive.
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These previous studies suggest that definite time-on-task increases in EEG power
(especially alpha and theta) occur in relation to sleep debt in non-sleep disordered
participants. However conventional sleep scoring is done in 20-30 second epochs, with
intrusions of alpha and theta usually requiring 3 or more seconds to be scored as micro-
sleeps. Further, there is a low level of correlation found between micro-sleep intrusion
and performance vigilance tests (Kingshott 1998a). It is still not clear if driving
accidents are a direct consequence of changes in the EEG (i.e. increases in power of
EEG bands) immediately before an incident, or as a result of the increasing demand of
sleepiness seen over time. For these reasons the concurrent EEG recorded during the
AusEd driving task was subject to Fast Fourier transformation (FFT) to allow smaller
blocks of time to be analysed and investigated to see if changes in EEG spectra occur
with driving incidents.
Therefore the hypothesis that changes in the EEG power would occur immediately prior
to driving incidents was evaluated using small time blocks of EEG recorded prior to all
driving incidents on the AusEd driving simulator and compared to a ten second period
of EEG not associated with driving incidents. Crashes and driving off the road incidents
are seen as exemplars of complete loss of control during the driving task (whether
recorded by controls or patients either before or after treatment), and as such all the
EEG prior to all driving events were to be analysed to investigate changes.
A second physiological measure, that of eye movements, has also been linked to
increasing sleepiness. In a review of blink rate as a measure of fatigue, Stern (1994)
reports that blink rate among other measures, (including blink duration and blink
amplitude) appears to increase with time-on-task over several conditions. These
include reading, vigilance tasks and performing on driving simulators. However reports
of blink rates vary, Home and Reyner (1996) found no differences in the blink rate from
the first to second hour of their driving task, despite increases in both subjective and
objective sleepiness. However, Hakkenan et al (1999) investigated blink duration as an
indicator of sleepiness in 20 bus drivers, ten with mild to moderate OSAHS and ten non
sleep-disordered, matched controls. Eye blinks were recorded using in-car cameras,
and scored frame by frame with a resolution of 400ms. They compared the sleep
latency on the MWT; blink duration, maintenance of speed and lane drifting in the two
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groups. After the OSAHS group underwent an average nine weeks of CPAP treatment,
all underwent the same driving task again. At baseline the OSAHS group had higher
mean blink duration and a shorter sleep latency score than the matched controls, but
they noted no differences between the two groups on blink frequency. Both blink
duration and MWT sleep onset latency were not significantly different to matched
controls after an average nine weeks of treatment, suggesting that some measures of
eye movement may be sensitive to sleepiness. However, there were no differences
between the two groups at either time period for speed maintenance or lane drifting (as
determined by an in-car automatic inspector).
Increases in blink rate may be affected by factors other than the levels of sleepiness.
Stern and Skelly (1984) highlight the issue that blink rate may be affected by task
difficulty. In their study Stern and Skelly (1984) compared blink rates of pilots and co¬
pilots in a flight simulator. They reported that pilots show an increase in blink rate
compared to the co-pilot and this difference in rate is held when the co-pilot takes flight
control. However, a study by Richter et al (1998) suggests the opposite. In their study
analysing psychophysiological variables during rural driving, they report blink rate
significantly reduces in proportion to the change in curvature of the road. In other
words that as task difficulty increases (controlling speed and lane position through a
chicane), blink rate reduces.
However, few studies have investigated blink rate as a function of time-on-task in a
standardised driving procedure in a sleep disordered population. Hakkenan et al (1999)
used real world driving, and so were unable to control for traffic exposure and weather
conditions etc. To investigate whether it is possible to detect a relationship between
sleepiness and blink rate in OSAHS patients compared to controls during a driving task,
EOG recording was to be analysed and compared for time-on-task effects between
patients and controls.
This chapter will investigate changes in EEG and blink rate in OSAHS patients and
matched controls undergoing a 30-minute simulated driving task.
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7.2 Study Population
Of the forty-five OSAHS patients and 19 control subjects who participated in the AusEd
driving simulator study, 61(19 controls) participants underwent concurrent
electroencephalographic (EEG) and electro-oculographic (EOG) recordings whilst
"driving" and these EEG and EOG data were analysed for this component of the thesis.
Of these 53 were male and 8 were female, demographic and anthropometric data is
reported in section 4.5 and 5.5.
7.3 Acquisition of the Electroencephalograph (EEG) Recordings
Each of the OSAHS patients underwent two simulated drives one before treatment of
OSAHS and again after one month on treatment, while the control subjects completed
one simulated drive. Each simulated drive lasted 30 minutes and EEG recordings were
produced for the same length of time.
Electrode placement was as previously described in section 3.1. A total of 102 EEG
tracings lasting 30 minutes were obtained. Due to problems with the sleep recording
equipment, one patient had no concurrent EEG for both his pre- and post-treatment
drives and a second patient did not have EEG recordings on his post treatment drive.
During four simulated driving performances the EEG signal was lost. This occurred in
one patient both in his pre and post treatment drive and twice in two other patients' post
treatment drive. To determine the cause of the signal degeneration I would have had to
enter the room and this disruption may have acted as a stimulus to the drivers, thereby
distorting the driving simulator results. Thus the EEG electrodes were not replaced and
EEG signals are unavailable for analysis. On inspection after the simulated drive two of
these signal losses were due to the EEG wires having been dislodged from the
recording device, one was an error in the recording device and the last was due to the
patient scratching at the EEG electrode and damaging the wire.
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7.3.1 EEG - Periods of Analysis
Periods of Analysis
To investigate if EEG frequency distribution changes occur prior to driving events, i.e.




Driving-off-road - crossing lane boundary to roadside verge
Changes in EEG occurring prior to the three types of crash events (n=95) were
analysed in one batch and changes in the driving-off-road events (n=74) were analysed
separately.
For each of the crash and driving-off-road events recorded, a ten-second-time block of
EEG starting 20 seconds before the event and a two-second-time block of EEG
immediately before the event were batched.
Each of these EEG blocks corresponding to events were compared to a ten-second
time block of EEG, designated a baseline EEG period (see section 3.9.1). This was
taken from the period 601 to 620 seconds of the driving simulation and corresponds to
the first twenty seconds of the second block of straight road surface. This period was
used to allow within-subject comparison of a block of EEG free from overlap from
driving events and RT activities.
Using two separate periods of EEG preceding off roads and crashes allowed
comparison to each other and the random time to try to determine if any EEG slowing is
evident up to twenty seconds before an event.
Fast Fourier Transformation (FFT) of the EEG
Each 30-minute EEG trace was recorded on the Compumedics system version 5.2;
saved in European data format files (EDF files). These raw files were then analysed
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using an FFT program (see section 3.9.2 for details). To limit the effect of blinks and
muscle artefact on the EEG, frequencies of lower than 4.9Hz and greater than 16Hz
were excluded by band pass filters. The FFT program provided power spectral density
values in microwatts/Hz (pW/Hz) for the three spectral bands on a second by second
basis. The three frequency bands used were;
High theta 5-7.9Hz (light sleep)
Alpha 8-11,9Hz (feeling drowsy with eyes closed)
Sigma 12-16Hz (awake)
These data were stored as excel files and the appropriate blocks of EEG, i.e. ten
second or two second blocks were transferred to the SPSS package and mean values
were obtained giving the mean absolute value per EEG frequency band.
No between-subjects analysis was performed. The three time points (baseline EEG,
ten-second time block of EEG before an event and two-second time block of EEG
before an event) were analysed on a within-subjects basis. This meant the EEG data
was 'self-calibrating' and required no standardisation of the EEG data.
On occasion EEG signals were temporarily lost due to excessive movement of the
wires (participants moving or scratching at wires) or muscle activity. Although the EEG
signals were subject to band pass filtering, each EEG block (either two or ten seconds)
to be used for analysis was checked by eye to ensure signal clarity.
Overall there were 169 driving events, of which 74 were classed as driving-off-road
events and 95 were classed as crashes. Of these only one, ten-second time block of
EEG before a driving-off-road event was unable to be analysed due to movement
artefact. Three of the remaining 168 ten second blocks corresponding to a driving
event consisted of only 8 seconds of mean standardised data, and again this was due
to brief loss of signal.
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rable7.1; Progression chart for EEG periods of analysis
Task performed
Step 1 AusEd driving simulator outputs - obtain driving events
Step 2 Note time (in seconds) for each event to be analysed
Step 3 Manually check EEG traces to detect loss of signal
Step 4 Note any time periods unable to analyse
Step 5 Transfer EEG traces to EDF format
Step 6 Perform FFT analysis on the raw data -provides absolute power for
frequency bands
Step 7 Transfer appropriate period to SPSS and compute the mean and SD
for each time period.
7.4 Acquisition of Blink data
In addition to the EEG recordings, electro-oculograms (EOG) were also recorded for
each patient and control subject for each of their 30-minute 'drives'. Electrode
placement was as previously described in section 3.1.
A total of 105 EOG recordings were obtained. EOG recordings were not possible for
one patient in both his pre and post-treatment drive due to problems with the
neurophysiological recording equipment, and a further two post-treatment drives were
unavailable due to loss of signal. The simulated drive was not interrupted to investigate
the cause of the loss of signal.
Further EOG recordings were obtained for 34 of the 45 patients on the vigilance task
SteerClear, performed by all patients pre-treatment. Due to technical problems,
concurrent EOG was unable to be recorded in 11 patients. Control subjects did not
undergo the SteerClear vigilance task.
7.4.1 Scoring blinks
The computerised polysomnography system provides real time outputs for both EEG
and EOG recordings. Blinks were manually scored from the EOG channel output.
Figure 7.1 shows a typical EOG trace with blink artefact. An in-house scoring criterion
was established with blinks only being scored if they appeared on both EOG channels.
Figure 7.1 demonstrates the blink artefact on the mix channels (corresponding to
Cz/Pf1 and Cz/Pf2), however these channels were not used for the scoring of blinks.
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Each 30-minute drive was scored for the presence of blinks using a 30-second epoch
window. The system allows for creation of scoring user defined events and this was
used with blinks being manually highlighted on the polysomnographic recording system.
An automated analysis program from the Series S Compumedics system was modified
to analyse the total number of blinks scored. Outputs reported the total of blinks per
study as well as the number of blinks per minute and per 30 second (1 epoch). This
data was available only on hard copy printed directly from the analysis program and
was manually inputted to the SPSS database. To ensure accuracy the data was
inputted twice one day apart and compared, any record showing differences were
deleted and the procedure was started over.
The SPSS system was used to compute the number of blinks in each quarter (7.5
minutes) of the simulated drive or vigilance task.








* = indicates blink
7.5 Statistics
7.5 1 EEG Data




Within-subject comparisons for continuous data for time-on-task analysis were analysed
using the non-parametric Friedman test and between-subjects comparisons were
conducted with Mann-Whitney U non-parametric tests.
All tests were run on the PC statistical package SPSS (SPSS for windows, Version 12,




Within subjects comparisons of the EEG frequency bands corresponding to crash and
driving-off-road events showed significant statistical differences between the baseline
EEG and the ten-second time block of EEG and two-second time block of EEG before
the event. Tables 7.2 and 7.3 show the mean and standard deviation of the spectral
density power in microwatts/hertz (pW/Hz) and significance levels for the three EEG
spectral bands.
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Baseline EEG and the ten-second time block of EEG before an event
There was no significant change in the mean spectral density power of the sigma and
alpha bands, however there was a significant increase in the mean spectral density
power of the theta frequency band between these two time periods.
Baseline EEG and the two-second time block of EEG before an event
There were significant changes in all three of the EEG bands between these two time
periods, with all three bands showing increased mean spectral density power from
baseline.
Ten-second and two-second blocks of EEG before an event
There was no further significant increase in the sigma and alpha bands between the
ten-second and two-second time blocks of EEG before an event. However the theta
band showed further significant increases in the mean spectral density power.
Figure 7.2 shows the changes in the three spectral bands across time.
Figure 7.2; Changes in mean spectral density power

























Seventy-four events were classed as driving-off-the road not leading to a crash. In
these events the subject continued to drive on the roadside before returning to the road.
Table 7.3 shows the means and significance levels of baseline and at 10 and two
seconds before driving off road. Figure 7.3 shows the changes in the mean absolute
power of the three bands.
Table 7.3: Changes in spectral density power of the EEG bands in driving-off-road









































































Figure 7.3; Changes in mean spectral density power of the

















Baseline EEG and the ten-second time block of EEG before an event
There were significant increases in the mean spectral density power value of all three
EEG spectral bands between the baseline and the ten-second time block before going
off-road.
Baseline EEG and the two-second time block of EEG before an event
Unlike the crash events the only significant increase in mean spectral density power in
the two-second block before the event was found in the theta EEG band, with no
significant changes being noted in the mean spectral density power of the sigma and
alpha EEG bands.
Ten-second and two-second time blocks of EEG before an event
Again these events showed a different pattern of change than the crash events. The
only band to show a significant change in mean spectral density power was the sigma
EEG band and this showed a reduction in the mean power from the ten-second time
block to the two-second time block.
7.6.2 Eye-blink analysis results
Eye-blink rate comparisons have been made between the three groups using four 7.5
minute time periods. Splitting the 30-minute drive into these four quarters was
performed due to the set-up of the AusEd driving simulator, wherein road type alters
from two minutes of chicane road to five minutes of straight road. As there has been
previous evidence to suggest blink rate differs on straight and chicane roads, the 30-
minute drive was split into four quarters each of 7.5 minutes. Each 7.5-minute quarter
contains five minutes of straight road and 2.5 minutes of chicane road.
To investigate possible sleepiness related effects on eye-blink rate, comparisons of
eye-blink rate were made between the OSAHS patients before commencing treatment
(n=44) with both the CPAP treated OSAHS patients (n=24) after one month of
treatment and the control group (n=19).
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As can be seen from table 7.4 there were no significant differences between the three
groups after comparing the mean number of eye-blinks in each time quarter. However
as the standard deviations suggest, there were very large differences in individual eye
blink rate seen across participants.

































































To investigate if blink rate changes across time, eye-blink rate across the four quarters
were also analysed by a Friedman test. There were significant changes in blink rate
found in all three groups by time-on-task (see table 7.5). These changes are
highlighted in graph 7.4.
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Ta ale 7.5; Within-subjects comparison of blinks per quarter for patients and controls
1st 2"d 3rd 4th
Quarter Quarter Quarter Quarter P-
Mean Mean Mean Mean value

























Controls 110.8 125.1 134.8 143.1
0.01
(n-19) (101.7) (110.5) (122.6) (126.9)















! 1 — ' 1 I
Quarter 1 Quarter 2 Qaurter 3 Quarter 4
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Table 7.6 shows the quarters that differ significantly, due to the number of comparisons
Bonferroni corrections were applied.
Table7.6; differences in mean blink rate
Q1-Q2 Q1-Q3 Q1-Q4 Q2-Q3 Q2-Q4 Q3-Q4
p levellT p levelfl p levelfl p leveljl p levelfl p levelfl
Pre treatment patients 0.003 0.003 0.003 0.02 0.003 0.003
CPAP treated patients 0.03 0.05 0.003 0.17 0.003 0.03
Controls 0.02 0.021 0.03 0.39 0.083 0.22
per quarters
U Bonferroni correction applied
Figure 7.5 displays the mean blink rate per minute for the three group's first drive on the
AusEd simulator. As can be seen from figure 7.5 five dips in blink rate are noted around
minutes 2, 8, 15, 22 and 29. Table 7.7 shows corresponding minutes and road types
and these times correspond to periods of chicane road surface.
Table 7.7; Minutes and corresponding road type
Minutes Corresponding road type
1 + 2 Chicane
3, 4, 5, 6, 7 Straight
8 + 9 Chicane
10, 11, 12, 13, 14, Straight
15 +16 Chicane
17, 18, 19, 20, 21 Straight
22 +23 Chicane
24, 25, 26, 27, 28 Straight
29 +30 Chicane
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Figure 7.5; AusEd: Mean blink rate per minute for firsl
drives
minutes
The three groups differed in their level of sleepiness. The pre-treatment patient group
had higher ESS and scored higher on the Karolinska sleepiness scale before starting
the simulator than both other groups. They also scored higher scores on the post drive
Karolinska sleepiness scale as compared to the controls but not the CPAP group. The
CPAP group and controls also differed with the control group scoring lower ESS and a
higher post-drive Karolinska sleepiness scale score.























ESS 14.1 (2.9) 9.9 (5.2) 4.9 (2.1) 0.002 0.002 0.002
Karolinska pre drive 4.7 (1.5) 3.8 (1.5) 2.7 (1.0) 0.03 0.002 >0.08
Karolinska post drive 5.9 (1.9) 5.3 (1.9) 3.2 (1.6) >0.15 0.002 0.002
U Bonferroni correction applied
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7.6.2.1 Events per time
To assess if this increase in blink rate was a physiological signal of fatigue, event rates
(crash or drive-off-road) were compared between the three groups and again over the
four quarters. Table 7.9 shows the means and standard deviations of events per
quarter. As with the eye-blink rate there were no statistically significant differences in
the three groups per quarter. However unlike the blink rate there was no time-on-task





























0.42 (0.87) 0.71 (1.3) 0.26 (0.56) >0.5 >0.7 >0.4
2nd
Quarter
0.38 (0.72) 0.46 (1.2) 0.42 (061) >0.5 >0.5 >0.2
3rd
Quarter
0.22 (0.70) 0.83 (2.2) 0.26 (0.56) >0.1 >0.5 >0.5
4th
Quarter
0.33 (0.74) 0.63 (1.7) 0.21 (0.63) >0.7 >0.3 >0.5
Table 7.10; Distribution of crash and off road events by time (7.5min per quarter) within-
subject comparison
1st Quarter 2nd Quarter 3rd Quarter 4th Quarter
Mean and Mean and Mean and Mean and p level
SD SD SD SD
Pts pre 0.42 (0.87) 0.38 (0.72) 0.22 (0.70) 0.33 (0.74) p>0.7
CPAP 0.71 (1.3) 0.46 (1.2) 0.83 (2.2) 0.63(1.8) p>0.2
Controls 0.26 (0.56) 0.42 (0.61) 0.26 (0.55) 0.21 (0.63) p>0.4
Overall 0.40 (0.89) 0.35 (0.79) 0.36 (1.2) 0.38 (1.0) p>0.8
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As can be seen from figure 7.6 each of the three groups have relatively small numbers
of events over the four time periods. This is a product of the small number of events
being recorded in total. Table 7.11 shows events by subject category and the number
of participants in each group reporting events. Only 12 patients recording a driving
event in the pre-treatment drive also recorded an event post treatment.
Overall the rate of events per drive is 1.5, and therefore the chances of finding a time-
on-task effect were low.
Figure 7.6; Driving events distribution over quarters
Quarter Quarter Qaurter Quarter
12 3 4





Table 7.11; Number of event and participants recording events






Pre treatment patients 65 21
CPAP treated patients 63 12





A time-on-task analysis was conducted to investigate eye-blink rate across time in the
sub sample of pre-treatment OSAHS patients who underwent EOG recording whilst
performing the SteerClear test. As with the AusEd data the 30-minute test was split into
4 quarters table 7.12 shows the mean eye-blink rate per quarter. Graph 7.5 illustrates
the three two-minute blocks with increased eye-blink rate; these three blocks
correspond to time periods when no steers were produced during the task. To
investigate if these blocks were influencing the time-on-task analysis they were not
included on a secondary analysis (four quarters of six minutes) table 7.12 shows the
mean and significance level for these comparisons. As with the AusEd simulator eye-
blink rate showed an increase over the four quarters, this held when the three time
blocks without steers were analysed. Again as with the eye-blink rate in the AusEd
simulated drive there were large individual differences between patients and this is
apparent when looking at the magnitude of the standard deviations.
Table 7.12: Eye-blink rate on the SteerClear test over four quarters and differences
between quarters
Including Steer-free 2 minute
blocks




91.4 (64.3) 57.2 (45.5)
Quarter 2
Mean and SD
109.2 (78.7) 79.2 (64.6)
Quarter 3
Mean and SD
114.6 (84.5) 82.6 (67.5)
Quarter 4
Mean and SD
133.3 (96.1) 91.9 (77.2)
Significance evel P=0.001 P=0.001





0.01 0.001 0.001 >0.2 0.002 0.004
U Bonferroni correction applied
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Figure 7.7; SteerClear; blink rate per minute for
OSAHS patients pre- treatment (n=34)
minute
7.7 Discussion.
As hypothesised there were changes in the mean spectral power density of FFT EEG
bands immediately prior to a crash incident compared to a period of EEG that was free
from incidents or the appearance of trucks on the simulator. These changes in
comparison to the baseline EEG time were seen up to ten seconds, 20 seconds before
the incident as an increase in the mean power of the theta EEG band. In the two-
second EEG time block immediately prior to the crash incidents all three EEG bands
showed significant increases in mean spectral power density from the baseline levels.
The theta band also continued to increase in power between the ten-second and two-
second time blocks prior to the crash incidents.
The pattern of EEG change was somewhat different in the 74 driving-off-road incidents
that did not result in a crash. All three bands showed increases in mean power between
the baseline and 10-second time block. A significant increase in the mean theta power
was noted between the baseline and two-second time block before an event, but no
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significant differences were found between alpha and sigma EEG bands. A significant
reduction was also noted in the mean spectral power density of the sigma EEG band
between the ten-second and two-second time blocks before going off road.
Due to the very different methodologies used between the current study and those
reported in section 7.1 it is not possible to compare these results directly to others'
outcomes. However, the results reported from this study, would seem to corroborate
previous research that has shown that an increase in objective sleepiness (increasing
power of alpha and/or theta) is linked with driving incidents. These data would suggest
that at around ten seconds, 20 seconds before a serious driving event (crashing as
opposed to crossing the lane boundary) increases in the mean theta and mean alpha
power density are evident, and this increase in theta continues to grow between the
ten-second and two-second time block. However this is also accompanied by an
increase in power of wakeful (sigma) EEG frequencies. One might speculate that this is
an attempt to counteract the increase of theta and alpha. The presence of sleepiness
and falling asleep behind the wheel if very different to that of sleepiness and falling
asleep in bed. Whilst driving, if one feels sleepy and does not pull over, one is
continuing to try and perform the task at hand and would try to resist sleep, unlike in
bed when one would willingly let oneself sleep.
The picture seems to be somewhat different in events that do not lead to crashes. For
these an increase in mean power density of all three EEG bands is seen at ten
seconds, 20 seconds prior to crossing off-road (compared to the baseline values).
However the only significant difference between the baseline EEG and the two-second
time block immediately prior to going off-road is seen as an increase in the theta band.
One might speculate that the increased power seen in the sigma and alpha bands at
ten seconds, 20 seconds before going off road (which is not seen in those events which
end in a crash) might somewhat counteract the increases in theta and these increased
levels of power in the wakeful band plus the stimulus of crossing the boundary are
enough to alert the driver and allow them to retake control of the vehicle. However this
would not necessarily explain the reduction in power of the sigma band seen in the two-
seconds immediately prior to crossing the road.
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Attempts to explain the differences in patterns of EEG changes found between the two
types of driving event would be speculative only. However, as one event leads to the
driver losing complete control of the vehicle (crash) and the other leads to momentary
lose of control that is re-gained, one might speculate that differences in EEG might
occur. Nevertheless even momentary loss of control at high speeds can be fatal.
Overall these results would seem to support the hypothesis that driving incidents are
linked to physiological EEG changes and may not be solely driver inattention.
With regards to a relationship between blink rate and sleepiness the results are less
clear. As has been reported by Home and Reyner (1996) there were very large
individual differences in blink rate, as demonstrated by the standard deviations.
Nevertheless, there were no statistically significant differences between the three
groups (patients pre treatment, CPAP treated patients and the control group) in the
mean number of total blinks recorded for 30 minutes, or between the mean number of
blinks in the four 7.5 minute quarters in the AusEd simulated drive. There was however
a time-on-task effect shown in this study within each of the three groups. When Mann-
Whitney U tests were computed these showed that pre treatment and CPAP treated
patients each showed the same time-on-task decrements with each quarter, more
mean blinks excepting quarters two and three. However within the control group the first
quarter was different only from blocks 2 and 4.
The significant difference between blocks 1 and 3 did not hold with the Bonferroni
correction, with evidence for a ceiling effect in blocks 2, 3 and 4, which did not differ
significantly.
This pattern makes it difficult to comment on a possible relationship with sleepiness, as
the CPAP treatment group reflected the same pattern of change as the untreated
patient group. However, Richter et al (1998) proposed that blink rate was reduced with
task difficulty (blink rate reduced with the change in curvature of the road).
Speculatively, this may explain the reduced number of blinks seen during the first
quarter in the control group. It may be that there is still a learning effect in the first
quarter despite all subjects having had a 10 minute practise run, and the overall
evening out of blink rate over the rest of the task may be due to increased familiarity
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with the task. This theory would also explain the qualitative dips in blink rate shown on
graph 7.4 at minutes 2, 8, 15, 22 and 28, which correspond to periods of chicane road
layout on the driving simulation. It is unlikely that the differences in blink rate between
the patient and control groups for time-on-task are related to a driving performance
measure as there were no differences between the three groups on the mean number
of driving incidents per quarter and no time-on-task effects for driving incidents were
seen in any of the groups.
Blink rate in the SteerClear task also shows a time-on-task effect and this mirrors the
patients' blink rate pattern in the AusEd simulator tasks with all quarters except 2 and 3
showing significant differences from each other. Graph 7.4 shows increased blink rates
in the three two minute blocks where no steers were present, further supporting the
notion that blink rate is reduced with task difficulty.
As there was a difference in the patient groups versus the control group in both ESS
score and the post drive Karolinska sleepiness scale, the differences seen in time-on-
task between the patients and control groups may be a function of sleepiness, with the
increased blink rate in the patients owing to increased difficulty in maintaining task due
to sleepiness.
However this remains somewhat speculative, as all groups show a time-on-task effect
and without an ongoing episodic or continuous measure of sleepiness during the driving
task (i.e. subjective ratings, changes in EEG either by power or intrusions of alpha or
theta) it is not possible to rule out other possible factors.
The control group were screened prior to participation in this study for symptoms of
sleep disorders and required as an entry criterion to have an average of six hours sleep
per night. This in addition to the fact that they had a mean ESS which was in the normal
range and showed only slightly increased score on the Karolinska sleepiness scale
(which was lower than both patients groups for their pre drive score) may argue that
driving incidents that they experienced on the simulator were unlikely to be sleep-
related. However, if the driving incidents in this group were caused by other factors this
would have served to reduce the chances of finding changes in the EEG power bands.
Therefore any future studies employing similar methods of investigating sleepiness and
driving incidents may provide clearer answers by excluding this group. However, as the
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general driving population have been shown to have accidents related to sleepiness,
perhaps a more prudent measure would be to assess these incidents on the basis of
behavioural sleepiness as conducted by the Loughborough research team.
Further the AusEd driving simulator was not programmed to detect crossings of the
central white line. Therefore if any such incidents happened during driving on the
AusEd simulator they would have been missed. Overall only 169 driving incidents were
recorded from 54.5 hours of subjects' driving. This might be an accurate reflection of
real world driving, but due to possible missing data from crossing of the central line it is
not possible to conclude that all possible sleep-related driving incidents were accounted
for.
It is also not possible to determine whether the changes in theta power were due to the
increasing blink rate (or possibly visa versa). Although bandpass filters excluded
frequencies under 5Hz, it is not possible to rule out the possibility of blink contamination
on the EEG. Also as EEG was measured using only two channels of frontal EEG and
as frequencies under 5Hz and over 16Hz were excluded, it is possible that the full
scope of changes occurring during sleepiness were not fully investigated using these
adopted methods. Nevertheless changes in EEG were noted prior to driving incidents.
Further the baseline period used as a comparator for changes in EEG prior to incidents
was taken at ten minutes from the start of the driving simulation. It is therefore possible
that slowing of the EEG towards sleep had already commenced by the baseline time,
and again this would limit the level of change detected, as such in future studies it may
be advisable to use a baseline block of EEG prior to commencing the drive. One could
also argue that the comparisons should be made both with baseline and with a random
sample during the drive so that differences between alert and normal driving and
between normal driving and pre-incident could be identified. It could also be argued that
the small time bands used to assess changes in the EEG would have little real world
validity. However in the real world, two to ten seconds of sleepiness or sleep behind
the wheel could have fatal consequences especially at high speeds. Nevertheless, the
validity and reproducibility of EEG changes over such small time bands are required.
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The FFT EEG bands were not subject to any form of standardisation although others
have used FFT without standardising the outputs (Lai and Craig 2002). This inhibited
the comparison of between EEG spectral band comparison, as well as between subject
or between driving event type. These methodological issues with the EEG component
of this chapter, including sample size might limit the ability of the study to detect
changes in EEG prior to driving incidents. Nevertheless significant changes were found
prior to both crashes and off-road events.
Methodological issues could also affect the results of the blink rate analysis. Although
blinks were scored using strict criteria it is possible that blinks were missed due to other
eye movements, especially those corresponding to the participants checking the
speedometer. Stern (1994) noted the possibility of blinks and saccadic eye movements
occurring together and postulated that this may occur to reduce the length of time that
ones attention is not on task.
Thus it is possible that if blinks occurring during or at the end of these saccadic events
appear different to the blinks in graph 7.1, or are not visible on the EOG they may have
not been scored. Using concurrent video images as well as scoring from EOG
channels could have been a more reliable tool for blink rate analysis. Due to the
limitations of the study previously mentioned it is not possible to determine if increased
blink rate is a consequence of sleepiness. However, as previous research has
suggested that blink duration and slow eye movements show correlations with
sleepiness in OSAHS patients (Hakkenan 1999, Kinnairi 2000) and others have
hypothesised that blink amplitude and as well as these factors have accounted for
larger proportions of variance in flight simulator studies (Stern 1994), these maybe the
best eye movement measures to investigate in future studies to determine if eye
movements are an indicator of sleepiness, and therefore a potential method for warning
against declining performance.
The valid use of blink rate as a measure of sleepiness cannot be confirmed from the
outcomes of this study.
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The results contained in this chapter suggest that driving incidents may be linked to
neurophysiological changes indicating sleepiness, and that these may be apparent from
20 seconds before the incident. This may indicate that driving incidents are not solely
due to inattention caused by sleepiness, but may in part be due to changes in the
density of the constituent EEG frequencies.
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Chapter 8: Driving history questionnaire study
8.1 Introduction
Surveys of motor vehicle accidents (MVAs) have been the commonest means through
which MVAs have been associated with sleepiness both in the general driving
population and in OSAHS patient series. Sleepiness, or the inclination to sleep most
likely affects driving performance due to a progressive reduction in attention on both the
road and surrounding traffic, slowed reaction times and aversive actions, and eventually
by a reduction in responsiveness with sleep onset (Brown 1994, Dinges 1992).
Recapping findings from some population-based surveys in the general public, as
reported in section 2.3, shows sleepiness to be a significant factor in a substantial
proportion of MVAs.
McCartt (1996) reported that 55% of 1000 people polled had felt sleepy whilst driving in
the previous year, 3% claimed that over their driving lifetime they had fallen asleep
while driving which led to a crash and an additional 2% reported having an MVA due to
sleepiness. Maycock (1997) reported that 29% of 4621 participants in their Transport
Research Laboratory questionnaire study reported having felt close to falling asleep
whilst driving in the previous year. Sagberg et al (1999) found that of 9200 respondents
questioned regarding the last accident they had reported to the insurance company,
3.9% of all accidents were related to sleep or feeling drowsy.
Accidents caused by sleepiness in the general population are most likely due to sleep
deprivation, and young males (25 years and younger) are over represented in sleep
related crashes (Pack 1995). These accidents also seem to mirror the circadian cycle of
sleepiness, with two peak times for sleep related accidents in the early hours of the
morning and mid-afternoon (Pack 1995, Garbarino et al 2001).
As OSAHS patients often report significant levels of daytime sleepiness, research has
been undertaken to assess the role of sleepiness and falling asleep behind the wheel in
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their MVAs. Such studies, as noted in section 2.5, find frequent self-reports of
sleepiness and sleep episodes behind the wheel in OSAHS patients. In OSAHS, the
clinical picture is complicated by the coexistence of sleepiness and nocturnal hypoxia.
Driving impairment in patients may thus occur as a consequence of sleepiness
impairing performance or through hypoxia-related cognitive deficiencies.
To recap, patients with OSAHS are between two (George et al 1987, Aldrich 1989,
Barbe 1998, George and Smiley 1999) and 7 (Findlay 1988) times more likely to have
an MVA than the normal population. The level of severity of OSAHS is, in some studies,
associated with MVA rate (Aldrich 1989, Young 1997, Teran-Santos et al 1999),
suggesting that there is a dose-response relationship between AHI severity and MVA
rates (Shiomi 2002 and Findley et al 1989a).
Small retrospective based studies report that many OSAHS patients report feeling
sleepy whilst driving (Guilleminault 1978). They also suggest that OSAHS patients with
an Al greater than 5 report significantly more sleepy spells whilst driving as compared
to people with an Al less than 5 and that these episodes contribute to the development
of MVAs (Cassell, 1990). In small studies the number of OSAHS patients reporting
MVAs ranges from 9% (Shiomi 2002), 12% (Hortsmann 2000) through 33% (Barbe
1998, Yamamoto 2000) to 44% (Cassell 1996), and 43% in a heterogeneous sample of
symptomatic snorers (Haraldsson 1995b).
Sleepiness related accidents have been reported by 9% of 60 patients (Lloberes 2003),
19% of 44 patients (Noda 1998) and 31% of 253 patients (Wu 1995) respectively.
The studies cited in section 2.6 suggest that OSAHS patients report that CPAP
treatment improves EDS, vigilance, ability to drive long distances, and reduces the
number of near miss and actual MVAs (Minemura 1993, George 1995, Engleman 1996,
Krieger 1997). Follow-up of 59 OSAHS patients by Cassell (1996) found a five-fold
improvement in self reported accident rates after one year's CPAP treatment. In
Yamamoto's (2000) prospective study of CPAP-treated patients the prevalence of those
reporting MVAs fell from 33% to none of 39 patients for a period of two years. In a
prospective study, 56 pathological snorers treated with UPPP, reported accident
prevalence fell from 31 accidents to nine accidents per five years. (Haraldsson 1996)
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Though some studies (Findley et al 1988, Young et al 1997, George et al 2001) have
accessed government databases of accidents, such objective data is available only in a
few places in the world. In Scotland, neither the sleepiness and MVA patterns of drivers
nor patients with OSAHS have been well investigated. The aim of this study was to use
a self-reporting survey to investigate the MVA rate in Scottish OSAHS sufferers before
and after treatment and compare these to those of community-acquired controls.
8.2 Study design
This postal based, case-controlled, retrospective questionnaire study investigated the
driving history and sleepiness of OSAHS patients and community-acquired controls.
The postal survey is included as Appendix 4.
The OSAHS patient surveys were acquired in two groups- those who had been using
CPAP treatment (on-CPAP) for at least 2 years, and those recently diagnosed with
OSAHS and were waiting to commence CPAP treatment (awaiting-CPAP). Gender and
postal-codes were used to match the community-acquired controls to the On-CPAP
group.
It was hypothesised that there would be no differences in the subjective ratings of
sleepiness, driving ability and accident rate between the on-CPAP group and the
community acquired controls, for the previous two years. Further, that the awaiting
CPAP group would report higher levels of sleepiness and accident rate and a reduced
driving ability compared to the other two groups for the same time period.
The on-CPAP patient group were also asked to report their sleepiness level, driving
ability and accident rate for the two year period before commencing CPAP and it was
prospectively hypothesised that there would be significant improvement in these
features after the commencement of CPAP.
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8.3 Statistics
The baseline comparisons for ordinal and continuous data for the three groups were
conducted using non-parametric Mann-Whitney U tests with Bonferroni correction for
multiple comparisons. Dichotomous and categorical level data were analysed with Chi-
square and Fishers exact non-parametric tests. Pre and post CPAP comparisons were
conducted using Wilcoxon signed-rank tests.
8.4 Results
8.4.1 Recruitment and Response Rate
On-CPAP patient group
All records for OSAHS patients who had commenced CPAP between February 1999
and March 2000 were reviewed. A total of 452 OSAHS patients had commenced
CPAP therapy during this period and of these 162 were initially excluded, as they did
not meet the following criteria;
• Aged18-75, holding full drivers licence, AHI >20 (AH/hr in bed>30 if diagnosed
on a home based study), ability to complete questionnaire, no record of other
sleep disorder in patient case-notes.
290 OSAHS patients were contacted by letter and asked to complete the driving history
questionnaire, of these 138 replies were received, giving a response rate of 48%. Five
OSAHS patients had died and family members of these patients responded and the
Edinburgh sleep centre records were accordingly updated.
The 138 on-CPAP patients (53.6 SD 8.1 years) included in the analysis were
significantly older than the 147 on-CPAP non-responders (50.3 SD 9.9 years; p=0.003),
but were not significantly older than those initially excluded (54.9 SD 11.9). The on-
CPAP patients included in the analysis (AHI 54.7 SD 31.1) had a significantly higher
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AHI than those initially excluded (AHI 30.0 SD 25.3; p=0.001) but were not significantly
different than the non-responders (AHI 51.2 SD 29.4). Gender differences were found
between the 138 On-CPAP patients (16 females) used in the analysis and the OSAHS
patients who were excluded from the study (44 females, x2=10.22, df=1; p=0.001). No
gender differences were found between the On-CPAP patients included in the analysis
and the non-responders (19 females, x2=0.076, df=1; ns)
Awaitinq-CPAP patient group
Two hundred and five OSAHS patients undergoing CPAP titrations between April and
December 2002 were identified. 54 did not meet the inclusion criteria, 151 patients
were suitable for inclusion and were contacted to participate in the study (inclusion
criteria was the same as for the ON-CPAP group). Of these 151 possible participants,
83 replied giving a response rate of 55%, one person was excluded as they did not hold
a driver's license.
The 82 awaiting-CPAP patients (50.5 SD 9.3 years) included in the analysis were not
significantly older than those excluded (54.9 SD 26.6 years) or the non-responders.
The Awaiting-CPAP patients included in the analysis (AHI 45.1 SD 27.3) had a
significantly higher AHI than those initially excluded (AHI 19.6 SD 20.2, p=0.001) but
was not significantly different than the non-responders (AHI 43.6 SD 25.1).
Gender differences were found between the 82 on-CPAP patients (11 females) used in
the analysis and the 55 awaiting-OSAHS patients who were excluded from the study
(16 females, x2=5.112, df=1; p=0.024). No gender differences were found between the
Awaiting-CPAP patients included in the analysis and the non-responders (12 females,
x2=0.513, df=1; ns).
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Community acquired control group
The control group comprised of community-acquired volunteers who were randomly
selected from the British Telecom telephone directory and were matched to the on-
CPAP patient group by gender and postal code. The inclusion criterion was as follows;
• Aged18-75, holds full drivers licence, ability to complete questionnaire.
Two hundred and sixty eight people were contacted (two volunteers were contacted for
each ON-CPAP OSAHS patients that was included in the study) of these 127 replies
were received giving a response rate of 47%. Under the inclusion criteria 85 controls
were used for analysis in the study, 29 were excluded, as they did not hold a driving
licence and 13 family members informed us that their family member had died.
Age was only reported by the 85 controls that completed the full questionnaire so it is
not possible to determine any age differences in those excluded and non-responders.
There were no significant differences in gender between the controls used in the
analysis (85, 5 females) and those excluded (37, 5 females, x2=1.405, df=1;ns) and the
non-responders (130, 11 females, x2=0.297,df=1 ;ns).
As can be seen from table 8.1, the awaiting CPAP group was 3 years younger and had
held their driving license for a shorter time and, as anticipated, reported greater
sleepiness than both the on-CPAP and control groups. There were no significant
differences between the on-CPAP and control group in age and the length of time they
held their driving license, but their subjective sleepiness score (ESS) was trending to
significance with the on-CPAP group having a lower score. The on-CPAP group had a
significantly higher diagnostic AHI than the awaiting CPAP group.
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8.4.2 Subject Demographics
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Chi square, y-yes, n-no, U Bonferroni correction applied
8.4.3 Differences in Reported Symptoms
On their recent visit to the Edinburgh Sleep Centre for investigation for OSAHS, the
Awaiting-CPAP group completed an in-house sleep/wake questionnaire (see section
3.7), which provided details on symptoms related to the condition. These symptom-
related questions were incorporated into the control group questionnaire. The
frequencies of these symptoms for the two groups are shown in tables 8.2-8.5.
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Table 8.2: OSAHS symptoms- snoring & breathing pauses
Snoring Breathing pauses
Frequency Awaiting CPAP Controls Awaiting CPAP Controls
Never 0% 16.7% 1.7% 52.4%
Rare 0% 16.7% 5% 8.3%
Occasionally 1.2% 25.0% 5% 9.5%
Often 1.2% 20.2% 31.6% 4.8%
Frequent/
Always
69.5% 17.9% 38.3% 2.4%
Don't know 1.2% 3.6% 18.4% 22.6%
p value p=0.001 p=0.001
Table 8.3: OSAHS symptoms- choking & excessive movements
Cho <ing Excessive movements
Frequency Awaiting CPAP Controls Awaiting CPAP Controls
Never 26.7% 84.5 16.7% 54.8%
Rare 13.3% 13.1 13.3% 26.2%
Occasionally 18.3% 0% 13.3% 8.3%
Often 15.0% 0% 13.3% 3.6%
Frequent/
Always
13.3% 0% 21.7% 4.8%
Don't know 13.3% 2.4% 21.6% 2.4%
p value p=0.001 p=0.001
Table 8.4: OSAHS jerking & coughing
Jerking Coug ling
Frequency Awaiting CPAP Controls Awaiting CPAP Controls
Never 16.7% 40.5% 25.0% 58.3%
Rare 10.0% 39.3% 23.3% 33.3%
Occasionally 18.3% 10.7% 15% 4.8%
Often 10.0% 2.4% 11.7% 1.2%
Frequent/
Always
30.0% 6.0% 10% 2.4%
Don't know 15.0% 1.2% 15% 0%
p value p=0.001 p=0.001
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Table 8.5: OSAHS symptoms- wheezinc & wakening to go to toilet
Wheezing Frequent wakening to go to toilet
Frequency Awaiting CPAP Controls Awaiting CPAP Controls
Never 41.7% 79.8% 25.0% 23.8%
Rare 18.3% 13.1% 11.7% 33.3%
Occasionally 10.0% 3.6% 21.7% 14.3%
Often 8.3% 2.4% 8.3% 14.3%
Frequent/
Always
6.7% 1.2% 31.7% 14.3%
Don't know 15% 0% 1.7% 0%
p value p=0.001 p=0.05
The awaiting CPAP group report significantly higher frequencies of each of the eight
OSAHS symptoms than the control group.
8.4.4 Perceived driving ability
Each of the three groups were questioned regarding the average number of days per
week they drove (1-4 scale), their ability to drive short distances (<75 miles) (1-5 scale),
their ability to drive long distances (>75 miles) (1-5 scale) as well as feeling sleepy
whilst driving (1-5 scale) and falling asleep whilst driving (1-5 scale). All groups were
asked to respond to these questions in regards to the previous two years. Table 8.6
shows the responses of all three groups on the perceived driving ability questions.
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There were no significant differences found between the groups on the average number
of days per week they drove, whether driving was required by their occupation, or the
self-perceived ability to drive short distances. The awaiting CPAP group did report
significantly poorer ability to drive long distances than the on-CPAP and control group.
The awaiting CPAP group also reported more frequently feeling sleepy whilst driving
and falling asleep more frequently whilst driving than on-CPAP and the controls. The
on-CPAP group also reported less frequently feeling sleepy whilst driving as compared
the control group.
8.4.5 Reported Motor Vehicle Accidents
As well as responding to questions regarding perceived driving ability and sleepiness,
the three groups were asked to report the number of MVAs they had been involved with
in the previous two years and to indicate the number of these associated with
sleepiness and at what time of day these accidents had occurred on.
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Accidents were classified thus:
Near Miss Accident, almost had a collision but avoided at last moment
Minor Accident, collided with property or person, but no people injured
Major Accident, collided with property or person, people injured
Reported MVAs for the previous two years
Table 8.7 shows the responses of all three groups on the reported motor vehicle
accident questions. As can be seen from table 8.7, the Awaiting group reported more
minor accidents than the On-CPAP and more sleep related near miss accidents than
both other groups. The On-CPAP groups also reported significantly fewer near misses
and minor accidents than the control group; there were no differences between these
two groups in relation to sleep-related accidents.
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Table 8.8 shows the frequency and percentages of number of participants in each
group reporting accidents. Fewer participants in the On-CPAP group reported having
minor/major accidents than the Awaiting CPAP group (p=0.002). There were also fewer
On-CPAP patients reporting near miss accidents than both other groups. When near
miss and actual accidents were analysed together, significantly fewer of the On CPAP
patients were involved than both other groups. On analysis of the numbers of
participants in each group reporting sleepiness related accidents, more participants in
the awaiting group reported sleep related near miss incidents than the other two
groups. However there were no differences in the three groups in the number of
participants reporting minor/major sleep related accidents.























































































*Chi square with Bonferroni correction
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8.4.6 Dose response relationship between AHI and MVAs in the Awaiting
group
An analysis of AHI and MVA prevalence was undertaken. Table 8.9 shows the AHI cut
off values and corresponding number of patients in the Awaiting-CPAP group reporting
a MVA or near miss incident. There were no dose response relationships between AHI
and driving incidents detected from the awaiting CPAP sample. Table 8.10 shows no
dose response relationship between the control group and the three AHI sub-groups of
awaiting CPAP group for near miss, minor and major accidents. All three of the AHI
groups reported more near miss incidents associated with sleepiness than the control
groups.
Table 8.9; Awaiting CPAP group - Dose response for AHI and MVAs
Number of group
having incidents
Number of group not
having incidents
p>0.9AHI 20-27/hour 10 18
AHI 28-41/hour 12 14
AHI 42+/hour 11 17











p value P value p value
Near Miss accidents
0.93 0.93 0.93





Minor accidents associated with
sleepiness
0.08 1.0 1.0
Major accidents 0.57 0.58 0.58




8.4.7 Secondary measures of measurement time of MVAs
MVA rate by time of day shows variability in the three groups. Analysis including the
near miss incidents indicates that there was no difference between the accident rates in
the awaiting CPAP and the control group at any time of day or night. The On-CPAP
group has fewer MVAs than the awaiting-CPAP group between the hours of 9am and
midday, and fewer MVAs than both the awaiting CPAP and controls between the hours
of midday and 6pm. Table 8.11 displays the differences of MVAs by time of day.
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Ta ole 8.12:Percentag e of MVAs across t ie day in hree-hour blocks




7.6% 16.3% 20.8% 30.7% 10.6% 12.1% 0.8% 1.1%
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When all incidents were grouped together by time of day 50% of these occurred
between 12pm and 6pm.
8.5 Changes in perceived driving ability and MVA rates with CPAP
As well as providing information on subjective sleepiness, perceived driving ability and
MVA rates in the previous two years, the On-CPAP group were also asked to provide
information on these areas for a period of two years before they commenced CPAP.
Tables 8.13 displays the changes in the On-CPAP group from before and after the
commencement of CPAP.
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Table 8.14 Changes in sleepiness after the commencement of CPAP
Percent of responses
Much more sleepy 0.7%
More sleepy 0.7%
About the same 8.7%
Less sleepy 34.1%
Much less sleepy 52.9%
Didn't respond 2.9%
Tables 8.13 shows that there was no change in the average days per week the group
drove and there were also no significant differences in the number of major and sleep
related major accidents reported. However the On-CPAP group reported significantly
improved subjective sleepiness (ESS) and on a five-point scale questioning CPAPs
effect on sleepiness 87% reported feeling less sleepy (table 8.14). Since the
commencement of CPAP the group reported improved ability to drive both short and
long distances, a reduction in near miss and minor accidents and a reduction in the
number of these accidents attributed to sleepiness. The On CPAP group also reported
a reduction in the frequency of feeling sleepy and falling asleep whilst driving.
8.6 Discussion
The hypothesis that the awaiting-CPAP group would report significantly higher
subjective sleepiness, reduced ability to drive long distances and higher frequencies of
symptoms of OSAHS than controls was supported by the results of the study. The
hypothesis that the awaiting-CPAP group would report higher numbers of motor vehicle
incidents (including near-miss incidents) was only supported for higher rates of sleep-
related near miss accidents than the control group and for more minor accidents
compared to the On-CPAP group. Also, the awaiting CPAP group reported higher
subjective daytime sleepiness, reduced ability to drive long distances and a higher total
number of accidents (including near miss incidents) than the on-CPAP group. The On-
CPAP and control groups showed no significant differences in subjective daytime
sleepiness, self-rated ability to drive long distances, or sleep-related driving incidents,
confirming the null hypothesis. However the On-CPAP group reported significantly
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fewer total numbers of motor vehicle incidents (which included both near miss incidents
and minor accidents) compared to the control group.
On analysis of the number of participants in each group reporting accidents, fewer On-
CPAP participants reported near miss incidents and being involved in a minor/major
accident than participants in the awaiting CPAP group. Further, fewer of the on-CPAP
participants reported near misses than the control group. Sleep associated incidents
were reported by more participants in the awaiting-CPAP group than either other group,
but there were no differences between the on-CPAP and control group for the
percentage of participants reporting sleep related accidents.
In comparison with the MVA prevalence reported in section 7.1 (9% Shiomi 2002), 12%
Hortsmann 2000, 33% Barbe 1998, Yamamoto 44%, Cassell 1996, 43% in a
heterogeneous sample of symptomatic snorers Haraldsson 1995b) for untreated
OSAHS, this current study reports MVA prevalence of 23% for actual accidents, rising
to 33% when near miss incidents are included. Meanwhile the prevalence of sleep
related MVAs in untreated OSAHS in this study is 5% for actual accidents and 22% for
all driving incidents. This 5% for sleep-related MVAs is lower than the estimates of
Lloberes and Wu respectively. The current study also found fewer near miss accident
reports in OSAHS patients (28%) than the case series of Noda (1998), where near
misses reportedly affected 50%.
Sleepiness and driving ability of the On-CPAP group in this study were congruent with
those observed by Minemura (1993) George (1995) and Engleman (1996) all of whom
report subjective improvement in EDS, ability to drive long distances and lower rates of
MVAs than untreated patients. Direct comparison to the prevalence reported by
Cassell (1996), Yamamoto (2000) and Haraldsson (1996) on reduction of MVA rates is
complicated due to the differences in study design. But this Scottish series showed a
higher percentage of participants reporting MVAs (6% major and minor, 21% for all
accidents types over 2 years) than the Yamomoto study (over two years). The awaiting
CPAP group also reported a higher actual collision rate than the on CPAP group, the
mean rates falling three-fold. The post-CPAP driving incident rate was lower than that of
the Cassell study, and Cassell's time window for reports was one year of CPAP use, as
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compared to two years in the present study. Haraldsson found that only nine accidents
occurred in sample of 56 patients over a five-year period, compared to the current
results of 11 accidents from 138 patients over a two-year period.
The community control group data in the present study were similar to that of Wu et al
(1996), in which 12 of 80 controls had had an MVA, compared to 8 of 85 patients in the
current study. However Wu et al do not report the time scale for the accidents. McCartt
(1995) reported that 2% of their respondents had reported an MVA associated with
sleepiness over their lifetime, a figure slightly lower than in our sample (3.5% reporting
that in the previous two years they had or nearly had and MVA due to sleepiness).
Unlike previous studies, there was no dose-response relationship by mean AHI level
detected in this Scottish series of untreated OSAHS patients. This may stem from the
small sample size available in the present study. Each of the studies cited in section
8.1 had sample sizes which ranged from 100+ (Aldrich 1988, Teran-Santos et al 1999
7) 400+ (Shiomi 2002) to 900+ (Young 1997) participants, except that of Findley which
had only 44 OSAHS which were spilt into mild (16) moderate (17) and severe (13).
However, Findley et al had the benefit of database information on driving accident rates
for the state of Virginia, and it was in comparison to these controls that the severe
OSAHS patients showed increased MVA rate.
A dose-response analysis in this Scottish series was undertaken retrospectively with
the cut off levels for disease severity determined by calculating three AHI bands to
produce similar number of participants in each group.
As there was a minimal level of AHI required for inclusion for the study, the lowest AHI
band spanned 20-27/h, while the Young study included AHI >5 as clinically relevant.
Thus the lack of a dose response may also be attributed to the differences in AHI
criteria as compared to the previously cited studies.
The secondary outcomes of the study, by time of day, also showed differences between
the three groups. The awaiting group reported more motor incidents than the on-CPAP
group in three-hour bands at 9am+, 12pm+ and 3pm+ when all accident types were
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included. The On-CPAP group also reported fewer total driving incidents than the
control group at 12pm+ and 3pm+.
Research on sleep related MVAs in the general population in England has provided
evidence that three peak times for sleep related accidents occur around 2-3am, 6-7am
and 4-5pm (Home and Reyner 1995). The pattern of MVAs over time in the current
study do not reflect this, with only 8.7% of all the MVAs reported occurring during 3-
9am. This almost certainly reflects the lower traffic densities at those times (Home and
Reyner 1995), and may in part be due to the differing age of the two study populations.
The Home and Reyner study had a predominantly younger sample as compared to the
middle aged sample in the current study, and these age differences will most likely
produce differing driving habits.
However, as no previous normative values have been established for OSAHS related
motor vehicle accidents in terms of time of accident, and as limited data was gathered
on this, it is not possible to completely attribute reasons for these differences between
the patient and volunteer groups. However in a study investigating MVAs by road type
in the general population on 15 roads of varying classification in England, Flately et al
(2004) report that MVAs and sleep related MVAs show variation by road type, lighting,
time of year and by changes in traffic density. Sleep related MVAs increased as traffic
volume increased on non-motorway roads. However on motorways as traffic density
increased sleep related MVAs showed a negative correlation with traffic density. As the
detail of information obtained regarding the time and place of accidents is limited in the
present study, it is not useful to speculate if any of these variables could have been
factors in the MVA rate.
The current study does highlight differences between the three groups for time of
accident and further investigation with more rigorous data collection of this areas are
required to establish if these differences between the three groups are sleep related.
A possible reason for the lack of significant differences between the awaiting CPAP and
control group in reported MVAs may stem from the lack of demographic and
anthropometric data for the control group, and a consequent inability to control for these
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factors. Questionnaire based studies must balance information requested against
length of questionnaire, leading inevitably to compromises on data comprehensiveness.
Unlike the patient group who would be aware of the role of sleepiness in driving, it is
very likely that the majority of the controls would not, and so it was prospectively
decided to request the minimum amount of personal information to try to maximise the
response rate of this group. Another factor in this lack of difference between the
awaiting CPAP group and the controls in accident rates may be the unwillingness of
OSAHS patients to accurately report accident rates prior to starting on effective
treatment, probably for fear of losing their licence (Engleman 1997 24).
The lack of personal data, especially that of previous medical history to some extent
may explain the higher MVA rate found in the control group (as compared to the On-
CPAP group). Conditions such as diabetes mellitus and cardiac problems, as well as
use of sedating drugs (i.e. antihistamines) or being male or younger than 25, have all
been associated with increased MVA rate. Also despite questions regarding OSAHS
symptoms and whether controls had been diagnosed with a sleep disorder, there is no
way to rule out possible sleep disordered breathing in the control group. This may
mean that MVAs in this particular group would be higher than a control group selected
for an absence of serious illness and SDB. Further, information regarding occupation
and lifestyle, for example shift work and self-induced sleep restriction, were not sought
and these factors are also linked with increased MVA.
Conversely, the differences in driving incidents reported by the control group, the
awaiting CPAP and on-CPAP patient groups may also be influenced by volunteer bias
in the patient group. Previous research has documented that responders to
questionnaire studies tend to be healthier than the non-responders (Altman 1991) and
so there is no way to exclude the possibility that only the patients who felt less affected
by OSAHS symptoms (in the awaiting group) or the patients who perceive better
benefits from CPAP responded self selecting themselves as responders.
However it has been documented previously that OSAHS patients often under-report
their involvement in MVAs both before commencing treatment (Engleman 1997) and
after treatment initiation (Findley 2000). Hence, the differences (and lack of
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differences) found between the three groups may in part be due to under-reporting from
the patient groups. Also participants were not questioned whether the accidents they
reported were their fault, hence it is not possible to rule out that an increased MVA rate
in any of the groups could have been due to them being involved in an accident which
was the fault of someone else. This information was not sought due to the dubiety as to
its validity.
A further possible methodological issue in the current study is the lack of an estimate of
annual mileage. Increased mileage is a known risk factor for MVAs, and this study did
not request an estimate of yearly mileage, precluding an ability to control for mileage.
However during the AusEd driving simulator study, patients and controls were asked to
supply this data, and a majority initially left this question unanswered. As it would not
be possible to contact each person responding to the questionnaire who left this blank it
was decided instead to employ as an estimate of driving exposure the average days per
week that subjects drove. Although this does not allow for controlling of mileage, this
data allowed us to compare a measure of driving exposure, unlike other studies
including Aldrich (1898) George (1999) Shiomi (2000) and Wu (1996). Driving
exposure in days per week was not significantly different in the three groups of the
Scottish survey.
These issues in part restrict the conclusions that can be drawn from this current study.
Nevertheless these issues are not limited to this study alone but are a by-product of
retrospective self-report methods of data collection.
Overall this study confirms earlier findings suggesting elevated self-reported MVA
incident rates and prevalence in untreated OSAHS patients, and that the prevalence of
sleep-related driving incidents are significantly higher than in community controls.
Further this study provides useful evidence that OSAHS patients, once on CPAP
therapy, pose no increased risk of road accidents.
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Chapter 9: Conclusions and future research
The AusEd driving simulator is a laboratory based task, designed as a tool to assess
fitness to drive in the obstructive sleep apnoea/hypopnoea syndrome (OSAHS).
Results from the treatment effect trial indicate that the AusEd simulator could not
discriminate driving performance; measured by steering deviation, lane position, speed
control, reaction time and driving incidents in treated and untreated OSAHS. In the
case-controlled study only reaction time was significantly poorer in the untreated
OSAHS patient group compared to the control group, and this difference was abolished
with CPAP therapy. However this difference in performance was not mirrored in the
other task components, further suggesting a lack of sensitivity of the simulator. It is
possible that differences in performance were not found because the OSAHS patient
group were too mildly affected or not impaired in their ability to drive. However as other
research groups (Risser et al 2000, Juniper et al 2000) have found differences in driving
performance in OSAHS patients with similar disease severity as those in the current
study, this seems unlikely.
EEG traces recorded during the AusEd driving task which were subjected to FFT
analysis indicated an increase in the spectral power density of the faster theta and
alpha bands from a baseline level. This provides some support for the hypothesis that
driving incidents may be a consequence of increasing sleepiness rather than driver
inattention or overt sleep. The second physiological measure of eye blinking during the
task was not a sensitive measure to discriminate between OSAHS patients (pre- or
post-treatment) and controls. Time-on-task increases in blink rate were seen in all
three groups, and these increases were not mirrored by the distribution of driving
incidents (i.e. crashes), leading one to speculate that blink rate may not be the best
method of assessing sleepiness.
Results from the driving questionnaire study were congruent with previous research,
suggesting that as a population untreated OSAHS patients are at increased MVA risk
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compared to treated OSAHS patients. This Scottish self reported accident and driving
ability study, shows similar results to surveys from other countries.
Although the AusEd simulator was unable to advance understanding of which aspects
of driving performance may be impaired in OSAHS patients, the study has highlighted
potential methodological issues with the use of PC based driving simulators as a tool for
assessing driving. The AusEd simulator was designed to assess three areas of driving
performance (tracking, visual search and speed control) important to maintaining safe
control of the vehicle. The lack of differences in performance between the patients and
control groups is most likely as a result of the insensitivity of the simulator, and
demonstrates that any simulator should undergo extensive research and validation to
adequately assess its ability to accurately mimic real driving. Although there were
programming problems with the AusEd simulator, the program was sound in theoretical
design and provides evidence that not every computer based driving program could
mimic real life driving. However, one can speculate that a PC based simulator will never
truly emulate a real-life driving task. Although PC simulators like the AusEd are
designed as 'safe' and economical methods of assessing performance, they do not
replicate the full driving experience. There is no restriction of seat belts, no manoeuvre
procedure (i.e. checking over ones shoulder before crossing lanes), no ability to
measure a person's use of the rear view mirror and indeed no measure of a person's
ability to assess changes in driving condition (i.e. turning on head lights or wind screen
wipers), all aspects which are tested for (either on road or in a written test) in the DVLA
driving test. Further, there is a lack of proprioceptive, vestibular and peripheral vision
cues of the motion of the car. When this is coupled with the fact that the consequences
of a crash or off-road event on the simulator does not have the same consequences as
in real life, the overall 'simulation' of driving is imperfect.
However, the gold standard of testing would be a real-world driving test and as noted in
section 2.10.1 this would be prohibitively expensive and possibly dangerous, hence the
need for exploration of driving simulators. It is my opinion that if driving simulators are
to be used as a tool to assess fitness to drive, a degree of realism is required.
Therefore simulators of the standard of the Swedish transportation simulator or the
Loughborough University simulator should be utilised. Simulators of these standards
offer larger viewing screens, moving bases, and steering wheel and pedal
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configurations of actual cars, giving a far more 'realistic' simulation of driving than one
which is PC based. However, the advantages these simulators have in design,
technology and sophistication are counterbalanced by their expense and the fact that
they are not portable. As a tool for fitness to drive is desirable due to the expanding
number of patients being investigated for OSAHS, and consequently the increasing
number of patients awaiting treatment, it seems unlikely that funding would be available
to purchase and maintain the number of these simulators required to assess large
number of patients.
However, even simulators of this realistic calibre have theoretical and practical issues.
The question regarding which aspects of driving performance represent impairment,
and at what level, is still unclear. Further, little evidence exists to show the correlation
between simulated driving performance and real life driving performance. Despite
evidence that simulators can discriminate en masse driving performance between
OSAHS patients, controls and non-sleep-disordered, sleep-deprived young adults, one
can speculate that PC based driving simulators are not currently valid tools for
assessing fitness to drive. Further, although others (Turkington 2003, Hack 2000,
George 1997) have shown that CPAP therapy reduces steering deviation and RT,
further research must be undertaken to investigate if these improvements in
performance may be maintained over long periods of time.
Due to the lack of correlations between simulated driving and real driving, and the lack
of understanding as to why some OSAHS patients are more susceptible than others to
MVAs, simulators are not yet sufficiently validated to be used as tools to discriminate
driving safety in individual OSAHS patients. Perhaps an intermediate approach could
be to implement a restricted drivers license scheme, which has been shown to be
effective in America for newly qualified drivers (McKnight and Peck 2003, Lin and Fearn
2003) who have recently passed their driving test. One could limit OSAHS patients
driving at night, by themselves or even on motorways, which is a restriction of the
provisional driver's licence in Britain. Further, as during simulated driving, evidence of
cumulative deleterious effects on driving performance in sleep-deprived adults and after
alcohol have been shown (Home et al 2003, Arnedt et al 2000), perhaps more
emphasis should be placed on untreated OSAHS patients avoiding alcohol. Of course,
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the issue of which drivers are at risk is still unanswered and a blanket restriction on all
OSAHS drivers until treatment is undesirable as this could have serious consequences
socially and financially to the subpopulation who have normal driving performance and
no increased risks of MVAs.
One of the main features of OSAHS is the increased level of daytime sleepiness. As
reported in the EEG data in chapter 7, increases in power in the theta and alpha band
prior to an off road event or crash suggest a slowing of the EEG may cause accidents.
This coupled with significantly higher numbers of MVAs and near misses associated
with sleepiness, as reported by the untreated OSAHS patients reported in chapter 8,
further suggests that it is sleepiness that causes MVAs. However, as it has been
suggested that individuals may not be aware of their own level of sleepiness (Kecklund
and Kerstedt 1994) or how imminent sleep may be (Home and Reyner 1995), simply
telling OSAHS patients not to drive while sleepy may not be sufficient.
Perhaps a restricted license should be given to only those OSAHS patients determined
to be hypersomnolent, but of course this debate is circular in nature, as the need for an
objective test for fitness to drive arose from the fact that the MWT was not an tailored
test for driving fitness.
Research into the OSAHS is in its infancy. Although large advances in understanding
of the condition have been made in the last few decades, our understanding of the
mechanisms and in turn the insults to the physiology of the body from this condition are
still evolving. Research is required to determine which physiological aspects of the
condition are responsible for the daytime sequelae of the condition, including
sleepiness, cognitive and motor deficits seen in OSAHS patients. This will allow a better
understanding of the condition and allow further research to be directed into which
aspects of the condition could impair driving. Although CPAP seems to treat OSAHS
adequately in tolerant users, ongoing research for a cure for the condition would be the
gold standard. As levels of sleepiness and MVAs seem to reduce with CPAP, one
would assume a cure would also reverse the increased levels of MVAs found in some
OSAHS patients. Until this time, untreated OSAHS patients and their families must be
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advised they should not drive if they feel or appear sleepy, as with any other driver,
even if healthy.
Unfortunately, although one might assume it would be OSAHS patients who perform
poorly on a driving simulator who also perform poorly in real life, the evidence to
support this is still lacking. Hence, simulators are not ready to be used as an objective
tool to assess fitness to drive in the patients with OSAHS.
In the future, studies with greater statistical power, more severe disease (either by
respiratory or sleepiness criteria) and more realistic simulators might, after adequate
validation, provide the research tools to discriminate drivers at excess risk of accidents
from those who have normal performance. Currently, the best indicator of accident
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Edinburgh Sleep Centre,






Our records show that you will shortly attend the Sleep Laboratory for investigation of the
obstructive sleep apnoea/hypopnoea syndrome (OSAHS). This is an illness that can be
successfully treated by wearing a nasal mask during sleep, in a treatment called continuous
positive airway pressure (CPAP) therapy. We would also like to assess the effects of an
experimental capsule treatment, taken by mouth for OSAHS.
As a suspected sufferer of this condition, we would like to ask you whether you might be willing
to help us with research into the effects of these two treatments for OSAHS on sleep quality,
driving ability and daytime sleepiness on concentration tests. The study would involve a full day
of testing the day after your overnight stay, finishing around 5pm. You would then be asked to
return at a later date for an overnight CPAP trial, to take for one month either the capsule
treatment or CPAP treatment, returning a month later for a further half-day of daytime testing.
Neither of these treatments has been associated with any serious side effects.
Further information about the study is contained within the enclosed information sheet and
consent form. Please phone Miss Lynne Anderson on 0131 536 4192 if you have other
unanswered queries about the study, or impartial advice can be obtained from Dr. Tom Mackay
of the Sleep Centre on 0131 536 2355.
We would be most grateful if you could complete the attached response form and return it in the
enclosed SAE to let us know if you might be interested. If you already feel happy to take part in
the study, having read the information sheet, please also sign and return the consent form.
Yours sincerely,
L Anderson, MA, Research Associate
Professor N J Douglas, Consultant Physician, FRCPE
Dr TW Mackay, Consultant, MRCPE
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INFORMATION SHEET
LABORATORY-BASED DRIVING TASK STUDY
The study
You have been asked to participate in a study of driving ability, sleepiness and concentration
before and after treatment for the obstructive sleep apnoea/hypopnoea syndrome (OSAHS), a
condition that causes breathing pauses during sleep. The results of this study will be used to
improve knowledge of the effects of OSAHS on daytime performance and the management of
other patients with this syndrome. The study is funded by the Chest, Heart and Stroke Scotland
charity.
You will be asked to have tests before and after 1 month of treatment with either a capsule, taken
by mouth, or continuous positive airway pressure (CPAP). A computer program will decide
which one treatment you will be asked to take, with a 50:50 chance of getting each.
The study treatments
1. CAPSULES that may ease your breathing problems during sleep by increasing the muscle
tone in your throat. Patients taking these have reported occasional headaches, rashes and
nausea.
2. CONTINUOUS POSITIVE AIRWAY PRESSURE (CPAP) which may prevent your
throat blocking during sleep by blowing a gentle stream of air into your airway through a
nasal mask. This treatment is the current standard treatment for OSAHS, and may cause
minor stuffiness of the nose or drying of the throat.
In the event of side effects or other adverse events related to treatments, please contact Dr. HM
Engleman of the Edinburgh Sleep Centre on 0131 536 2360/ 2355 or the respiratory registrar on
call 0131 536 1000.
The procedures
Before you start treatment, you'll be asked to attend for monitoring over a full night and day.
The tests will involve being 'wired up' with skin sensors that detect brainwaves, breathing and
oxygen levels. Only the scalp and face sensors will be left on for the daytime tests. The daytime
tests will involve 4 assessments of sleepiness, during which you'll be asked to stay awake for
periods in a dimly lit room. In between these, you'll be asked to complete questionnaires about
your everyday sleepiness level, and concentration tests resembling puzzles and computer games.
You will be asked to come back for a second night to try the CPAP treatment and then start your
one-month of treatment at home thereafter, and to return in one month for an appointment to
perform again a driving-based concentration test. At the end of the study, depending on your
local health authorities approval, you will be offered the standard treatment for OSAHS, CPAP.
If CPAP is not available at this time you will be placed on a waiting list.
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Further information
Impartial advice can be obtained from Dr. TW Mackay, Edinburgh Sleep Centre, Wd 48, Royal
Infirmary (tel. 0131 536 2355).
If you agree to take part in this study, we will contact your GP and keep them informed of any
clinically relevant results. It is understood that you can withdraw at any time without prejudice
to the quality ofyour treatment for SAHS. If you understand the requirements and procedures of
the study and agree to take part, please sign the consent form.
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CONSENT FORM
Title of proposed research: Laboratory-based driving task
Name of investigators: L Anderson, HM Engleman and NJ Douglas
Address: Edinburgh Sleep Centre, Ward 48, Royal Infirmary of Edinburgh
Further information is available from: Miss Lynne Anderson, Edinburgh Sleep Centre, Ward
48, Royal Infirmary of Edinburgh. Impartial advice can be gained from Dr. TW Mackay,
Edinburgh Sleep Centre.
In this study, funded by the Chest Heart and Stroke Scotland charity, you will be asked to
have an overnight sleep study and a daytime assessment in the Edinburgh Sleep Centre.
During these, you will be 'wired up' with skin sensors to detect physiological activity, and
will be asked to sleep during the night, and then undergo sleepiness tests, questionnaires
and concentration tests the next day. You will subsequently be asked to take for one month
either a capsule taken by mouth or to use continuous positive airway pressure (CPAP)
treatment, and return for a driving-based concentration test at the end of the month's
treatment.
Either of these two treatments may be effective in reducing the breathing pauses in sleep
which are seen in the sleep apnoea/hypopnoea syndrome. The capsule may alter muscle
activity in the upper airway. CPAP treatment works by keeping the airway open during
sleep with a gentle stream of air blown through a nasal mask. Each of these treatments
may produce minor side effects, which resolve with simple measures or with the
discontinuation of treatment. Occasional rashes, headaches and nausea have been
associated with the capsule treatment, but no serious side effects have been seen. CPAP
treatment can cause a runny nose or a dry throat in some users.
AS YOUR CONSULTANT TOLD YOU, PLEASE DO NOT DRIVE IF YOU FEEL SLEEPY
OR TIRED
• I agree to participate in this study.
• I have read this consent form and Patient/Subject Information Sheet and had the opportunity
to ask questions about them.
• I agree for notice to be sent to my General Practitioner about my participation in this study.
• I agree to the provision of any clinically significant information to be sent to my General
Practitioner.
• I understand that I am under no obligation to take part in this study and that a decision not to
participate will not alter the treatment that I would normally receive.
• I understand that I have the right to withdraw from this study at any stage and that to do so
will not affect my treatment.
• I understand that this is non-therapeutic research from which I cannot expect to derive any
benefit.
Name of Patient: Signature of Patient: Date:
Signature of Investigator: Date:
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Edinburgh Sleep Centre,







The above named patient has, as you know, been attending my sleep clinic and is currently under
diagnosis for the obstructive sleep apnoea/hypopnoea syndrome (OSAHS). Your patient has
kindly agreed to enter a randomised controlled trial of sleepiness and daytime performance,
involving a sleep study and two daytime testing sessions at the Edinburgh Sleep Centre. Your
patient will be randomised to receive one month of treatment with the continuous positive
airway pressure (CPAP) device or one month of an oral treatment, and will be offered the
standard treatment for OSAHS, CPAP therapy, at completion of or withdrawal from the study.
Participation in this study will not delay treatment even for capsule-treated patients, as only
patients awaiting CPAP treatment have been approached.
The study has the approval of the Lothian Health Board Medical Ethics Committee. It is
important that the nature of the tablet therapy is not divulged to the patient, but equally I
recognise that it is important that you have immediate access to information about the capsules if
this is required in an emergency. I thus enclose a sealed envelope containing information about
the capsules. I would be grateful if you can let me know ifyou need to open this envelope during
the study. After the end of the study the envelope and its contents can be destroyed.
I can assure you that the capsules being used are unlikely to cause significant side effects. Please
do not hesitate to contact me if you require any further information.
Yours sincerely,
NEIL J. DOUGLAS
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CAN YOU SPARE FOUR HOURS OF YOUR TIME TO HELP
WITH A RESEARCH PROJECT IN THE ROYAL INFIRMARY OF
EDINBURGH?
WE ARE CONDUCTING RESEARCH ON A NEW PC BASED
DRIVING SIMULATOR AND ARE LOOKING FOR MALES
AGED 30 to 60 TO HELP.
THE STUDY IS NON INVASIVE. NO NEEDLES OR DRUGS
INVOLVED.
IF YOU SPEAK ENGLISH AS YOUR FIRST LANGUAGE, AND
YOU ARE NOT AN ENROLLED STUDENT THEN PLEASE












Further to our recent conversation we write to ask you whether you would be kind enough to
help with a medical research project assessing performance on a driving simulator.
Chest, Heart and Stroke Scotland, has funded a three-year project based in the Edinburgh Sleep
Centre, Royal Infirmary of Edinburgh, to evaluate whether performance on a driving simulator
accurately reflects 'real life' driving. We are studying the performance of people with the sleep
apnoea/hypopnoea syndrome (SAHS), a condition known to affect driving ability, and need to
compare their results with members of the normal healthy population of identical age and sex.
We can assure you that the research is not painful and will involve you attending the Edinburgh
sleep Centre for one half day.
Further information about the study is contained within the enclosed information sheet and
consent form. Please phone Miss Lynne Anderson on 0131 536 4192 if you have other
unanswered queries about the study, or impartial advice can be obtained from Dr. Tom Mackay
of the Sleep Centre on 0131 536 2355.
We would be most grateful if you could complete the attached response form and return it in the
enclosed SAE to let us know if you might be interested. If you already feel happy to take part in
the study, having read the information sheet, please also sign and return the consent form. We
also ask that you complete the enclosed questionnaire and return it with your response form, so
we can determine if you fit the criteria for the study.
Yours sincerely,
L Anderson, MA, Research Associate
Dr TW Mackay, Consultant, MRCPE
Professor N J Douglas, Consultant Physician, FRCPE
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INFORMATION SHEET
LABORATORY-BASED DRIVING TASK STUDY
The study
You have been asked to participate in a study looking at driving performance on a PC based
driving simulator. In this study we are comparing the performance of people suffering from the
obstructive sleep apnoea/hypopnoea syndrome (OSAHS) and normal healthy people who are
identical in age and sex.
The results of this study will be used to improve our knowledge about how driving performance
differs between sufferers and non-sufferers of OSAHS and will help in the management of
patients with this syndrome.
The study is funded by the Chest, Heart and Stroke Scotland charity.
The procedures
Once we have received the questionnaire back, if you still fit the criteria and match up with a
OSAHS sufferer, a time will be arranged for you to attended the Edinburgh Sleep Centre for a
half day.
You will be asked to complete questionnaires about your everyday health, and complete
concentration tests resembling puzzles, in addition to 'driving' on the simulator. The tests will
involve being 'wired up' with skin sensors that detect brainwaves, and being video recorded
whilst on the driving simulator.
We can assure you that none of the tests are invasive or painful. The tests should be able to be
completed in around 4 hours.
Further information
Impartial advice can be obtained from Dr. TW Mackay, Edinburgh Sleep Centre, WD
48, Royal Infirmary (tel. 0131 536 2355).
If you agree to take part in this study it is understood that you can withdraw at any time. If you









Dear Sir or Madam:
I am a research associate for the University of Edinburgh currently based in the Edinburgh Sleep
Centre in the Royal Infirmary of Edinburgh, and I am writing to ask if you would please
consider placing the enclosed advert on your notice board.
Here at the Sleep Centre we conduct research in a condition called the sleep apnoea/hypopnoea
syndrome, which causes sleepiness and is known to affect driving performance in sufferers
before treatment is established.
We are currently conducting research with a PC based driving simulator to investigate whether
the driving simulator can detect differences in driving performance before and after treatment in
sufferers of this condition.
However, we require healthy volunteers to act as control subjects for our study so that we can
determine if the simulator can also detect differences in performance between sufferers and non-
sufferers.
We are writing to a variety of places in and around Edinburgh and would be most grateful for
your help.
If you have any questions or queries about the advert please do not hesitate to contact me on
0131 536 4192 or by e-mailing me at Lynne.Anderson@ed.ac.uk
Yours faithfully,
Lynne Anderson
Research Associate to Professor N.J. Douglas
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Name: Date of Birth:
SLEEP/WAKE QUESTIONNAIRE
Please find enclosed a questionnaire for you to fill in and return.
For most questions several options are available, please circle the answer that is most
appropriate.
All answers will remain confidential.
Thank you for your co-operation.
Are you a student? YES NO





Height: ft and inches/ metres
Collar Size : inches / cm Age:
Marital Status: single / married / divorced / widowed
Do you have regular bedpartner?
Date of Birth :
Tel No:
Gender : Male / Female
Number of Children:











Do you perform shift-work or night work? Yes / No
If so, please specify shift rotation pattern and how long you are on each shift
Are you a: smoker / non-smoker / ex-smoker for years
Tobacco use: Caffeinated and alcoholic drinks:
cigarettes Number per day tea cups per week
cigars Number per day coffee cups per week
tobacco (own rolled) Oz. per week beer pints per week
tobacco (pipe) Oz. per week wine glasses per week
spirits drinks per week
sherry/port glasses per week
Please list below all medications, including sleeping pills and inhalers, which you are currently
taking





Have you ever had any of the following conditions or operations?
Please circle those applicable to you.
Asthma Chronic bronchitis Emphysema Hay fever
High bloodpressure Stroke Heart attack Angina
Nasal congestion Nose operations Throat operations Broken nose
Kidney/ Liver problems Diabetes Thyroidproblems Epilepsy
Depression/Anxiety M.EJ Chronic fatigue syndrome Nervous breakdown
Have you any other health problems, which might be relevant? If so, please give details below.
YOUR SLEEP PATTERN
Please give a single 'best guess' answer to the following:
1. What time do you usually go to bed at night?
2. How long does it usually take you to fall asleep at night?
3. What time do you usually get up in the morning?
3. How many hours of actual sleep do you usually get at night
(This may be different than the number of hours you spend in bed)
4. Do you usually have problems with awakenings from sleep
(Excluding visits to the toilet)? Yes /No Yes/No





Please tick one column for each question to let us know about the presence and frequency of the
following sleep-related problems in the recent past. Your bedpartner, if applicable, may be a






























awakenings to use the
toilet
Snoring
14. If you snore, is the volume level: Quiet / Moderate / Heavy
(heard in bedroom only) (heard outside bedroom)
15. If you snore, is this: When on back only / On back and side / all positions
DAYTIME EVENTS
16. How likely are you to doze off or fall asleep in the following situations, in contrast to feeling
just tired? This refers to your usual way of life in recent times. Even if you have not done some
of these things recently, try to work out how they would have affected you. Use the following
scale to choose the most appropriate number for each situation.
Scale
0 = would never doze
1 = slight chance of dozing
2 = moderate chance of dozing
3 = high chance of dozing
Situation Chance of Dozing
Sitting and reading
Watching TV
Sitting, inactive in a public place (e.g. a theatre or a meeting)
As a passenger in a car for an hour without a break
Lying down to rest in the afternoon when circumstances permit
Sitting and talking to someone
Sitting quietly after a lunch without alcohol
In a car, while stopped for a few minutes in traffic
TOTAL
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Please tick one column for each question to let us know about the presence and frequency of the











































Please circle the one most appropriate answer, below:
24. During a typical week, how often do you struggle to resist sleep during the day or evening?
Never / rarely / 1-2 times per week / 3-6 times per week / Every day / More than once per day
25. During a typical week, how often do you actually fall asleep during the daytime (9 am to 5
pm)?
Never / rarely / 1-2 times per week / 3-6 times per week / Every day / More than once per day
26. During a typical week, how many times might you have a nap during the evening (5 to 11
pm)?




27. Do you hold a driving licence? Yes / No
28. If yes, is this licence: Car / HGV / PSV
(circle all that apply)
29. Do you drive to and from work? Yes / No
30. Is driving essential for your job? Yes / No
33. How many miles do you drive annually (include business and personal driving)?
0 - 500 / 501 - 5,000 / 5,001 - 15,000 / more than 15,000 miles
34. Over the past year, how frequently have you experienced the following problems whilst
driving? Please tick one column for each question.







(less than 1 hour)
35. Have you ever nodded off whilst driving? Yes / No
36. Please tell us below of any driving incidents, by filling in the number of events you have









(e.g. veering out of lane, running a red
traffic light or failing to give way at a




Please circle any of the following events that you have ever experienced:
Hallucinations or vivid dreams whilst still conscious, Paralysis or inability to move,
occurring at sleep onset or on awakening occurring at sleep onset or on awakening
Muscular weakness or collapse Sensation ofrestlessness or crawling in
whilst laughing or during strong emotions legs, relieved by standing or
walking
Bed-wetting (as an adult) Sleepwalking
37. If you are an adult, have you experienced any changes in your sex drive or sexual function?
Increased / Unchanged / Decreased
38. Have you experienced any recent changes in weight?
Increased / Unchanged / Decreased by kg / lbs over years
39. Are you excessively irritable or short tempered? Yes / No
40. Do you feel depressed or 'low'? Yes / No




Short Form 36 Questionnaire (SF36)
Functional Outcome of Sleep Questionnaire (FOSQ)
Epworth Sleepiness Scale (ESS)
In-Flouse symptom scale
In-House driving questionnaire parti
In-House driving questionnaire part 2
In-House computer questionnaire
Karolinska sleepiness scale
CPAP side effects questionnaire
Placebo side effects questionnaire
Treatment usage questionnaire
National Adult Reading Test (NART)
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.9F-3R HFAI TH SI IRVFY
INSTRUCTIONS: This survey asks for your views about your health. This information will
help keep track of how you feel and how well you are able to do your usual activities.
Answer every question by marking the answer as indicated. If you are unsure about how to
answer a question, please give the best answer you can.







2. Compared to one year ago, how would you rate your health in general now?
(circle one)
Much better now than one year ago 1
Somewhat better now than one year ago 2
About the same as one year ago 3
Somewhat worse now than one year ago 4
Much worse now than one year ago 5
Copyright© 1992 Medical Outcomes Trust
All rights reserved.
(U.K. Version of Stanford Sf-36 Health Survey)
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3. The following questions are about activities you might do during a typical day. Does your










a. Vigorous activities, such as running, lifting heavy
objects, participating in strenuous sports
1 2 3
b. Moderate activities, such as moving a table, pushing
a vacuum cleaner, bowling, or playing golf
1 2 3
c. Lifting or carrying groceries 1 2 3
d. Climbing several flights of stairs 1 2 3
e. Climbing one flight of stairs 1 2 3
f. Bending, kneeling, or stooping 1 2 3
g. Walking more than a mile 1 2 3
h. Walking half a mile 1 2 3
i. Walking one hundred yards 1 2 3
j. Bathing or dressing yourself 1 2 3
4. During the past 4 weeks, have you had any of the following problems with your work or
other regular daily activities as a result of your physical health?
YES NO
a. Cut down on the amount of time you spent on work or other
activities
1 2
b. Accomplished less than you would like 1 2
c. Were limited in the kind ofwork or other activities
1 2
d. Had difficulty performing the work or other activities (for
example, it took extra effort)
1 2
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5. During the past 4 weeks, have you had any of the following problems with your
work or other regular daily activities as a result of any emotional problems (such as feeling
depressed or anxious)?
(circle one number on each 1 ine)
YES NO
Cut down on the amount of time you spent on work or other activities 1 2
k Accomplished less than you would like 1 2
Didn't do work or other activities as carefully as usual 1 2
6. During the past 4 weeks, to what extent has your physical health or emotional problems
interfered with your normal social activities with family, friends, neighbours, or groups?
(circle one)
Not at all 1
Slightly 2
Moderately 3
Quite a bit 4
Extremely 5









8. During the past 4 weeks, how much did pain interfere with your normal work (including
both work outside the home and housework)?
(circle one)
Not at all 1
A little bit 2
Moderately 3
Quite a bit 4
Extremely 5
9. These questions are about how you feel and how things have been with you during the past 4
weeks. For each question, please give the one answer that comes closest to the way you
have been feeling. How much of the time during the past 4 weeks -




















a. Did you feel full of life? 1 2 3 4 5 6
b. Have you been a very
nervous person?
1 2 3 4 5 6
c. Have you felt so down in the
dumps that nothing could
cheer you up
1 2 3 4 5 6
d. Have you felt calm and
peaceful?
1 2 3 4 5 6
e. Did you have a lot of energy? 1 2 3 4 5 6
f. Have you fell downhearted
and low?
1 2 3 4 5 6
g- Did you feel worn out? 1 2 3 4 5 6
h. Have you been a happy
person?
1 2 3 4 5 6
i. Did you feel tired? 1 2 3 4 5 6
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10. During the past 4 weeks . how much of the time has your physical health or emotional
problems interfered with your social activities (like visiting friends, relatives, etc)?
(circle one)
All of the time 1
Most if the time 2
Some of the time 3
A little of the time 4
None of the time 5
11. How TRUE or FALSE is each of the following statements for you?











a. I seem to get ill more easily
than other people
1 2 3 4 5
b. I am as healthy as anybody I
know
1 2 3 4 5
c. I expect my health to get
worse
1 2 3 4 5
d. My health is excellent 1 2 3 4 5
Copyright© 1992 Medical Outcomes Trust
All rights reserved.
(U.K. Version of Stanford Sf-36 Health Survey)
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Name: Date:
FUNCTIONAL OUTCOMES OF THE SLEEP QUESTIONAIRE
(FOSQ)
Some people have difficulty performing everyday activities when they feel tired or sleepy. The
purpose of this questionnaire is to find out if you generally have difficulty carrying out certain
activities because you are too sleepy or tired. In this questionnaire, when the words "sleepy" or
"tired" are used, it means the feeling that you can't keep your eyes open, your head is droopy,
that you want to "nod off', or that you feel the urge to take a nap. The words do not refer to the
tired or fatigued feeling you may have after you have exercised.
DIRECTIONS: Please put a tick (3) in the box for your answer to each question. Select only
one answer for each question. Please try to be as accurate as possible. All information will be
kept confidential.
(0) (4) (3) (2) (1)
I don't do No Yes, Yes, Yes,
this activity difficulty a little moderate extreme
for other difficulty difficulty difficulty
reasons
1 Do you have difficulty
concentrating on the things you do
because you are sleepy or tired?
2 Do you generally have difficulty
remembering things, because you
are sleepy or tired?
3 Do you have difficulty finishing a
meal because you become sleepy
or tired?
4 Do you have difficulty working on
a hobby (for example, sewing,
collecting, gardening) because you
are sleepy or tired?
□ □ □ □
□ □ □ □
□ □ □ □
□ □ □ □
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(0) (4) (3) (2) (1)
I don't do No Yes, Yes, Yes,
this activity difficulty a little moderate extreme
for other difficulty difficulty difficulty
reasons
Do you have difficulty doing
work around the house (for
example, cleaning the house,
doing laundry, taking out the
rubbish, repair work) because
you are sleepy or tired?
□ □ □ □ □
Do you have difficulty
operating a motor vehicle for
short distances (less than 100
miles) because your sleepy or
tired?
□ □ □ □ □
Do you have difficulty
operating a motor vehicle for
long distances (greater than
100 miles) because your
sleepy or tired?
Do you have difficulty getting
things done because you are
too sleepy or tired to drive or
take public transportation?
□ □ □ □ □
□ □ □ □ □
Do you have difficulty taking
care of financial affairs and
doing paperwork (for
example, writing cheques,
paying bills, keeping financial
records, filling out tax forms,
etc) because you are sleepy or
tired?
□ □ □ □
10 Do you have difficulty
performing paid or volunteer
work because you are sleepy
or tired?
□ □ □ □ □
11 Do you have difficulty
maintaining a telephone
conversation because you
become sleepy or tired?
□ □ □ □ □
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12 Do you have difficulty
visiting with your family
or friends in your home
because you become sleepy
or tired?
13 Do you have difficulty
visiting with your family or
friends in their home
because you become sleepy
or tired?
14 Do you have difficulty
doing things for your
family or friends because
you are too sleepy or tired?
(4) (3) (4) (5)
No Yes, Yes, Yes,
a little moderately extremely
15 Has your relationship with
family, friends or work
colleagues been affected
because you are sleepy or
tired?





















□ □ □ □ □
□ □ □ □ □
□ □ □ □ □
□ □ □ □
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16 Do you have difficulty
exercising or participating in
a sporting activity because
you are too sleepy or tired?
17 Do you have difficulty
watching a film or videotape
because you become sleepy
or tired?
(0) (4) (3) (2) (1)
I don't do No Yes, a Yes, Yes,
this activity difficulty little moderate extreme
for other difficulty difficulty difficulty
reasons
18 Do you have difficulty
enjoying the theatre or a
lecture because you become
sleepy or tired?
19 Do you have difficulty
enjoying a concert because
you become sleepy or tired?
20 Do you have difficulty
watching TV because you
are sleepy or tired?
21 Do you have difficulty
participating in religious
services, meetings or a group
or a club because you are
sleepy or tired?
22 Do you have difficulty being
as active as you want to be
in the evening because you
are sleepy or tired?
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(0) (4) (3) (2) (1)
I don't do No Yes, a Yes, Yes,
this activity difficulty little moderate extreme
for other difficulty difficulty difficulty
reasons
□ □ □ □ □
□ □ □ □ □
□ □ □ □ □
□ □ □ □ □
□ □ □ □ □
□ □ □ □ □
□ □ □ □
23 Do you have difficulty being
as active as you want to be
in the morning because you
are sleepy or tired?
24 Do you have difficulty being
as active is you want to be in
the afternoon because you
are sleepy or tired?
24 Do you have difficulty
keeping pace with others
your own age because you
are sleepy or tired?
□ □ □ □
□ □ □ □
□ □ □ □
(1) (2) (3) (4)
Very low Low Medium High
26 How would you rate your i i f ~ j j f ]
general level of activity?
©Weaver, September 1996
Functional Outcomes of Sleep Questionnaire (FOSQ)
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EPWORTH SLEEPINESS SCALE
MW Johns. Sleep 1991, 14(6), 540-5.
Name: Study:
Date:
How likely are you to doze of or fall asleep in the following situations, in contrast to feeling just
tired? This refers to your usual way if life in recent times. Even if you have not done some of
these things try to work out how they would have effected you. Use the following scale to
choose the most appropriate number for each situation.
0 = would never doze
1 = slight chance of dozing
2 = moderate chance of dozing
3 = high chance of dozing
SITUATION Chance of dozing
Sitting reading
Watching TV
Sitting, inactive in a public place (e.g. a theatre or a meeting)
As a passenger in a car for an hour without a break
Lying down to rest in the afternoon when circumstances permit
Sitting and talking to someone
Sitting quietly after lunch without alcohol
In a car, when stopped for a few minutes in the traffic





We would like to know which, if any, night time or daytime symptoms associated with sleep
apnoea you have experienced in the last month.
Please tick a column for each symptom to let us know if it is present and how severe it has been
for you.
(The don't know column will be useful for some symptoms if you have no partner to witness
















Breathing pauses in sleep
Choking attacks in sleep
Unrefreshed by night time
sleep
Falling asleep in the daytime
Falling asleep in the evening
Tiredness
Feeling sleepy whilst driving
Falling asleep when driving
Feeling depressed and Tow'
Low sex drive
Excessive irritability with
friends, colleagues or family
Concentration problems
Forgetfulness
Falling asleep at work
Poor performance at work
Other
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DRIVING HISTORY QUESTIONNAIRE 1
We would like to know about your experience of driving in the past 5 years. This information
is entirely confidential and will not be passed to insurers, police or other authorities. Please
complete all of this section.
1. How many years have you been able to drive?
2. Approximately how many miles per year do you drive? miles
3. Is driving required by your occupation? Please tick □ YES □ NO
4. In an average week how many days do you drive? Please tick □ 5+ □ 3-4 □ 1-2 □ Less
frequently
5. We would like to know about your ability to drive long distances (>75 miles) in the last five
years, compared to other drivers. Please tick a single column
VERY
GOOD






6. We would like to investigate how sleepiness is related to road accidents. The definitions of
accident types are as follows:
Near Miss Accident- Almost had a collision but avoided at last moment
Minor Accident - Collided with property or person, but no people injured
Major Accident- Collided with property or person, and people were hurt
In the past 5 years how many of each of the following events happened to you?
NEAR MISS
ACCIDENT







Please follow the example given below, to give a short description of all the accidents you have


























About 20 mins Yes No
Please give a brief description






















































Please give a brief description
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DRIVING HISTORY QUESTIONNAIRE 2
We would like to know about your experience of driving in the last month. This information is
entirely confidential and will not be passed to insurers, police or other authorities. Please
complete all of this section.
1. How many years have you been able to drive?
2. Approximately how many miles per year do you drive? Miles
3. Is driving required by your occupation? Please tick □ YES □ NO
4. In an average week how many days do you drive? Please tick D5+ □ 3-4 □ 1-2 □ Less
frequently
5. We would like to know about your ability to drive long distances (>75 miles) in the last
month, as compared to other drivers. Please tick a single column
VERY
GOOD






6. We would like to investigate how sleepiness is related to road accidents. The definitions of
accident types are as follows:
Near Miss Accident- Almost had a collision but avoided at last moment
Minor Accident - Collided with property or person, but no people injured
Major Accident- Collided with property or person, and people were hurt
In the past month how many of each of the following events happened to you?
NEAR MISS
ACCIDENT







In the past 5 years how many of each of the following events happened to you?
NEAR MISS
ACCIDENT






Please follow the example given below, to give a short description of all the accidents you have


























About 20 mins Yes No
Please give a brief description




































Please give a brief description
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Name: DOB: Date: Study:
COMPUTER QUESTIONNAIRE
Please read the questions below and circle the appropriate answer(s).
1. Do you use a computer in your place ofwork?
Yes No Not applicable
2. In an average week how many days do you use a computer for work?
5+ 3-4 1-2 Less frequently
3. Do you have access to a computer at home?
Yes No
4. In an average week how many days do you use a computer for leisure purposes?
5+ 3-4 1-2 Less frequently
5. If you use a computer what do you use it for, please circle all that apply:
Word processing Spreadsheets Home Finances Games
Internet E-mail Other please specify
6. Do you use your computer to play games?
Yes No
7. In an average week how many days do you use a computer for playing games?
5+ 3-4 1-2 Less frequently Don't play games






Please circle the number below that best describes how you feel right now.
8
Extremely Alert Neither Sleepy - Extremely





CPAP SIDE EFFECTS QUESTIONNAIRE
Name:
Date:
1. In the last month, have you had any problems associated with using CPAP
(Please circle) Yes / No
2. Please tick a box for each of the following problems to let us know how severe the



























Wake up with mask off
Red or soar eyes
Difficulty in falling asleep or
frequent wakenings
Stomach bloating or 'wind'
Chest Wheeze
Difficulty in exhaling with
mask
Sore or rubbing mask
Leaking of air from mask
Unpleasant appearance of
CPAP equipment
Excessive noise from CPAP
unit (for you or your partner)
Inconvenience not worth the
benefits
Other
(please specify any other
problem and it's severity)
PLEASE CHECK THAT ALL APPROPRIATE SECTIONS OF THIS FORM ARE FILLED IN
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CAPSULE SIDE EFFECT QUESTIONNAIRE
Name:
Date:
3. In the last month, have you had any problems associated with taking the capsule?
(Please circle) Yes / No
4. Please tick a column for each of the following problems to let us know how severe the


































any other problems and
there severity





We would like to know how useful and how convenient you have found your current
treatment. Please circle a number from 1 to 10 on the scale below to indicate your
experience.




1 2 3 4 5 6 7




12 3 4 5 6 7














4. How much have you been able to use your current treatment over the last month? Please
indicate an average number of nights per week, and an average number of hours on the nights





5. For how long did you use your treatment for last night?
hours
308





























Patient invitation letter for driving questionnaire study












We write to ask you whether you would be kind enough to help with a research study which is
investigating how sleepiness is associated with road traffic accidents.
As a sufferer of the sleep apnoea/hypopnoea syndrome we would appreciate it if you could take
15 minutes of your time to complete the enclosed 'Driving Survey' asking about your driving
history in the last few years. Even if you do not drive we would appreciate if you could fill in
the first question. All information that you give us will remain completely confidential and will
not be passed on to the police, insurers or other authorities and we can assure you it will not
affect the treatment you receive in any way.
By helping us with this Survey Study, we will be better able to understand how sleepiness
affects driving.
Please return the survey to us in the self addressed envelope.
If you have any questions regarding the survey please call Miss Lynne Anderson on 0131 536
4192.
Thank you very much for your help it is greatly appreciated.
Yours sincerely,
Miss L Anderson, MA, Research Associate
Dr TW Mackay, Consultant, MRCPE
Professor N J Douglas, Consultant Physician, FRCPE
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Edinburgh Sleep Centre,






We are randomly writing to people in Scotland to ask you whether you would be kind enough to
help with a research study which is investigating how sleepiness is associated with road traffic
accidents.
At the Edinburgh Sleep Centre in the Royal Infirmary of Edinburgh, we conduct research in a
condition called the sleep apnoea/hypopnoea syndrome, which causes sleepiness and is known to
affect driving performance in suffers before treatment is established. We are currently
investigating how driving history compares between sufferers and other people in the
community. We hope you will help us by being a community normal subject.
We would appreciate it if you could take 10 minutes of your time to help this medical research
by completing the enclosed 'Community Sample Driving Survey' asking about your driving
history in the last few years. Even if you do not drive we would appreciate if you could fill in
the first question. All information that you give us will remain completely confidential and will
not be passed on to anyone out with the sleep centre and we can assure you the information will
be used only to help us better understand how sleepiness is associated with driving performance
and road traffic accidents.
If you have any questions concerning this survey, please call Miss Lynne Anderson on 0131 536
4192, or impartial advice can be obtained from Dr. Tom Mackay of the Sleep Centre on 0131
536 2355.
We would be most grateful if you could complete the questionnaire and return it in the enclosed
self-addressed envelope.
Yours sincerely,
L Anderson, MA, Research Associate
DrTW Mackay, Consultant, MRCPE
Professor N J Douglas, Consultant Physician, FRCPE
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Driving Survey
This questionnaire should take 10-15 minutes to complete; all the answers will
remain completely confidential and will not be passed on to insurers or the
police, and will not affect your treatment in any way. Please try and answer all
the questions as accurately as possible, however if you are unsure of the exact
answer to any of the questions please answer as best as you can.
Your time and help are greatly appreciated
THANK YOU.
Do you hold a Full drivers Licence? NO
If NO please return the survey now.
survey.
YES
If YES please complete the rest of the
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YOU AND CPAP
1. Are you still using your CPAP machine? Please Circle
NO YES
2. If you are not using your CPAP machine when did you stop? month
year
3. Apart from CPAP are you currently using any other treatment for your snoring/sleep
apnoea?
Please Circle
YES pleas eNO specify
4. How many nights a week do you currently use your CPAP machine?
Please circle one number
0 1 2 3 4 5 6 7
5. When you use your machine, how many hours do you sleep with it? hrs




7. How likely are you to doze off or fall asleep in the following situations, in contrast to
feeling just tired? Even if you have not done some of these things, try to work out how
they would affect you both NOW you are using CPAP and BEFORE you started CPAP
therapy.
Use the following scale to choose the most appropriate number for each situation.
Scale
0 = would never doze
1 = slight chance of dozing
2 = moderate chance of dozing
3 = high chance of dozing
Try to think how you would have been affected in these situations both now and before








Sitting, inactive in a public place (e.g. a theatre or a meeting)
As a passenger in a car for an hour without a break
Lying down to rest in the afternoon when circumstances
permit
Sitting and talking to someone
Sitting quietly after lunch without alcohol
In a car, when stopped for a few minutes in the traffic
8. Since starting CPAP are you:
Please Circle one answer
Much more sleepy / More sleepy / About the same / Less sleepy / Much less sleepy
DRIVING HISTORY
We would like to investigate how sleepiness is related to road accidents. In the
following sections we will ask you questions concerning your driving performance both
before you started using CPAP and now that you are on treatment. This information is
entirely confidential and will not be passed to insurers, police or other authorities.
9. How long have you held a full drivers license yrs.
BEFORE STARTING CPAP THERAPY
The following questions are referring to your driving experiences in the 2 years before
you started on CPAP therapy. Although you may not remember exactly, please try your
best to answer the questions.
10. Was driving required by your occupation? Please circle
YES NO
11. In an average week how many days did you drive? Please circle
5+ 3-4 1-2 Less frequently
12. Before you started CPAP therapy had you ever felt sleepy while driving? Please
circle
Never / Occasionally / Often / Daily / Every Journey
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13. Before you started CPAP therapy how many times did you feel sleepy while
driving?
times
14. Before you started CPAP therapy did you ever fall asleep while driving? Please
circle
Never / Occasionally / Often / Daily / Every Journey
15. Before you started CPAP therapy how many times have you fallen asleep while
driving?
times
16. We would like to know about your ability to drive SHORT distances (less than 75
miles), and LONG distances (more than 75 miles) in the 2 years before you started
CPAP therapy, compared to other drivers.
Please tick one box each for short and long.
VERY











17. The definitions of accident types are as follows:
Near Miss Accident- Almost had a collision but avoided at last moment
Minor Accident - Collided with property or person, but no people injured
Major Accident- Collided with property or person, and people were hurt
In the 2 years before you started using CPAP therapy how many of each of the above
events have happened to you? Please write the numbers in all boxes.
NEAR MISS
ACCIDENT





18. Before starting CPAP therapy if you had any accidents we would also like to know
at what time approximately, the accidents you entered in the table above happened.
Please enter the number of accidents you have had in the different time bands. Please
write the number in each box.







If you did not have any accidents please tick
19. Again if you had any accidents in the 2 years before starting CPAP therapy we
would like to know the number of accidents that occurred on each of the following types
of road.




















If you did not have any accidents please tick
DRIVING HISTORY SINCE STARTING CPAP THERAPY
The following questions are referring to your driving experiences in the last 2 years that
you have been using CPAP. Although you may not remember exactly, please try your
best to answer the questions.
20. Is driving required by your occupation? Please circle
YES NO
21. In an average week how many days do you drive? Please circle
5+ 3-4 1-2 Less frequently
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22. When you use CPAP do you ever feel sleepy while driving? Please circle
Never / Occasionally / Often / Daily / Every Journey
23. When you use CPAP how many times have you felt sleepy while driving?
times
24. When you use CPAP do you ever fall asleep while driving? Please Circle
Never / Occasionally / Often / Daily / Every Journey
25. When you use CPAP how many times have you fallen asleep while driving?
times
26. We would like to know about your ability to drive SHORT distances (less than 75
miles), and LONG distances (more than 75 miles) in the last 2 years that you have been
using CPAP, compared to other drivers.

















27. The definitions of accident types are as follows
Near Miss Accident- Almost had a collision but avoided at last moment
Minor Accident - Collided with property or person, but no people injured
Major Accident- Collided with property or person, and people were hurt
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In the last 2 years that you have been using CPAP how many of each of the above
events have happened to you? Please write the number in all boxes.
NEAR MISS
ACCIDENT






28. After starting CPAP therapy if you had any accidents we would also like to know at
what time approximately, the accidents you entered in the table above happened.
Please enter the number of accidents you have had in the different time bands. Please
write the number in each box.
6am + 9am + 12pm
+








If you have not had any accidents please tick
29. Again if you had any accidents in the 2 years since starting CPAP therapy we
would like to know the number of accidents that occurred on each of the following types
of road.





















If you have not had any accidents please tick
THANK YOU FOR YOUR CO-OPERATION
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Driving Survey
The questionnaire should take 10-15 minutes to complete, all the answers will
remain completely confidential and will not be passed on to insurers or the
police, and will not affect your treatment in any way. Please try and answer all
the questions as accurately as possible, however if you are unsure of the exact
answer to any of the questions please answer as best as you can.
Your time and help are greatly appreciated
THANK YOU.
Do you hold a Full drivers Licence? YES NO




1. How likely are you to doze off or fall asleep in the following situations, in contrast to
feeling just tired? Even if you have not done some of these things, try to work out how
they would affect you.
Use the following scale to choose the most appropriate number for each situation.
Scale
0 = would never doze
1 = slight chance of dozing
2 = moderate chance of dozing
3 = high chance of dozing






Sitting, inactive in a public place (e.g. a theatre or a meeting)
As a passenger in a car for an hour without a break
Lying down to rest in the afternoon when circumstances
permit
Sitting and talking to someone
Sitting quietly after lunch without alcohol
In a car, when stopped for a few minutes in the traffic
DRIVING HISTORY
We would like to investigate how sleepiness is related to road accidents. In this section
we will ask you questions concerning your driving. This information is entirely
confidential and will not be passed to insurers, police or other authorities.
2. How long have you held a full drivers license yrs.
The following questions are referring to your driving experiences in the last 2 years.
Although you may not remember exactly, please try your best to answer the questions.
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3. Is driving required by your occupation? Please circle
YES NO
4. In an average week how many days do you drive? Please circle
5+ 3-4 1-2 Less frequently
5. In the last two years have you ever felt sleepy while driving? Please circle
Never / Occasionally / Often / Daily / Every Journey
In the last two years how many times have you felt sleepy while driving?
times
7. In the last two years have you ever fallen asleep while driving?
Never / Occasionally / Often / Daily / Every Journey
In the last two tears how many times have you fallen asleep while driving?
times
9. We would like to know about your ability to drive SHORT distances (less than 75
miles), and LONG distances (more than 75 miles) in the last two years, compared to
other drivers.
Please tick one box each for short and long.











10. The definitions of accident types are as follows:
Near Miss Accident- Almost had a collision but avoided at last moment
Minor Accident - Collided with property or person, but no people injured
Major Accident- Collided with property or person, and people were hurt
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In the last two years how many of each of the above events have happened to you?












11. If you had any accidents in the last two years we would also like to know at what
time approximately, the accidents you entered in the table above happened. Please
enter the number of accidents you have had in the different time bands. Please write
the number in each box.







12. Again if you had any accidents in the last two years we would like to know the
number of accidents that occurred on each of the following types of road.

























Community Sample Driving Survey
This questionnaire should take 10-15 minutes to complete, all the answers will
remain completely confidential and will not be passed on to insurers or the
police. Please try and answer all the questions as accurately as possible,
however if you are unsure of the exact answer to any of the questions please
answer as best as you can.
Your time and help are greatly appreciated
THANK YOU.
Do you hold a Full drivers Licence? YES
If NO please return the survey now.
survey.
NO
If YES please complete the rest of the
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SLEEPINESS
1. How likely are you to doze off or fall asleep in the following situations, in contrast to
feeling just tired? Even if you have not done some of these things, try to work out how
they would have affected you in the last 2 years
Use the following scale to choose the most appropriate number for each situation.
Scale
0 = would never doze
1 = slight chance of dozing
2 = moderate chance of dozing
3 = high chance of dozing
Try to think how you would have been affected in these situations.
Chance of dozing
SITUATION In the last 2 years
Sitting reading
Watching TV
Sitting, inactive in a public place (e.g. a theatre or a
meeting)
As a passenger in a car for an hour without a break
Lying down to rest in the afternoon when circumstances
permit
Sitting and talking to someone
Sitting quietly after lunch without alcohol
In a car, when stopped for a few minutes in the traffic
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EVENTS DURING SLEEP
Please tick one column for each question to let us know about the presence and
frequency of the following sleep-related problems in the recent past. Your bedpartner, if




































10. If you snore, is the volume level: Quiet / Moderate / Heavy
bedroom)
11. If you snore, is this: When on back only / On back and side / all
positions
12. Have you ever been diagnosed with a sleep disorder? Please circle
NO YES please
specify
Are you currently using any treatment for a diagnosed sleep disorder? Please circle
NO YES please specify
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DRIVING HISTORY
We would like to investigate how sleepiness is related to road accidents. In this section
we will ask you questions concerning your driving. This information is entirely
confidential and will not be passed to insurers, police or other authorities.
14. How long have you held a full drivers license years.
The following questions are referring to your driving experiences in the last 2 years.
Although you may not remember exactly, please try your best to answer the questions.
15. Is driving required by your occupation? Please circle
YES NO
16. In an average week how many days do you drive? Please circle
5+ 3-4 1-2 Less frequently
17. In the last 2 years have you ever felt sleepy when driving? Please circle
Never / Occasionally / Often / Daily / Every Journey
18. In the last 2 years how many times have you felt sleepy while driving?
times
19. In the last 2 years have you ever fallen asleep when driving? Please circle
Never / Occasionally / Often / Daily / Every Journey
20. In the last 2 years how many times have you fallen asleep while driving?
times
21. We would like to know about your ability to drive SHORT distances (less than 75
miles), and LONG distances (more than 75 miles) in the last 2 years, compared to other
drivers.
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22. The definitions of accident types are as follows:
Near Miss Accident- Almost had a collision but avoided at last moment
Minor Accident- Collided with property or person, but no people injured
Major Accident- Collided with property or person, and people were hurt
In the last 2 years how many of each of the above events have happened to you?
Please write the numbers in all boxes.
NEAR MISS
ACCIDENT






23. In the last 2 years if you had any accidents we would also like to know at what time
approximately, the accidents you entered in the table above happened. Please enter
the number of accidents you have had in the different time bands. Please write the
number in each box.







If you have not had any accidents please tick
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24. Again if you had any accidents in the last 2 years we would like to know the
number of accidents that occurred on each of the following types of road.





















If you have not had any accidents please tick




Anderson L, Vennelle M, MacKay TW, Engleman HM, Douglas NJ.
Controlled study of reported driving impairment in patients with the sleep
apnoea/ hypopnoea syndrome
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